
<html lang="en"     class="pb-page"  data-request-id="c840044e-1978-4a4d-bc83-d1732149f657"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/jm901453q;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2010.53.issue-5;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer" /></meta><meta name="dc.Creator" content="Xiong  Cai" /></meta><meta name="dc.Creator" content="Hai-Xiao  Zhai" /></meta><meta name="dc.Creator" content="Jing  Wang" /></meta><meta name="dc.Creator" content="Jeffrey  Forrester" /></meta><meta name="dc.Creator" content="Hui  Qu" /></meta><meta name="dc.Creator" content="Ling  Yin" /></meta><meta name="dc.Creator" content="Cheng-Jung  Lai" /></meta><meta name="dc.Creator" content="Rudi  Bao" /></meta><meta name="dc.Creator" content="Changgeng  Qian" /></meta><meta name="dc.Description" content="By incorporating histone deacetylase (HDAC) inhibitory functionality into the pharmacophore of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) inhibi..." /></meta><meta name="Description" content="By incorporating histone deacetylase (HDAC) inhibitory functionality into the pharmacophore of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) inhibi..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 9, 2010" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm901453q" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2010 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm901453q" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm901453q" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm901453q" /></link>
        
    
    

<title>Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm901453q" /></meta><meta property="og:title" content="Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0015.jpeg" /></meta><meta property="og:description" content="By incorporating histone deacetylase (HDAC) inhibitory functionality into the pharmacophore of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) inhibitors, we synthesized a novel series of compounds with potent, multiacting HDAC, EGFR, and HER2 inhibition and identified 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide 8 (CUDC-101) as a drug candidate, which is now in clinical development. 8 displays potent in vitro inhibitory activity against HDAC, EGFR, and HER2 with an IC50 of 4.4, 2.4, and 15.7 nM, respectively. In most tumor cell lines tested, 8 exhibits efficient antiproliferative activity with greater potency than vorinostat (SAHA), erlotinib, lapatinib, and combinations of vorinostat/erlotinib and vorinostat/lapatinib. In vivo, 8 promotes tumor regression or inhibition in various cancer xenograft models including nonsmall cell lung cancer (NSCLC), liver, breast, head and neck, colon, and pancreatic cancers. These results suggest that a single compound that simultaneously inhibits HDAC, EGFR, and HER2 may offer greater therapeutic benefits in cancer over single-acting agents through the interference with multiple pathways and potential synergy among HDAC and EGFR/HER2 inhibitors." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm901453q"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm901453q">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm901453q&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm901453q&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm901453q&amp;href=/doi/10.1021/jm901453q" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2010</span><span class="cit-fg-volume">, 53</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 2000-2009</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/53/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm901407s" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm901518t" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-<i>N</i>-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiong++Cai">Xiong Cai</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hai-Xiao++Zhai">Hai-Xiao Zhai</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jing++Wang">Jing Wang</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jeffrey++Forrester">Jeffrey Forrester</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hui++Qu">Hui Qu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ling++Yin">Ling Yin</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Cheng-Jung++Lai">Cheng-Jung Lai</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rudi++Bao">Rudi Bao</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Changgeng++Qian">Changgeng Qian</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info"><span class="aff-text">Curis Inc., 45 Moulton Street, Cambridge, Massachusetts 02138</span></div><div class="corresp-info"><strong>*</strong>To whom correspondence should be addressed. Phone: 617-503-6656. Fax: 617-503-6501. E-mail: <a href="/cdn-cgi/l/email-protection#2e564d4f476e4d5b5c475d004d4143"><span class="__cf_email__" data-cfemail="2e564d4f476e4d5b5c475d004d4143">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm901453q&amp;href=/doi/10.1021%2Fjm901453q" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2010</span></span><span class="cit-volume">, 53</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 2000–2009</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 9, 2010</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>1 October 2009</li><li><span class="item_label"><b>Published</b> online</span>9 February 2010</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 11 March 2010</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm901453q" title="DOI URL">https://doi.org/10.1021/jm901453q</a></div><div class="article_header-article-copyright"><strong>Copyright © 2010 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2000%26pageCount%3D10%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DXiong%2BCai%252C%2BHai-Xiao%2BZhai%252C%2BJing%2BWang%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D53%26issueNum%3D5%26contentID%3Djm901453q%26title%3DDiscovery%2Bof%2B7-%25284-%25283-Ethynylphenylamino%2529-7-methoxyquinazolin-6-yloxy%2529-N-hydroxyheptanamide%2B%2528CUDC-101%2529%2Bas%2Ba%2BPotent%2BMulti-Acting%2BHDAC%252C%2BEGFR%252C%2Band%2BHER2%2BInhibitor%2Bfor%2Bthe%2BTreatment%2Bof%2BCancer%26numPages%3D10%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2009%26publicationDate%3DMarch%2B2010">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm901453q"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">7105</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">164</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm901453q" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Xiong&quot;,&quot;last_name&quot;:&quot;Cai&quot;},{&quot;first_name&quot;:&quot;Hai-Xiao&quot;,&quot;last_name&quot;:&quot;Zhai&quot;},{&quot;first_name&quot;:&quot;Jing&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Jeffrey&quot;,&quot;last_name&quot;:&quot;Forrester&quot;},{&quot;first_name&quot;:&quot;Hui&quot;,&quot;last_name&quot;:&quot;Qu&quot;},{&quot;first_name&quot;:&quot;Ling&quot;,&quot;last_name&quot;:&quot;Yin&quot;},{&quot;first_name&quot;:&quot;Cheng-Jung&quot;,&quot;last_name&quot;:&quot;Lai&quot;},{&quot;first_name&quot;:&quot;Rudi&quot;,&quot;last_name&quot;:&quot;Bao&quot;},{&quot;first_name&quot;:&quot;Changgeng&quot;,&quot;last_name&quot;:&quot;Qian&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2010&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;09&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;53&quot;,&quot;pages&quot;:&quot;2000-2009&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm901453q&quot;},&quot;abstract&quot;:&quot;By incorporating histone deacetylase (HDAC) inhibitory functionality into the pharmacophore of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) inhibitors, we synthesized a novel series of compounds with potent, multiacting HDAC, EGFR, and HER2 inhibition and identified 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide 8 (CUDC-101) as a drug candidate, which is now in clinical development. 8 displays potent in vitro inhibitory activity against HDAC, EGFR, and HER2 with an IC50 of 4.4, 2.4, and 15.7 nM, respectively. In most tumor cell lines tested, 8 exhibits efficient antiproliferative activity with greater potency than vorinostat (SAHA), erlotinib, lapatinib, and combinations of vorinostat/erlotinib and vorinostat/lapatinib. In vivo, 8 promotes tumor regression or inhibition in various cancer xenograft models including nonsmall cell lung cancer (NSCLC), liver, breast, head and neck, colon, and pancreatic cancers. These results sugges&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm901453q&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm901453q" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm901453q&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm901453q" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm901453q&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm901453q" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm901453q&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm901453q&amp;href=/doi/10.1021/jm901453q" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm901453q" /></input><a href="/doi/pdf/10.1021/jm901453q" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm901453q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm901453q%26sid%3Dliteratum%253Aachs%26pmid%3D20143778%26genre%3Darticle%26aulast%3DCai%26date%3D2010%26atitle%3DDiscovery%2Bof%2B7-%25284-%25283-Ethynylphenylamino%2529-7-methoxyquinazolin-6-yloxy%2529-N-hydroxyheptanamide%2B%2528CUDC-101%2529%2Bas%2Ba%2BPotent%2BMulti-Acting%2BHDAC%252C%2BEGFR%252C%2Band%2BHER2%2BInhibitor%2Bfor%2Bthe%2BTreatment%2Bof%2BCancer%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D53%26issue%3D5%26spage%3D2000%26epage%3D2009%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/53/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/medium/jm-2009-01453q_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901453q&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">By incorporating histone deacetylase (HDAC) inhibitory functionality into the pharmacophore of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) inhibitors, we synthesized a novel series of compounds with potent, multiacting HDAC, EGFR, and HER2 inhibition and identified 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-<i>N</i>-hydroxyheptanamide <b>8</b> (CUDC-101) as a drug candidate, which is now in clinical development. <b>8</b> displays potent in vitro inhibitory activity against HDAC, EGFR, and HER2 with an IC<sub>50</sub> of 4.4, 2.4, and 15.7 nM, respectively. In most tumor cell lines tested, <b>8</b> exhibits efficient antiproliferative activity with greater potency than vorinostat (SAHA), erlotinib, lapatinib, and combinations of vorinostat/erlotinib and vorinostat/lapatinib. In vivo, <b>8</b> promotes tumor regression or inhibition in various cancer xenograft models including nonsmall cell lung cancer (NSCLC), liver, breast, head and neck, colon, and pancreatic cancers. These results suggest that a single compound that simultaneously inhibits HDAC, EGFR, and HER2 may offer greater therapeutic benefits in cancer over single-acting agents through the interference with multiple pathways and potential synergy among HDAC and EGFR/HER2 inhibitors.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12675" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12675" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The human epidermal growth factor receptor (HER) family of receptor tyrosine kinases (RTKs<a class="ref internalNav" href="#fn1" aria-label="a">a</a><div class="NLM_fn" id="fn1">a<p class="last">Abbreviations: HDAC(s), histone deacetylase(s); RTKs, receptor tyrosine kinases; EGFR, epidermal growth factor receptor; HER, human epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; NSCLC, nonsmall cell lung cancer; HNSCC, head and neck squamous cell carcinoma; CTCL, cutaneous T-cell lymphoma; SAR, structure−activity relationship; HDLP, HDAC like protein; PK, pharmacokinetics; PD, pharmacodynamics; MTD, maximum tolerated dose; PDB, protein data bank.</p></div>) is recognized as a key mediator of cancer progression.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4">(1-4)</a> The HER tyrosine kinase family consists of four structurally related cellular receptors: the epidermal growth factor receptor (EGFR; HER1), HER2 (ErbB2), HER3 (ErbB3), and HER4.<a onclick="showRef(event, 'ref2 ref5'); return false;" href="javascript:void(0);" class="ref ref2 ref5">(2, 5)</a> The EGFR inhibitors erlotinib and gefitinib as well as the dual EGFR/HER2 inhibitor lapatinib (Chart <a class="ref internalNav" href="#cht1" aria-label="1">1</a>) are FDA-approved cancer drugs that are effective against multiple solid tumor cancers.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> However, their efficacy is restricted to a small subset of patients due to molecular heterogeneity among and within tumors.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7, 8)</a> Their effectiveness is also limited by the drug resistance that frequently emerges following treatment.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9, 10)</a></div><figure id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/medium/jm-2009-01453q_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Structure of Known Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901453q&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To overcome the low response rate and acquired resistance to RTK inhibitors, a number of strategies have been tested, including combination therapies and multitargeted inhibitors to inhibit multiple pathogenic pathways.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> One particularly promising approach is the modulation of RTK pathways by the inhibition of histone deacetylases (HDACs). HDACs comprise a family of 18 genes in humans and are divided into four classes.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Among them are the Class I (HDAC1, HDAC2, HDAC3, and HDAC8) and II (HDAC4, HDAC5, HDAC6, HDAC7, HDAC9, and HDAC10) zinc-containing hydrolases. HDAC inhibitors can impact a variety of cell functions by blocking the deacetylation of histone or nonhistone proteins, such as HSP90 and tubulin, causing cell cycle arrest, differentiation, and/or apoptosis.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> The HDAC inhibitor vorinostat (SAHA) (Chart <a class="ref internalNav" href="#cht1" aria-label="1">1</a>) is an FDA-approved drug for the treatment of cutaneous T-cell lymphoma (CTCL).<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></div><div class="NLM_p">HDAC inhibitors have also been shown to synergize with other agents, including RTK inhibitors, to suppress proliferation and induce apoptosis in tumor cells.<a onclick="showRef(event, 'ref15 ref16 ref17 ref18 ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17 ref18 ref19 ref20 ref21">(15-21)</a> In our own study, two reference compounds, vorinostat and erlotinib, were used to achieve HDAC and EGFR inhibition, respectively, and a well-established mathematical model for studying multidrug interactions<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> was applied to assess whether there is a synergistic effect between HDAC and RTK inhibition.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Using this mathematical model, IC50s of growth inhibition of several cancer cells treated with vorinostat, erlotinib, or their combination were compared, and combination indices were calculated to interpret the effect of concurrent inhibition of the HDAC and RTK targets. Our results show that cotreatment with vorinostat and erlotinib (1:1 ratio) results in greater growth inhibition and with combination indices well below 1, indicating considerable synergy between the inhibition of these two targets (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> Table S1). We also carried out similar studies by applying varying ratios of vorinostat and erlotinib. In all cases, the combination indices were calculated to be well below 1,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> indicating that the inhibition between these two targets is synergistic and that this synergy is not affected by the specific dosing ratio. This result suggests that a single molecule that simultaneously inhibits HDAC and RTK activities could act synergistically in treated cancer cells. With combined inhibitory activities and synergistic effects, such a multiacting single molecule may not only enhance drug efficacy but also overcome the current clinical limitations of EGFR/HER2 inhibitors, such as poor overall response rates and the rapid emergence of drug resistance. Unlike combinations of two or more EGFR/HER2 and HDAC inhibitors, a single agent with EGFR/HER2 and HDAC inhibitory activities offers key advantages, including concurrent pharmacokinetics, minimized off-target adverse effects, and drug−drug interactions caused by multiple agents, as well as increased patient compliance and reduced drug cost.</div><div class="NLM_p last">Investigating the structural requirements of EGFR/HER2 and HDAC inhibitors led us to design and synthesize a series of novel, potent multitargeted inhibitors. Here, we describe the design, synthesis, and structure−activity relationship (SAR) of these novel compounds and the identification of <b>8</b> (CUDC-101) as a clinical candidate currently in phase I clinical trials.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Compound Design</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51753" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51753" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Several EGFR, HER2, and HDAC inhibitors have been reported.<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23, 24)</a> These studies reveal hydroxamic acid as a broad class of HDAC inhibitors with high affinity for HDACs that depend on zinc chelation for their activity.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Additionally, quinazolines are a well-characterized scaffold of kinase inhibitors, including EGFR and HER2 inhibitors.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The X-ray cocrystal structures of EGFR with erlotinib and HDAC with vorinostat have been reported.<a onclick="showRef(event, 'ref24 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref24 ref27 ref28">(24, 27, 28)</a> Our compound design strategy was to fully analyze the structure requirements of these ligand−protein interactions and design our own novel multitargeted inhibitors through a structure-based rational drug design approach. It has been reported that erlotinib binds to the EGFR binding domain with quinazoline occupying the adenine region of the ATP binding site and forming two hydrogen bonds at N1 and N3, the phenyl-amino group occupying the hydrophobic pocket, and the two methoxy-ethoxy groups at C-6 and C-7 of the quinazoline ring sticking out of the receptor.<a onclick="showRef(event, 'ref24 ref27'); return false;" href="javascript:void(0);" class="ref ref24 ref27">(24, 27)</a> The cocrystal structure of trichostatin A (TSA) or vorinostat with HDLP (an HDAC-like protein) reveals that both compounds bind to HDLP with their large hydrophobic groups (phenyl) binding to the hydrophobic part of the enzyme, the aliphatic chain sitting in the 11 Å tube-like channel through multiple contacts with hydrophobic residues, and the terminal hydroxamic acid interacting with zinc at the active site to disrupt enzyme activity.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28, 29)</a> Since the methoxy-ethoxy groups extend outside of the EGFR binding pocket and are flexible, we reasoned that the modification of these side chains should not dramatically affect binding to EGFR. Through careful analysis of the ligand−protein interactions, we deduced that a group containing a side-chain of a certain length that terminates with a hydroxamic acid is essential for HDAC binding and that such a group is well-suited to be incorporated into the quinazoline-based EGFR/HER2 inhibitors. We predicted that the best place to introduce hydroxamic acid functionality without sacrificing EGFR/HER2 binding affinity is the site in which the methoxy-ethoxy groups of erlotinib are located (C-6 or C-7 of the quinazoline ring). We also predicted that the hydrophobic pocket within the HDAC dimeric interface should be large enough to accommodate the phenylaminoquinazoline backbone of EGFR/HER2 inhibitors, and that the incorporated side chain with the terminal hydroxamic acid should be able to reach the active site and interact with zinc as required to disrupt the HDAC enzyme activity. Therefore, to obtain and optimize HDAC, EGFR, and HER2 inhibitory activities in a single molecule, we incorporated hydroxamic acid functionality into the quinazoline pharmacophore of EGFR/HER2 inhibitors with a proper spacer, which served as a bridge to properly display HDAC and EGFR/HER2 inhibitory pharmacophores (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). This novel design strategy proved to be highly effective in producing single molecules with potent multiacting HDAC/EGFR/HER2 inhibition and low molecular weights.</div><figure id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/medium/jm-2009-01453q_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Design of multitargeted EGFR/HER2/HDAC inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901453q&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13702" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13702" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The preparation of analogues with various chain lengths and aniline substitution (<b>1</b>−<b>11</b>) is shown in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. Compounds <b>31</b>−<b>35</b> were prepared through the coupling of anilines <b>27</b>−<b>30</b> with either quinazolines <b>25</b><a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> or <b>26</b>.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Hydrolysis of the acetyl group on C-6 of compounds <b>31</b>−<b>35</b> using lithium hydroxide gave corresponding C6-OH quinazolines <b>36</b>−<b>40</b>. Alkylation of the C6-OH of <b>36</b>−<b>40</b> with various chain lengths of ethyl or methyl bromoalkanoate yielded ester products <b>41</b>−<b>51</b>. Conversion of esters <b>41</b>−<b>51</b> to hydroxamic acids using freshly prepared hydroxylamine yielded final compounds <b>1</b>−<b>11</b>. Alternatively, these compounds may be prepared by installing the ester side chain prior to constructing the quinazoline core as shown in Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>. This process is more suited to the synthesis of certain analogues and is easy to scale up. Compound <b>52</b> was treated with iodomethane or 2-methoxyethyl-4-methylbenzenesulfonate to give corresponding intermediates <b>53</b> and <b>54</b>. Alkylation of <b>53</b> and <b>54</b> with ethyl 7-bromoheptanoate gave intermediates <b>55</b> and <b>56</b>, which were then treated with fuming nitric acid to introduce a nitro group onto the phenyl ring to yield <b>57</b> and <b>58</b>. Reduction of nitro compounds <b>57</b> and <b>58</b> with iron/hydrochloric acid gave corresponding amines <b>59</b> and <b>60</b>. Cyclization of <b>59</b> and <b>60</b> using formamide and ammonium formate gave quinazoline intermediates <b>61</b> and <b>62</b>. Chlorination of <b>61</b> and <b>62</b> using phosphoryl chloride yielded the desired intermediates <b>63</b> and <b>64</b>. The coupling of <b>63</b> and <b>64</b> with <b>27</b> and <b>28</b> gave corresponding esters <b>48</b> and <b>65</b>, which were finally reacted with freshly prepared hydroxylamine to form final product <b>8</b> and <b>12</b>, respectively.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/medium/jm-2009-01453q_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901453q&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) Isopropanol, reflux; (b) LiOH, CH<sub>3</sub>OH, H<sub>2</sub>O; (c) ethyl or methyl bromoalkanoate, K<sub>2</sub>CO<sub>3</sub>, 40 °C; (d) NH<sub>2</sub>OH, CH<sub>3</sub>OH, 0 °C to rt.</p></p></figure><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/medium/jm-2009-01453q_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901453q&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) CH<sub>3</sub>I or 2-methyoxyethyl-4-methylbenzenesulfonate, K<sub>2</sub>CO<sub>3</sub>, DMF; (b) ethyl 7-bromoheptanoate, K<sub>2</sub>CO<sub>3</sub>, DMF, 60 °C; (c) HNO<sub>3</sub>, HOAc, 20 °C; (d) Fe, HCl, EtOH, H<sub>2</sub>O, reflux; (e) HCONH<sub>2</sub>, HCOONH<sub>4</sub>, 180 °C; (f) PCl<sub>3</sub>, reflux; (g) <b>27</b> or <b>28</b>, isopropanol, reflux; (h) NH<sub>2</sub>OH, CH<sub>3</sub>OH, 0 °C to rt.</p></p></figure><div class="NLM_p">The preparation of amide linker compound <b>13</b> is shown in Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>. Conversion of the chloro group of <b>66</b> to the methoxy group using in situ formed sodium methoxide gave the corresponding methoxy compound <b>67</b>. Treatment of <b>67</b> with phosphoryl chloride gave the chloride <b>68</b>. Coupling of <b>68</b> with <b>27</b> gave nitro compound <b>69</b>. Reduction of <b>69</b> with iron/hydrochloric acid gave the corresponding amine <b>70</b>. Coupling of <b>70</b> with methyl 5-chloro-5-oxopentanoate yielded amide <b>71</b>. Final compound <b>13</b> was obtained by the treatment of <b>71</b> with freshly prepared hydroxylamine.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/medium/jm-2009-01453q_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901453q&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) Na, CH<sub>3</sub>OH, sealed tube; (b) POCl<sub>3</sub>, reflux; (c) <b>27</b>, isopropanol, reflux; (d) Fe, HCl, EtOH, H<sub>2</sub>O, reflux; (e) methyl 5-chloro-5-oxopentanoate, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>; (f) NH<sub>2</sub>OH, CH<sub>3</sub>OH, 0 °C to rt.</p></p></figure><div class="NLM_p">The sulfur and sulfone-linked side chain compounds <b>14</b> and <b>15</b> were synthesized according to Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>. Conversion of amino group of <b>70</b> to iodo group was achieved by first forming a diazonium salt and subsequently reacting it with cuprous iodide to yield compound <b>72</b>. Treatment of compound <b>72</b> with thiobenzoic acid gave compound <b>73</b>. Hydrolysis of the thioester <b>73</b> using potassium carbonate generated free thio compound, which was then reacted with ethyl 7-bromoheptanoate to give compound <b>74</b>. Oxidation of <b>74</b> with KMNO<sub>4</sub> gave the sulfone intermediate <b>75</b>. Final hydroxamic acid compounds <b>14</b> and <b>15</b> were obtained by reacting esters <b>74</b> and <b>75</b> with freshly prepared hydroxylamine, respectively.</div><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/medium/jm-2009-01453q_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901453q&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) NaNO<sub>2</sub>, H<sub>2</sub>SO<sub>4</sub>, AcOH, KI; (b) thiobenzoic acid, 1,10-phenathroline, CuI, DIPEA, toluene, 110 °C; (c) ethyl 7-bromoheptanoate, K<sub>2</sub>CO<sub>3</sub>, DMF, 50 °C; (d) KMnO<sub>4</sub>, CH<sub>3</sub>CN, H<sub>2</sub>O, 65 °C; (e) NH<sub>2</sub>OH, CH<sub>3</sub>OH, 0 °C to rt.</p></p></figure><div class="NLM_p">The synthesis of the benzylamine series of analogues <b>16</b>−<b>22</b> is shown in Scheme <a class="ref internalNav" href="#sch5" aria-label="5">5</a>. Compounds <b>83</b>−<b>89</b> were synthesized by the coupling of compound <b>25</b> with commercially available amines <b>76</b>−<b>82.</b> In the reaction condition, the C-6 acetyl group was cleaved to form C-6 OH. Alkylation of the C-6 OH of <b>83</b>−<b>89</b> with ethyl 7-bromoheptanoate gave compounds <b>90</b>−<b>96</b>. Final hydroxamic acids <b>16</b>−<b>22</b> were prepared through the conversion of esters <b>90</b>−<b>96</b> using freshly prepared hydroxylamine.</div><figure id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/medium/jm-2009-01453q_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901453q&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) Isopropanol, 60 °C; (b) ethyl 7-bromoheptanoate, K<sub>2</sub>CO<sub>3</sub>, DMF, 60 °C; (c) NH<sub>2</sub>OH, CH<sub>3</sub>OH, 0 °C to rt.</p></p></figure><div class="NLM_p">The preparation of position analogues <b>23</b> and <b>24</b> is shown in Scheme <a class="ref internalNav" href="#sch6" aria-label="6">6</a>. Alkylation of the C-4 OH of <b>52</b> with ethyl 7-bromoheptanoate gave compound <b>97</b>. Methylation of the C-3 OH of <b>97</b> using iodomethane gave compound <b>98</b>. Introduction of a nitro group onto compound <b>98</b> to form compound <b>99</b> was accomplished by treating <b>98</b> with fuming HNO<sub>3</sub> and AcOH. Reduction of <b>99</b> using iron/hydrochloric acid gave its corresponding amine <b>100</b>. Cyclization of <b>100</b> using formamide and ammonium formate gave the quinazoline intermediate <b>101</b>. Chlorination of <b>101</b> using phosphoryl chloride gave intermediate <b>102</b>. Coupling of <b>102</b> with anilines <b>27</b> and <b>28</b> yielded compounds <b>103</b> and <b>104</b>, respectively. Treatment of <b>103</b> and <b>104</b> with freshly prepared hydroxylamine gave the final position analogues <b>23</b> and <b>24</b>.</div><figure id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/medium/jm-2009-01453q_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901453q&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) Ethyl 7-bromoheptanoate, K<sub>2</sub>CO<sub>3</sub>, DMF; (b) CH<sub>3</sub>I, K<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C; (c) HNO<sub>3</sub>, AcOH, 20 °C; (d) Fe, HCl, EtOH, reflux; (e) HCONH<sub>2</sub>, HCOONH<sub>4</sub>, 180 °C; (f) POCl<sub>3</sub>, reflux; (g) <b>27</b> or <b>28</b>, isopropanol, reflux; (h) NH<sub>2</sub>OH, CH<sub>3</sub>OH, 0 °C to rt.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00350" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00350" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">To study structure−activity relationships, compounds were evaluated in EGFR and HER2 kinase activity assays, as well as an HDAC enzyme assay. For the purpose of SAR analysis, all compounds were assigned to four groups including chain length and phenyl ring substitution analogues, quinazoline ring substitution analogues, benzylamine analogues, and position analogues. The in vitro enzymatic inhibition assay results of these four types of compounds are summarized in Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>−<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Structure and In Vitro Activity of Chain Length and Ring Substitution Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/medium/jm-2009-01453q_0010.gif" alt="" id="_i13" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/medium/jm-2009-01453q_0011.gif" alt="" id="_i14" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Synthesized in-house.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">HDAC inhibitory activity was determined using the Biomol Color de Lys system.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">EGFR and HER2 kinase activity was measured using HTScan EGF receptor and HER2 kinase assay kits (Cell Signaling Technology).</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Structure and In Vitro Activity of Quinazoline Ring Substitution Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/medium/jm-2009-01453q_0012.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top"><th align="left"> </th><th align="left"> </th><th align="left"> </th><th colspan="3" align="center" char=".">IC<sub>50</sub> (nM) in enzyme assays</th></tr><tr valign="top"><th align="center">compd</th><th align="center">X</th><th align="center">R<sub>3</sub></th><th align="center" char=".">HDAC<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th align="center" char=".">EGFR<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th align="center" char=".">HER2<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top"><td align="left"><b>7</b></td><td align="left">O</td><td align="left">CH<sub>3</sub>O-</td><td align="char" char=".">6.5</td><td align="char" char=".">3.1</td><td align="char" char=".">19.0</td></tr><tr valign="top"><td align="left"><b>11</b></td><td align="left">O</td><td align="left">H-</td><td align="char" char=".">4.4</td><td align="char" char=".">84.2</td><td align="char" char=".">43.5</td></tr><tr valign="top"><td align="left"><b>12</b></td><td align="left">O</td><td align="left">CH<sub>3</sub>OCH<sub>2</sub>CH<sub>2</sub>O-</td><td align="char" char=".">8.4</td><td align="char" char=".">10.4</td><td align="char" char=".">24.0</td></tr><tr valign="top"><td align="left"><b>13</b></td><td align="left">CONH</td><td align="left">CH<sub>3</sub>O-</td><td align="char" char=".">15.3</td><td align="char" char=".">2.1</td><td align="char" char=".">20.1</td></tr><tr valign="top"><td align="left"><b>14</b></td><td align="left">S</td><td align="left">CH<sub>3</sub>O-</td><td align="char" char=".">39.6</td><td align="char" char=".">1.99</td><td align="char" char=".">24.2</td></tr><tr valign="top"><td align="left"><b>15</b></td><td align="left">SO<sub>2</sub></td><td align="left">CH<sub>3</sub>O-</td><td align="char" char=".">121.7</td><td align="char" char=".">15.4</td><td align="char" char=".">>2000</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">HDAC inhibitory activity was determined using the Biomol Color de Lys system.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">EGFR and HER2 kinase activity was measured using HTScan EGF receptor and HER2 kinase assay kits (Cell Signaling Technology).</p></div></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Structure and In Vitro Activity of Right-Side Phenyl Ring Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/medium/jm-2009-01453q_0013.gif" alt="" id="fx4" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top"><th align="left"> </th><th align="left"> </th><th align="left"> </th><th align="left"> </th><th colspan="3" align="center" char=".">IC<sub>50</sub> (nM) in Enzyme Assays</th></tr><tr valign="top"><th align="center">compd</th><th align="center">Y</th><th align="center">R<sub>1</sub></th><th align="center">R<sub>2</sub></th><th align="center" char=".">HDAC<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th align="center" char=".">EGFR<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th align="center" char=".">HER2<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top"><td align="left"><b>7</b></td><td align="left">direct bond</td><td align="left">F</td><td align="left">Cl</td><td align="char" char=".">6.5</td><td align="char" char=".">3.1</td><td align="char" char=".">19.0</td></tr><tr valign="top"><td align="left"><b>16</b></td><td align="left">CH<sub>2</sub></td><td align="left">F</td><td align="left">Cl</td><td align="char" char=".">11.3</td><td align="char" char=".">72.0</td><td align="char" char=".">478.2</td></tr><tr valign="top"><td align="left"><b>17</b></td><td align="left">CH<sub>2</sub></td><td align="left">H</td><td align="left">H</td><td align="char" char=".">4.2</td><td align="char" char=".">99.4</td><td align="char" char=".">225.2</td></tr><tr valign="top"><td align="left"><b>18</b></td><td align="left">CH<sub>2</sub></td><td align="left">F</td><td align="left">H</td><td align="char" char=".">5.6</td><td align="char" char=".">268.0</td><td align="char" char=".">295.4</td></tr><tr valign="top"><td align="left"><b>19</b></td><td align="left">(S)-CHCH<sub>3</sub></td><td align="left">H</td><td align="left">H</td><td align="char" char=".">25.7</td><td align="char" char=".">5077.0</td><td align="char" char=".">>2000</td></tr><tr valign="top"><td align="left"><b>20</b></td><td align="left">(R)-CHCH<sub>3</sub></td><td align="left">H</td><td align="left">H</td><td align="char" char=".">98.4</td><td align="char" char=".">12.8</td><td align="char" char=".">27.8</td></tr><tr valign="top"><td align="left"><b>21</b></td><td align="left">(R)-CHCH<sub>3</sub></td><td align="left">F</td><td align="left">H</td><td align="char" char=".">165.3</td><td align="char" char=".">125.6</td><td align="char" char=".">175.0</td></tr><tr valign="top"><td align="left"><b>22</b></td><td align="left">(R)-CHCH<sub>3</sub></td><td align="left">Cl</td><td align="left">H</td><td align="char" char=".">188.0</td><td align="char" char=".">614.0</td><td align="char" char=".">556.9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">HDAC inhibitory activity was determined using the Biomol Color de Lys system.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">EGFR and HER2 kinase activity was measured using HTScan EGF receptor and HER2 kinase assay kits (Cell Signaling Technology).</p></div></div></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Structure and In Vitro Activity of Side Chain Position Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/medium/jm-2009-01453q_0014.gif" alt="" id="fx5" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top"><th align="left"> </th><th align="left"> </th><th align="left"> </th><th colspan="3" align="center" char=".">IC<sub>50</sub> (nM) in enzyme assays</th></tr><tr valign="top"><th align="center">compd</th><th align="center">R1</th><th align="center">R2</th><th align="center" char=".">HDAC<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th align="center" char=".">EGFR<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th align="center" char=".">HER2<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top"><td align="left"><b>7</b></td><td align="left">F</td><td align="left">Cl</td><td align="char" char=".">6.5</td><td align="char" char=".">3.1</td><td align="char" char=".">19.0</td></tr><tr valign="top"><td align="left"><b>23</b></td><td align="left">F</td><td align="left">Cl</td><td align="char" char=".">66.6</td><td align="char" char=".">7.0</td><td align="char" char=".">71.2</td></tr><tr valign="top"><td align="left"><b>8</b></td><td align="left">H</td><td align="left">C≡CH</td><td align="char" char=".">4.4</td><td align="char" char=".">2.4</td><td align="char" char=".">15.7</td></tr><tr valign="top"><td align="left"><b>24</b></td><td align="left">H</td><td align="left">C≡CH</td><td align="char" char=".">34.1</td><td align="char" char=".">8.2</td><td align="char" char=".">51.6</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">HDAC inhibitory activity was determined using the Biomol Color de Lys system.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">EGFR and HER2 kinase activity was measured using HTScan EGF receptor and HER2 kinase assay kits (Cell Signaling Technology).</p></div></div></div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Chain Length and Phenyl Ring Substitution Analogues (<b>1</b>−<b>10</b>, Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>)</h3><div class="NLM_p last">Our data suggest that increasing the length of the hydroxamic acid side chain increases HDAC inhibitory activity. The short chain analogues (compounds <b>1</b> and <b>2</b>) have weak HDAC inhibitory activity. Appreciable HDAC inhibition was observed only when the carbon chain length between the quinazoline C-6 oxygen and the hydroxamic acid carbonyl group reached four carbons (<i>n</i> = 3) (compounds <b>3</b> and <b>4</b>). The HDAC inhibitory activity further increased with a carbon chain length of five carbons (<i>n</i> = 4) (compounds <b>5</b> and <b>6</b>). The optimal carbon chain length is six (<i>n</i> = 5), which gives an IC<sub>50</sub> of HDAC inhibition in the single-digit nanomolar range (compounds <b>7</b>, <b>8</b>, and <b>9</b>). Small substituents on the phenyl ring do not affect the HDAC inhibitory activity, but a large group, such as 3-fluorophenylmethoxy decreases potency of HDAC inhibition (<b>10</b>, IC<sub>50</sub> = 58.1 nM). These results suggest that the length of the hydroxamic acid side chain is important for HDAC inhibition. In contrast, EGFR and HER2 inhibition were largely unaffected by the change in carbon chain length and phenyl ring substitution (EGFR inhibition IC<sub>50</sub> = 2.4 nM − 15.1 nM; HER2 inhibition IC<sub>50</sub> = 10.1 nM − 38.4 nM) with the exception of compound <b>9</b>, which had relatively low inhibitory activities against EGFR (IC<sub>50</sub> = 28.8 nM) and HER2 (IC<sub>50</sub> = 76.5 nM). These data suggest that the side chain on the quinazoline ring and substitution on the phenyl ring are not critical for EGFR/HER2 inhibition, and that the optimal carbon chain length to achieve maximum inhibitory activities against HDAC and EGFR/HER2 is six carbons (<i>n</i> = 5). Among four six-carbon chain (<i>n</i> = 5) compounds (<b>7</b>, <b>8</b>, <b>9</b>, <b>10</b>), <b>7</b> and <b>8</b> are more promising, with potent inhibitory activities against all three targets, HDAC, EGFR, and HER2. Compared with reference compounds, <b>7</b> and <b>8</b> inhibit HDAC and EGFR activity with higher potency than vorinostat and erlotinib (or lapatinib), respectively. Moreover, <b>7</b> and <b>8</b> exhibit greater or equal potency of HER2 inhibition compared to erlotinib or lapatinib, respectively.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Quinazoline Ring Substitution Analogues (<b>7</b>,<b>11−15</b>, Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>)</h3><div class="NLM_p last">Keeping the optimal carbon chain length of six (<i>n</i> = 5), our next step was to examine the influence of C-7 substitution (R<sub>3</sub>) and the C-6 oxygen atom of the quinazoline ring on inhibitory activities. When X is an oxygen, varying R<sub>3</sub> does not affect HDAC inhibition (all such compounds displayed a single-digit nanomolar IC<sub>50</sub>), while the potency of EGFR or HER2 inhibition has the following order: OCH<sub>3</sub> (compound <b>7</b>) > OCH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub> (compound <b>12</b>) > H (compound <b>11</b>). When R<sub>3</sub> is fixed to be OCH<sub>3</sub>, the linker X does affect HDAC, EGFR, and HER2 inhibitory activities. For HDAC inhibition, an oxygen linker (compound <b>7</b>) is more potent than an amide linker (compound <b>13</b>), which is more potent than a sulfur linker (compound <b>14</b>), while a sulfone linker <b>15</b> has lowest potency. For EGFR and HER2 inhibition, <b>7</b>, <b>13</b>, and <b>14</b> have similar potency, but sulfone linker <b>15</b> showed reduced potency in EGFR inhibition (IC<sub>50</sub> = 15.4 nM) and greatly reduced HER2 inhibition (IC<sub>50</sub> > 2000 nM).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Benzylamine Analogues (<b>16</b>−<b>22</b>, Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>)</h3><div class="NLM_p last">Unlike the aniline analogues discussed earlier, the benzylamine series disrupted the conjugation of the quinazoline ring with the phenyl ring. The HDAC inhibition drops to half when changing aniline (<b>7</b>, IC<sub>50</sub> = 6.5 nM) to benzylamine (<b>16</b>, IC<sub>50</sub> = 11.3 nM), but is restored when R<sub>1</sub> and R<sub>2</sub> are both H (<b>17</b>, IC<sub>50</sub> = 4.2 nM) or R<sub>1</sub> is F and R<sub>2</sub> is H (<b>18</b>, IC<sub>50</sub> = 5.6 nM). When a methyl group is added onto the benzylamine methelene of compound <b>17</b> to create a pair of enantiomers, the S isomer shows a 6-fold drop (<b>19</b>, IC<sub>50</sub> = 25.7 nM) and the R isomer shows a 23-fold drop (<b>20</b>, IC<sub>50</sub> = 98.4 nM) in HDAC inhibition compared to <b>17</b>. When changing H on R<sub>1</sub> of compound <b>20</b> to F (<b>21</b>) or Cl (<b>22</b>), an additional 1.5- to 2-fold drop of HDAC inhibition is observed compared to compound <b>20</b>. For EGFR and HER2 inhibition, the replacement of aniline (<b>7</b>) with benzylamine (<b>16</b>) resulted in a more than 20-fold drop in EGFR and HER2 inhibition. Unlike HDAC inhibition, the R isomers (<b>20</b>, <b>21</b>, and <b>22</b>) all have much higher EGFR and HER2 inhibitory activities than the S-isomer (<b>19</b>), which shows very weak inhibitory activity against EGFR (IC<sub>50</sub> = 5077 nM) and HER2 (IC<sub>50</sub> >2000 nM). Among the three R isomers, the potency of EGFR and HER2 inhibition is related to the phenyl ring substitution and has the following order: unsubstituted <b>20</b> > monofluoro-substituted <b>21</b> > monochloro-substituted <b>22</b>. Overall, the changing of an aniline to a benzylamine resulted in less potent compounds.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Position Analogues (<b>7</b>, <b>8</b>, <b>23</b>, <b>24</b>, Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>)</h3><div class="NLM_p">To investigate the effect of the hydroxamic acid side chain position on inhibitory activities, we synthesized <b>23</b> (a position analogue of <b>7</b>) and <b>24</b> (a position analogue of <b>8</b>). Compound <b>23</b> showed a 10-fold drop in HDAC inhibition, a 2.2-fold drop in EGFR inhibition, and a 3.5-fold drop in HER2 inhibition compared to <b>7</b>. Similarly, compound <b>24</b> showed a 8-fold drop in HDAC inhibition, a 3.4-fold drop in EGFR inhibition, and a 3.3-fold drop in HER2 inhibition compared to compound <b>8</b>.</div><div class="NLM_p">The SAR study led to the identification of compound <b>7</b> and <b>8</b> as the most potent compounds in inhibiting HDAC, EGFR, and HER2. In addition, these two compounds display balanced inhibitory activities against all three targets, a desirable feature for a multitargeted inhibitor. We further evaluated these two compounds, along with other selected compounds from the above SAR studies, for their antiproliferative effects on tumor cells. In NSCLC, liver, breast, and pancreatic cancer cell lines, compound <b>8</b> consistently exhibits greater potency than compound <b>7</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>). Compound <b>8</b> was further evaluated in a series of in vitro cell-based assays, selectivity assays, in vivo efficacy models and PK/PD, metabolism, and toxicology studies.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Here, we describe the salient properties of this compound.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Inhibition of Proliferation in Selected Human Cancer Cell Lines by Compound <b>8</b>, <b>7</b>, and Reference Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top"><th align="left"> </th><th align="left"> </th><th colspan="7" align="center" char=".">IC<sub>50</sub> (uM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th></tr><tr valign="top"><th align="center">cancer type</th><th align="center">cell line</th><th align="center" char="."><b>8</b></th><th align="center" char="."><b>7</b></th><th align="center" char=".">vorinostat</th><th align="center" char=".">erlotinib</th><th align="center" char=".">vorinostat + erlotinib</th><th align="center" char=".">lapatinib</th><th align="center" char=".">vorinostat + lapatinib</th></tr></thead><tbody><tr valign="top"><td align="left">NSCLC</td><td align="left">HCC827</td><td align="char" char=".">0.60</td><td align="char" char=".">0.93</td><td align="char" char=".">1.80</td><td align="char" char=".">7.50</td><td align="char" char=".">2.3</td><td align="char" char="."> </td><td align="char" char="."> </td></tr><tr valign="top"><td align="left">NSCLC</td><td align="left">H358</td><td align="char" char=".">0.40</td><td align="char" char=".">0.71</td><td align="char" char=".">2.50</td><td align="char" char=".">6.00</td><td align="char" char=".">1.10</td><td align="char" char="."> </td><td align="char" char="."> </td></tr><tr valign="top"><td align="left">NSCLC</td><td align="left">H460</td><td align="char" char=".">0.70</td><td align="char" char=".">0.90</td><td align="char" char=".">1.70</td><td align="char" char=".">8.20</td><td align="char" char=".">1.40</td><td align="char" char="."> </td><td align="char" char="."> </td></tr><tr valign="top"><td align="left">Liver</td><td align="left">HepG2</td><td align="char" char=".">0.13</td><td align="char" char=".">0.29</td><td align="char" char=".">1.66</td><td align="char" char=".">>20</td><td align="char" char=".">1.95</td><td align="char" char=".">6.27</td><td align="char" char=".">1.23</td></tr><tr valign="top"><td align="left">Liver</td><td align="left">Hep3B2</td><td align="char" char=".">0.23</td><td align="char" char=".">0.60</td><td align="char" char=".">2.44</td><td align="char" char=".">>20</td><td align="char" char=".">2.64</td><td align="char" char=".">5.49</td><td align="char" char=".">2.36</td></tr><tr valign="top"><td align="left">Liver</td><td align="left">Sk-Hep-1</td><td align="char" char=".">0.22</td><td align="char" char=".">0.33</td><td align="char" char=".">3.46</td><td align="char" char=".">10.37</td><td align="char" char=".">3.97</td><td align="char" char=".">5.30</td><td align="char" char=".">1.50</td></tr><tr valign="top"><td align="left">Pancreatic</td><td align="left">Capan1</td><td align="char" char=".">0.80</td><td align="char" char=".">1.73</td><td align="char" char=".">7.30</td><td align="char" char=".">>20</td><td align="char" char=".">4.40</td><td align="char" char="."> </td><td align="char" char="."> </td></tr><tr valign="top"><td align="left">Pancreatic</td><td align="left">BxPc3</td><td align="char" char=".">0.27</td><td align="char" char=".">0.38</td><td align="char" char=".">2.70</td><td align="char" char=".">7.60</td><td align="char" char=".">1.00</td><td align="char" char="."> </td><td align="char" char="."> </td></tr><tr valign="top"><td align="left">Breast</td><td align="left">MCF-7</td><td align="char" char=".">0.55</td><td align="char" char=".">1.10</td><td align="char" char=".">2.80</td><td align="char" char=".">>20</td><td align="char" char=".">2.70</td><td align="char" char=".">6.60</td><td align="char" char=".">2.60</td></tr><tr valign="top"><td align="left">Breast</td><td align="left">MDA-MB-231</td><td align="char" char=".">0.10</td><td align="char" char=".">0.37</td><td align="char" char=".">2.11</td><td align="char" char=".">>20</td><td align="char" char=".">2.00</td><td align="char" char=".">5.40</td><td align="char" char=".">1.80</td></tr><tr valign="top"><td align="left">Breast</td><td align="left">Sk-Br-3</td><td align="char" char=".">0.04</td><td align="char" char=".">0.17</td><td align="char" char=".">1.19</td><td align="char" char=".">1.56</td><td align="char" char=".">0.90</td><td align="char" char=".">0.04</td><td align="char" char=".">0.05</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Cancer cell lines were plated at 5000 to 10 000 cells per well in 96-well flat-bottomed plates with varying concentrations of compounds. The cells were incubated with compounds for 72 h in the presence of 0.5% of fetal bovine serum. Growth inhibition was assessed by an adenosine triphosphate (ATP) content assay using the Perkin-Elmer (Waltham, MA) ATPlite kit.</p></div></div></div><div class="NLM_p">In vitro, <b>8</b> inhibits both class I and class II HDACs (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> Table S2), but not class III, Sir-type HDACs (data not shown). <b>8</b> displays broad antiproliferative activity in many human cancer cell types and in most cases has a higher potency than erlotinib, lapatinib, and combinations of vorinostat with either erlotinib or lapatinib (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>).<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a><b>8</b> is a potent and selective HDAC, EGFR, and HER2 inhibitor with only weak inhibition of the following protein kinases (IC<sub>50</sub>): KDR (VEGFR2) (849 nM), Src (11000 nM), Lyn (840 nM), Lck (5910 nM), Abl-1 (2890 nM), FGFR-2 (3430 nM), Flt-3 (1500 nM), and Ret (3200 nM).</div><div class="NLM_p">In vivo, <b>8</b> induces tumor regression in the Hep-G2 liver cancer model and is more efficacious than erlotinib at its maximum tolerated dose (MTD)<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and vorinostat at an equimolar concentration dose (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>, Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). <b>8</b> is also highly efficacious in a number of other xenograft models (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). In the erlotinib-resistant A549 NSCLC xenograft model, <b>8</b> shows potent inhibition of tumor growth. In the erlotinib-sensitive H358 NSCLC models, <b>8</b> inhibits tumor growth in a dose-dependent manner. <b>8</b> causes significant tumor regression in the lapatinib-resistant, HER2-negative, EGFR-overexpressing MDA-MB-468 breast cancer model and the EGFR-overexpressing CAL-27 head and neck squamous cell carcinoma (HNSCC) model. <b>8</b> also inhibits tumor growth in the K-ras mutant HCT116 colorectal and EGFR/HER2 (neu)-expressing HPAC pancreatic cancer models.</div><figure id="fig2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/medium/jm-2009-01453q_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. <b>8</b>, dosed at 120 mg/kg, iv, daily, induced tumor regression in the Hep-G2 liver cancer model and was more efficacious than erlotinib at its maximum tolerated dose (MTD, 25 mg/kg, po, daily) and vorinostat at an equimolar concentration (72 mg/kg, iv, daily).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901453q&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. In Vivo Efficacy of Compound <b>8</b> in Mice Human Tumor Xenograft Models</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top"><th align="center">cancer type</th><th align="center">cell line</th><th align="center">dosing schedule<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th align="center" char=".">T/C % or regression (−)<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top"><td align="left">NSCLC</td><td align="left">H358</td><td align="left"><b>8</b>, 15 mg/kg</td><td align="char" char=".">41.9</td></tr><tr valign="top"><td align="left"> </td><td align="left"> </td><td align="left"><b>8</b>, 30 mg/kg</td><td align="char" char=".">10.3</td></tr><tr valign="top"><td align="left"> </td><td align="left"> </td><td align="left"><b>8</b>, 60 mg/kg</td><td align="char" char=".">6.5</td></tr><tr valign="top"><td align="left"> </td><td align="left">A549</td><td align="left"><b>8</b>, 120 mg/kg</td><td align="char" char=".">35.9</td></tr><tr valign="top"><td align="left">breast</td><td align="left">MDA-MB468</td><td align="left"><b>8</b>, 120 mg/kg</td><td align="char" char=".">−13.7</td></tr><tr valign="top"><td align="left"> </td><td align="left"> </td><td align="left">Lapatinib,75 mg/kg</td><td align="char" char=".">51.0</td></tr><tr valign="top"><td align="left">colon</td><td align="left">HCT116</td><td align="left"><b>8</b>, 60 mg/kg</td><td align="char" char=".">35.3</td></tr><tr valign="top"><td align="left">HNSCC</td><td align="left">CAL-27</td><td align="left"><b>8</b>, 120 mg/kg</td><td align="char" char=".">−36.5</td></tr><tr valign="top"><td align="left">liver</td><td align="left">HepG2</td><td align="left"><b>8</b>, 120 mg/kg</td><td align="char" char=".">−21.3</td></tr><tr valign="top"><td align="left"> </td><td align="left"> </td><td align="left">Erlotinib, 25 mg/kg</td><td align="char" char=".">50.8</td></tr><tr valign="top"><td align="left"> </td><td align="left"> </td><td align="left">Vorinostat, 72 mg/kg</td><td align="char" char=".">26.0</td></tr><tr valign="top"><td align="left">pancreatic</td><td align="left">HPAC</td><td align="left"><b>8</b>, 120 mg/kg</td><td align="char" char=".">35.1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">Compound <b>8</b> was dosed iv, daily, except in the H358 NSCLC model, where <b>8</b> was dosed iv on 7−6−5 (on−off−on) schedule, and in HCT116 colorectal cancer model, <b>8</b> was dosed iv on 5−2−5 (on−off−on) schedule. Lapatinib was dosed po, bid. Erlotinib was dosed po, daily, and vorinostat was dosed iv, daily.</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last">During each animal study, tumors were measured with calipers, tumor size determined using the formula: tumor volume = (length × width<sup>2</sup>)/2, and tumor size changes in percent calculated. In most cases, % <i>T</i>/<i>C</i> values were calculated using the following formula: % <i>T</i>/<i>C</i> = 100 × Δ<i>T</i>/Δ<i>C</i> if Δ<i>T</i> > 0, where <i>T</i>/<i>C</i> is the tumor size change ratio in treated animals (<i>T</i>) and control animals (<i>C</i>), Δ<i>T</i> is the tumor size change in treated animal between last tumor size measurement and predosing (<i>T</i><sub>0</sub>) tumor size measurement, Δ<i>C</i> is the tumor size change in control animal between last tumor size measurement and predosing tumor size measurement. In cases where tumor regression occurred (Δ<i>T</i> < 0), however, the following formula was used: % <i>T</i>/<i>T</i><sub>0</sub> = 100 × Δ<i>T</i>/<i>T</i><sub>0</sub>, where <i>T</i>/<i>T</i><sub>0</sub> is the tumor size change ratio in treated animal. Values of <42% are considered significant.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></p></div></div></div><div class="NLM_p">Our studies on the mechanism of action suggest that <b>8</b> may overcome drug resistance via the sustained blockade of survival pathways. We have demonstrated that besides EGFR and HER2 inhibition, <b>8</b> also suppresses HER3 expression, Met amplification, and AKT reactivation in tumor cells.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><div class="NLM_p last">In conclusion, compound <b>8</b> is a potent HDAC, EGFR, and HER2 inhibitor with favorable drug-like properties. It also displays a favorable preclinical safety profile (data not shown). Its simultaneous blockade of HDAC and RTK pathways represents a novel approach to cancer therapy and may provide high efficacy and overcome limitations in the treatment of certain cancers with RTK inhibitors. Therefore, compound <b>8</b> has advanced to clinical development as a novel anticancer agent.</div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74650" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74650" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Chemistry</h3><div class="NLM_p last">Anhydrous solvents and other solvents were purchased from commercial suppliers. All other chemicals were from commercial suppliers and used without further purification. <sup>1</sup>H NMR spectra were recorded on a Bruker AVANCE III 400 MHz or Varian Mercury-VX-300 300 MHz NMR spectrometer at ambient temperature and proton chemical shifts are relative to TMS as an internal standard. Melting points were determined on a X-4 micromelting point apparatus in microscope slides and cover glass, or a WRS-1B digital melting point apparatus in an open capillary tube and are uncorrected (both melting point apparatuses were manufactured by Shanghai Precision & Scientific Instrument Co., Ltd.).</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> LCMS</h3><div class="NLM_p last">The purity of the compounds was analyzed by reversed-phase liquid chromatography and mass spectrometry (Agilent 6110 quadruple ion trap mass spectrometer or Shimadzu LCMS-2010EV chromatograph mass spectrometer) with a UV detector at 214 and 254 nm and electrospray ionization source (ESI) as described in further detail in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>. All final compounds (<b>1</b>−<b>24</b>) were assayed by LCMS methods and showed purity of at least 95%.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Preparative HPLC</h3><div class="NLM_p last">The separation of certain compounds was accomplished by using reverse-phase preparative HPLC (Gilson GX-281) with a UV detector at 214 nm as described in further detail in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> General Procedure for the Synthesis of <b>31</b>−<b>35</b></h3><div class="NLM_p last">A mixture of 4-chloroquinazolines derivatives (<b>25</b>−<b>26</b>, 5 mmol) and appropriate substituted anilines (<b>27</b>−<b>30</b>, 10 mmol) in isopropanol (45 mL) was stirred at reflux for 3 h. The reaction mixture was cooled to room temperature and the resultant precipitate was collected by filtration. The solid was further dried in vacuo to give the compounds <b>31</b>−<b>35</b>.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> General Procedure for the Synthesis of <b>36</b>−<b>40</b></h3><div class="NLM_p last">A mixture of 4-phenylamino-quinazoline derivatives (<b>31</b>−<b>35</b>, 3.5 mmol) and LiOH·H<sub>2</sub>O (0.5 g, 11.7 mmol) in methanol (100 mL) and H<sub>2</sub>O (100 mL) was stirred at room temperature for 0.5 h. The mixture was neutralized by the addition of diluted acetic acid. The resultant precipitate was collected by filtration, washed, and dried to give compounds <b>36</b>−<b>40</b>.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> General Procedure for the Synthesis of <b>41</b>−<b>51</b></h3><div class="NLM_p last">A mixture of 4-phenylaminoquinazolin-6-ol derivatives (<b>36</b>−<b>40</b>, 1.0 mmol), appropriate ethyl or methyl bromoalkanoate (1.1 mmol), and potassium carbonate (323 mg, 2.4 mmol) in DMF (6 mL) was stirred at 40 °C for 30 min. The reaction mixture was filtered and the filtrate was concentrated in vacuo. The residue was washed with diethyl ether and dried to give compounds <b>41</b>−<b>51</b>.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> General Procedure for the Synthesis of <b>1</b>−<b>24</b> from Their Corresponding Esters</h3><div id="sec5_7_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> Preparation of Fresh Hydroxylamine solution</h4><div class="NLM_p last">A solution of potassium hydroxide (11.2 g, 199.6 mmol) in methanol (28 mL) was added to a stirred solution of hydroxylamine hydrochloride (9.34 g, 134.4 mmol) in methanol (48 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 30 min. The resultant precipitate was removed by filtration. The filtrate was collected to provide free hydroxylamine solution which was stored in a refrigerator before use.</div></div><div id="sec5_7_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> Preparation of Compounds <b>1</b>−<b>24</b></h4><div class="NLM_p last">The appropriate esters (11.0 mmol) were added to the above freshly prepared hydroxylamine solution (30 mL) at 0 °C. The reaction mixture was warmed to room temperature and stirred at 25 °C for 1 to 24 h until the reaction was complete (reaction progess was monitored by TLC or LCMS). The reaction mixture was neutralized with acetic acid. The formed precipitate was collected by filtration, washed with water, and dried to give the title compounds. If a precipitate did not form after neutralization, the solvent was removed to yield a crude mixture, which was purified by reverse-phase preparative HPLC to give the title compounds.</div></div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> EGFR and HER2 Inhibition Assay</h3><div class="NLM_p last">EGFR and HER2 kinase activity were measured using HTScan EGF receptor and HER2 kinase assay kits (Cell Signaling Technology). Briefly, the GST-EGFR fusion protein was incubated with synthetic biotinylated peptide substrate and varying concentrations of drugs in the presence of 400 mM ATP. Phosphorylated substrate was captured with strapavidin-coated 96-well plates. The level of phosphorylation was monitored by antiphospho-tyrosine- and europium-labeled secondary antibodies (DELFIA, Perkin-Elmer). The enhancement solution was added at the end of the assay and enzyme activity was measured in the Wallac Victor II 1420 microplate reader at 615 nM.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> HDAC Inhibition Assay</h3><div class="NLM_p last">The activities of Class I and II HDACs were assessed using the Biomol Color de Lys system. Briefly, HeLa cell nuclear extracts were used as a source of HDACs. Different concentrations of drugs were added to HeLa cell nuclear extracts in the presence of a colorimetric artificial substrate. Developer was added at the end of the assay and enzyme activity was measured in the Wallac Victor II 1420 microplate reader at 405 nM.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Cell Growth, Viability, and Apoptosis Assay</h3><div class="NLM_p last">Cancer cell lines were plated at 5000 to 10 000 cells per well in 96-well flat-bottomed plates with varying concentrations of compounds. The cells were incubated with compounds for 72 h in the presence of 0.5% of fetal bovine serum. Growth inhibition was assessed by an adenosine triphosphate (ATP) content assay using the Perkin-Elmer (Waltham, MA) ATPlite kit. Apoptosis was routinely assessed by measuring the activities of Caspase-3 and -7 using Promega (Madison, WI) Apo-ONE Homogeneous Assay Kit.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Efficacy Studies in Human Cancer Xenograft Model</h3><div class="NLM_p last">Four- to six-week-old female athymic mice (nude nu/nu CD-1, Charles River, Wilmington, MA) were inoculated subcutaneously into the right hind flank region with 1 to 5 × 10<sup>6</sup> cells in a medium suspension of 100−200 μL. For orthotopic implantation of breast cancer cells, a cell suspension in 100 μL of medium was injected directly into the mammary fat pads through a 27G needle. Different doses of <b>8</b>, standard anticancer agents and vehicle were administered orally, intraperitoneally, or via tail vein injection as indicated.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i39"><a href="/doi/suppl/10.1021/jm901453q">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24805" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24805" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Details of synthesis and analytical data, the LCMS method used for the determination of purity and the HPLC method used for compound separation, HDAC and RTK inhibition synergy data, HDAC class I and class II inhibitory activity of <b>8</b>. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm901453q/suppl_file/jm901453q_si_001.pdf">jm901453q_si_001.pdf (164.39 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm901453q" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37048" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37048" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiong Cai</span> - <span class="hlFld-Affiliation affiliation">Curis Inc., 45 Moulton Street, Cambridge, Massachusetts 02138</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#88f0ebe9e1c8ebfdfae1fba6ebe7e5"><span class="__cf_email__" data-cfemail="f68e95979fb69583849f85d895999b">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hai-Xiao Zhai</span> - <span class="hlFld-Affiliation affiliation">Curis Inc., 45 Moulton Street, Cambridge, Massachusetts 02138</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jing Wang</span> - <span class="hlFld-Affiliation affiliation">Curis Inc., 45 Moulton Street, Cambridge, Massachusetts 02138</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffrey Forrester</span> - <span class="hlFld-Affiliation affiliation">Curis Inc., 45 Moulton Street, Cambridge, Massachusetts 02138</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hui Qu</span> - <span class="hlFld-Affiliation affiliation">Curis Inc., 45 Moulton Street, Cambridge, Massachusetts 02138</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ling Yin</span> - <span class="hlFld-Affiliation affiliation">Curis Inc., 45 Moulton Street, Cambridge, Massachusetts 02138</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cheng-Jung Lai</span> - <span class="hlFld-Affiliation affiliation">Curis Inc., 45 Moulton Street, Cambridge, Massachusetts 02138</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rudi Bao</span> - <span class="hlFld-Affiliation affiliation">Curis Inc., 45 Moulton Street, Cambridge, Massachusetts 02138</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Changgeng Qian</span> - <span class="hlFld-Affiliation affiliation">Curis Inc., 45 Moulton Street, Cambridge, Massachusetts 02138</span></div></li></ul></li><li></li><li></li><li></li></ul></div><div class="ack"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i38">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04802" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04802" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank Zihong Guo, Tianhao Wang, Keyou Xue, Hui Liu, Xiaoyue Su, Xiongwen Yang and Liangbin Jia of Curis chemistry FTE team at Shanghai ChemPartner Co., Ltd. for conducting chemical synthesis of compounds, Carmen Pepicelli and Mark Noel of Curis for helpful discussions and their review of this manuscript, and Nicole Davis for her assistance in the preparation of this manuscript.</p></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i40">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26711" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26711" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 32 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Sergina, N. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moasser, M. M.</span><span> </span><span class="NLM_article-title">The HER Family and Cancer: Emerging Molecular Mechanisms and Therapeutic Targets</span> <span class="citation_source-journal">Trends Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">527</span><span class="NLM_x">–</span> <span class="NLM_lpage">534</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=527-534&author=N.+V.+Serginaauthor=M.+M.+Moasser&title=The+HER+Family+and+Cancer%3A+Emerging+Molecular+Mechanisms+and+Therapeutic+Targets"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSergina%26aufirst%3DN.%2BV.%26aulast%3DMoasser%26aufirst%3DM.%2BM.%26atitle%3DThe%2520HER%2520Family%2520and%2520Cancer%253A%2520Emerging%2520Molecular%2520Mechanisms%2520and%2520Therapeutic%2520Targets%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2007%26volume%3D13%26spage%3D527%26epage%3D534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Hynes, N. E</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H. A.</span><span> </span><span class="NLM_article-title">ERBB Receptors and Cancer: the Complexity of Targeted Inhibitors</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">341</span><span class="NLM_x">–</span> <span class="NLM_lpage">354</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm901453q&amp;key=10.1038%2Fnrc1609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm901453q&amp;key=15864276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm901453q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=341-354&author=N.+E+Hynesauthor=H.+A.+Lane&title=ERBB+Receptors+and+Cancer%3A+the+Complexity+of+Targeted+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">ERBB receptors and cancer: the complexity of targeted inhibitors</span></div><div class="casAuthors">Hynes, Nancy E.; Lane, Heidi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">341-354</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  ERBB receptor tyrosine kinases have important roles in human cancer.  In particular, the expression or activation of epidermal growth factor receptor and ERBB2 are altered in many epithelial tumors, and clin. studies indicate that they have important roles in tumor etiol. and progression.  Accordingly, these receptors have been intensely studied to understand their importance in cancer biol. and as therapeutic targets, and many ERBB inhibitors are now used in the clinic.  We will discuss the significance of these receptors as clin. targets, in particular the mol. mechanisms underlying response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrimBiy4bn4LrVg90H21EOLACvtfcHk0lhJ3LZP76vOZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D&md5=54a45e004711da7017ee0f016696a36e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc1609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1609%26sid%3Dliteratum%253Aachs%26aulast%3DHynes%26aufirst%3DN.%2BE%26aulast%3DLane%26aufirst%3DH.%2BA.%26atitle%3DERBB%2520Receptors%2520and%2520Cancer%253A%2520the%2520Complexity%2520of%2520Targeted%2520Inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D341%26epage%3D354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Moasser, M. M.</span><span> </span><span class="NLM_article-title">Targeting the Function of the HER2 Oncogene in Human Cancer Therapeutics</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">6577</span><span class="NLM_x">–</span> <span class="NLM_lpage">6592</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm901453q&amp;key=10.1038%2Fsj.onc.1210478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm901453q&amp;key=17486079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm901453q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFCkt7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=6577-6592&author=M.+M.+Moasser&title=Targeting+the+Function+of+the+HER2+Oncogene+in+Human+Cancer+Therapeutics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the function of the HER2 oncogene in human cancer therapeutics</span></div><div class="casAuthors">Moasser, M. M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">6577-6592</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The year 2007 marks exactly two decades since human epidermal growth factor receptor-2 (HER2) was functionally implicated in the pathogenesis of human breast cancer.  This finding established the HER2 oncogene hypothesis for the development of some human cancers.  An abundance of exptl. evidence compiled over the past two decades now solidly supports the HER2 oncogene hypothesis.  A direct consequence of this hypothesis was the promise that inhibitors of oncogenic HER2 would be highly effective treatments for HER2-driven cancers.  This treatment hypothesis has led to the development and widespread use of anti-HER2 antibodies (trastuzumab) in clin. management resulting in significantly improved clin. antitumor efficacies that have transformed the clin. practice of oncol.  In the shadows of this irrefutable clin. success, scientific studies have not yet been able to mechanistically validate that trastuzumab inhibits oncogenic HER2 function and it remains possible that the current clin. advances are a consequence of the oncogene hypothesis, but not a translation of it.  These looming scientific uncertainties suggest that the full promise of the treatment hypothesis may not yet have been realized.  The coming decade will see a second generation of HER2-targeting agents brought into clin. testing and a renewed attempt to treat HER2-driven cancers through the inactivation of HER2.  Here, I review the development of treatments that target HER2 in the context of the HER2 oncogene hypothesis, and where we stand with regards to the clin. translation of the HER2 oncogene hypothesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXXzfJk2kvX7Vg90H21EOLACvtfcHk0lhJ3LZP76vOZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFCkt7vK&md5=4c585356ad9ede3a85a774ad772b8ba6</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210478%26sid%3Dliteratum%253Aachs%26aulast%3DMoasser%26aufirst%3DM.%2BM.%26atitle%3DTargeting%2520the%2520Function%2520of%2520the%2520HER2%2520Oncogene%2520in%2520Human%2520Cancer%2520Therapeutics%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D6577%26epage%3D6592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Moasser, M. M.</span><span> </span><span class="NLM_article-title">The Oncogene HER2: Its Signaling and Transforming Functions and Its Role in Human Cancer Pathogenesis</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">6469</span><span class="NLM_x">–</span> <span class="NLM_lpage">6487</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm901453q&amp;key=10.1038%2Fsj.onc.1210477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm901453q&amp;key=17471238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm901453q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFagsbnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=6469-6487&author=M.+M.+Moasser&title=The+Oncogene+HER2%3A+Its+Signaling+and+Transforming+Functions+and+Its+Role+in+Human+Cancer+Pathogenesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis</span></div><div class="casAuthors">Moasser, M. M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">6469-6487</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The year 2007 marks exactly two decades since Human Epidermal Growth Factor Receptor-2 (HER2) was functionally implicated in the pathogenesis of human breast cancer.  This finding established the HER2 oncogene hypothesis for the development of some human cancers.  The subsequent two decades have brought about an explosion of information about the biol. of HER2 and the HER family.  An abundance of exptl. evidence now solidly supports the HER2 oncogene hypothesis and etiol. links amplification of the HER2 gene locus with human cancer pathogenesis.  The mol. mechanisms underlying HER2 tumorigenesis appear to be complex and a unified mechanistic model of HER2-induced transformation has not emerged.  Numerous hypotheses implicating diverse transforming pathways have been proposed and are individually supported by exptl. models and HER2 may indeed induce cell transformation through multiple mechanisms.  Here I review the evidence supporting the oncogenic function of HER2, the mechanisms that are felt to mediate its oncogenic functions, and the evidence that links the exptl. evidence with human cancer pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoP3J_STszvOrVg90H21EOLACvtfcHk0lhJ3LZP76vOZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFagsbnN&md5=1ca26e99dc27692105e2751c90ccdb45</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210477%26sid%3Dliteratum%253Aachs%26aulast%3DMoasser%26aufirst%3DM.%2BM.%26atitle%3DThe%2520Oncogene%2520HER2%253A%2520Its%2520Signaling%2520and%2520Transforming%2520Functions%2520and%2520Its%2520Role%2520in%2520Human%2520Cancer%2520Pathogenesis%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D6469%26epage%3D6487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Burgess, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, H.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, T. P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leahy, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemmon, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokoyama, S.</span><span> </span><span class="NLM_article-title">An Open-and-shut Case? Recent Insights Into the Activation of EGF/ErbB Receptors</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">541</span><span class="NLM_x">–</span> <span class="NLM_lpage">552</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2003&pages=541-552&author=A.+W.+Burgessauthor=H.-S.+Choauthor=C.+Eigenbrotauthor=K.+M.+Fergusonauthor=T.+P.+J.+Garrettauthor=D.+J.+Leahyauthor=M.+A.+Lemmonauthor=M.+X.+Sliwkowskiauthor=C.+W.+Wardauthor=S.+Yokoyama&title=An+Open-and-shut+Case%3F+Recent+Insights+Into+the+Activation+of+EGF%2FErbB+Receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBurgess%26aufirst%3DA.%2BW.%26aulast%3DCho%26aufirst%3DH.-S.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DFerguson%26aufirst%3DK.%2BM.%26aulast%3DGarrett%26aufirst%3DT.%2BP.%2BJ.%26aulast%3DLeahy%26aufirst%3DD.%2BJ.%26aulast%3DLemmon%26aufirst%3DM.%2BA.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DWard%26aufirst%3DC.%2BW.%26aulast%3DYokoyama%26aufirst%3DS.%26atitle%3DAn%2520Open-and-shut%2520Case%253F%2520Recent%2520Insights%2520Into%2520the%2520Activation%2520of%2520EGF%252FErbB%2520Receptors%26jtitle%3DMol.%2520Cell%26date%3D2003%26volume%3D12%26spage%3D541%26epage%3D552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Press, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, H.-J.</span><span> </span><span class="NLM_article-title">EGFR, HER2 and VEGF Pathways: Validated Targets for Cancer Treatment</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">2045</span><span class="NLM_x">–</span> <span class="NLM_lpage">2075</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=2045-2075&author=M.+F.+Pressauthor=H.-J.+Lenz&title=EGFR%2C+HER2+and+VEGF+Pathways%3A+Validated+Targets+for+Cancer+Treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPress%26aufirst%3DM.%2BF.%26aulast%3DLenz%26aufirst%3DH.-J.%26atitle%3DEGFR%252C%2520HER2%2520and%2520VEGF%2520Pathways%253A%2520Validated%2520Targets%2520for%2520Cancer%2520Treatment%26jtitle%3DDrugs%26date%3D2007%26volume%3D67%26spage%3D2045%26epage%3D2075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Epidermal Growth Factor Receptor Mutations in Lung Cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm901453q&amp;key=10.1038%2Fnrc2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm901453q&amp;key=17318210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm901453q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=169-181&author=S.+V.+Sharmaauthor=D.+W.+Bellauthor=J.+Settlemanauthor=D.+A.+Haber&title=Epidermal+Growth+Factor+Receptor+Mutations+in+Lung+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Sharma, Sreenath V.; Bell, Daphne W.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-181</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The development and clin. application of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the broader field of targeted cancer therapies.  We review the results of genetic, biochem. and clin. studies focused on somatic mutations of EGFR that are assocd. with the phenomenon of oncogene addiction, describing 'oncogenic shock' as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors.  Understanding the genetic heterogeneity of epithelial tumors and devising strategies to circumvent their rapid acquisition of resistance to targeted kinase inhibitors are essential to the successful use of targeted therapies in common epithelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKw7Y4FUFM7Vg90H21EOLACvtfcHk0lhQK-rGLEh0fQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D&md5=46219ea3ae7b9f0977e4a4b7243fd875</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrc2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2088%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DEpidermal%2520Growth%2520Factor%2520Receptor%2520Mutations%2520in%2520Lung%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D169%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berezov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drebin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murali, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, M. I.</span><span> </span><span class="NLM_article-title">ErbB Receptors: from Oncogenes to Targeted Cancer Therapies</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">2051</span><span class="NLM_x">–</span> <span class="NLM_lpage">2058</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2007&pages=2051-2058&author=H.+Zhangauthor=A.+Berezovauthor=Q.+Wangauthor=G.+Zhangauthor=J.+Drebinauthor=R.+Muraliauthor=M.+I.+Greene&title=ErbB+Receptors%3A+from+Oncogenes+to+Targeted+Cancer+Therapies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DBerezov%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DDrebin%26aufirst%3DJ.%26aulast%3DMurali%26aufirst%3DR.%26aulast%3DGreene%26aufirst%3DM.%2BI.%26atitle%3DErbB%2520Receptors%253A%2520from%2520Oncogenes%2520to%2520Targeted%2520Cancer%2520Therapies%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2007%26volume%3D117%26spage%3D2051%26epage%3D2058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib is Associated with a Second Mutation in the EGFR Kinase Domain</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e73</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=e73&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=Acquired+Resistance+of+Lung+Adenocarcinomas+to+Gefitinib+or+Erlotinib+is+Associated+with+a+Second+Mutation+in+the+EGFR+Kinase+Domain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520Resistance%2520of%2520Lung%2520Adenocarcinomas%2520to%2520Gefitinib%2520or%2520Erlotinib%2520is%2520Associated%2520with%2520a%2520Second%2520Mutation%2520in%2520the%2520EGFR%2520Kinase%2520Domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3De73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Avizienyte, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garner, A. P.</span><span> </span><span class="NLM_article-title">Comparison of the EGFR Resistance Mutation Profiles Generated by EGFR-targeted Tyrosine Kinase Inhibitors and the Impact of Drug Combinations</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">415</span><span class="NLM_x">, </span> <span class="NLM_fpage">197</span><span class="NLM_x">–</span> <span class="NLM_lpage">206</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=415&publication_year=2008&pages=197-206&author=E.+Avizienyteauthor=R.+A.+Wardauthor=A.+P.+Garner&title=Comparison+of+the+EGFR+Resistance+Mutation+Profiles+Generated+by+EGFR-targeted+Tyrosine+Kinase+Inhibitors+and+the+Impact+of+Drug+Combinations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAvizienyte%26aufirst%3DE.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DGarner%26aufirst%3DA.%2BP.%26atitle%3DComparison%2520of%2520the%2520EGFR%2520Resistance%2520Mutation%2520Profiles%2520Generated%2520by%2520EGFR-targeted%2520Tyrosine%2520Kinase%2520Inhibitors%2520and%2520the%2520Impact%2520of%2520Drug%2520Combinations%26jtitle%3DBiochem.%2520J.%26date%3D2008%26volume%3D415%26spage%3D197%26epage%3D206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Rubin, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duensing, A.</span><span> </span><span class="NLM_article-title">Mechanisms of Resistance to Small Molecule Kinase Inhibition in the Treatment of Solid Tumors</span> <span class="citation_source-journal">Lab. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">981</span><span class="NLM_x">–</span> <span class="NLM_lpage">986</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2006&pages=981-986&author=B.+P.+Rubinauthor=A.+Duensing&title=Mechanisms+of+Resistance+to+Small+Molecule+Kinase+Inhibition+in+the+Treatment+of+Solid+Tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRubin%26aufirst%3DB.%2BP.%26aulast%3DDuensing%26aufirst%3DA.%26atitle%3DMechanisms%2520of%2520Resistance%2520to%2520Small%2520Molecule%2520Kinase%2520Inhibition%2520in%2520the%2520Treatment%2520of%2520Solid%2520Tumors%26jtitle%3DLab.%2520Invest.%26date%3D2006%26volume%3D86%26spage%3D981%26epage%3D986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Marks, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.-S.</span><span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitors: Potential in Cancer Therapy</span> <span class="citation_source-journal">J. Cell. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">600</span><span class="NLM_x">–</span> <span class="NLM_lpage">608</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2009&pages=600-608&author=P.+A.+Marksauthor=W.-S.+Xu&title=Histone+Deacetylase+Inhibitors%3A+Potential+in+Cancer+Therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarks%26aufirst%3DP.%2BA.%26aulast%3DXu%26aufirst%3DW.-S.%26atitle%3DHistone%2520Deacetylase%2520Inhibitors%253A%2520Potential%2520in%2520Cancer%2520Therapy%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2009%26volume%3D107%26spage%3D600%26epage%3D608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Pandolfi, P. P.</span><span> </span><span class="NLM_article-title">Histone Deacetylases and Transcriptional Therapy with Their Inhibitors</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">S17</span><span class="NLM_x">–</span> <span class="NLM_lpage">19</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2001&pages=S17-19&issue=Suppl+1&author=P.+P.+Pandolfi&title=Histone+Deacetylases+and+Transcriptional+Therapy+with+Their+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPandolfi%26aufirst%3DP.%2BP.%26atitle%3DHistone%2520Deacetylases%2520and%2520Transcriptional%2520Therapy%2520with%2520Their%2520Inhibitors%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2001%26volume%3D48%26issue%3DSuppl%25201%26spage%3DS17%26epage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Mann, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Justice, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazdur, R. FDA</span><span> </span><span class="NLM_article-title">Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-cell Lymphoma</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1247</span><span class="NLM_x">–</span> <span class="NLM_lpage">1252</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=1247-1252&author=B.+S.+Mannauthor=J.+R.+Johnsonauthor=M.+H.+Cohenauthor=R.+Justiceauthor=R.+FDA+Pazdur&title=Approval+Summary%3A+Vorinostat+for+Treatment+of+Advanced+Primary+Cutaneous+T-cell+Lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMann%26aufirst%3DB.%2BS.%26aulast%3DJohnson%26aufirst%3DJ.%2BR.%26aulast%3DCohen%26aufirst%3DM.%2BH.%26aulast%3DJustice%26aufirst%3DR.%26aulast%3DPazdur%26aufirst%3DR.%2BFDA%26atitle%3DApproval%2520Summary%253A%2520Vorinostat%2520for%2520Treatment%2520of%2520Advanced%2520Primary%2520Cutaneous%2520T-cell%2520Lymphoma%26jtitle%3DOncologist%26date%3D2007%26volume%3D12%26spage%3D1247%26epage%3D1252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Qian, D. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kachhap, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atadja, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pili, R.</span><span> </span><span class="NLM_article-title">The Histone Deacetylase Inhibitor NVP-LAQ824 Inhibits Angiogenesis and Has a Greater Antitumor Effect in Combination with the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor PTK787/ZK222584</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">6626</span><span class="NLM_x">–</span> <span class="NLM_lpage">6634</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=6626-6634&author=D.+Z.+Qianauthor=X.+Wangauthor=S.+K.+Kachhapauthor=Y.+Katoauthor=Y.+Weiauthor=L.+Zhangauthor=P.+Atadjaauthor=R.+Pili&title=The+Histone+Deacetylase+Inhibitor+NVP-LAQ824+Inhibits+Angiogenesis+and+Has+a+Greater+Antitumor+Effect+in+Combination+with+the+Vascular+Endothelial+Growth+Factor+Receptor+Tyrosine+Kinase+Inhibitor+PTK787%2FZK222584"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DD.%2BZ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DKachhap%26aufirst%3DS.%2BK.%26aulast%3DKato%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DAtadja%26aufirst%3DP.%26aulast%3DPili%26aufirst%3DR.%26atitle%3DThe%2520Histone%2520Deacetylase%2520Inhibitor%2520NVP-LAQ824%2520Inhibits%2520Angiogenesis%2520and%2520Has%2520a%2520Greater%2520Antitumor%2520Effect%2520in%2520Combination%2520with%2520the%2520Vascular%2520Endothelial%2520Growth%2520Factor%2520Receptor%2520Tyrosine%2520Kinase%2520Inhibitor%2520PTK787%252FZK222584%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D6626%26epage%3D6634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Bali, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pranpat, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swaby, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiskus, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balasis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocha, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Victoria, Richon</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapil, Bhalla</span><span> </span><span class="NLM_article-title">. Activity of Suberoylanilide Hydroxamic Acid Against Human Breast Cancer Cells with Amplification of Her-2</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">6382</span><span class="NLM_x">–</span> <span class="NLM_lpage">6389</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm901453q&amp;key=10.1158%2F1078-0432.CCR-05-0344" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm901453q&amp;key=16144943" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm901453q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpslansbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=6382-6389&author=P.+Baliauthor=M.+Pranpatauthor=R.+Swabyauthor=W.+Fiskusauthor=H.+Yamaguchiauthor=M.+Balasisauthor=K.+Rochaauthor=H.-G.+Wangauthor=Richon+Victoriaauthor=Bhalla+Kapil&title=.+Activity+of+Suberoylanilide+Hydroxamic+Acid+Against+Human+Breast+Cancer+Cells+with+Amplification+of+Her-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of Suberoylanilide Hydroxamic Acid Against Human Breast Cancer Cells with Amplification of Her-2</span></div><div class="casAuthors">Bali, Purva; Pranpat, Michael; Swaby, Ramona; Fiskus, Warren; Yamaguchi, Hirohito; Balasis, Maria; Rocha, Kathy; Wang, Hong-Gang; Richon, Victoria; Bhalla, Kapil</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6382-6389</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: We detd. the effects of suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, on hsp90 and its client proteins Her-2, AKT, and c-Raf, as well as evaluated the cytotoxic effects of cotreatment of SAHA with trastuzumab or docetaxel in human breast cancer BT-474 and SKBR-3 cells contg. amplification of Her-2.  Exptl. Design: The cells were treated with SAHA (1.0-5.0 μmol/L) and/or trastuzumab (5-40 μg/mL) or docetaxel (5-20 nmol/L).  Following this, apoptosis and the levels of p21WAF1, p27KIP1, AKT, c-Raf, and Her-2, as well as of the key regulators of apoptosis were detd.  Synergistic interaction between drugs was evaluated by median dose-effect anal.  Results: Treatment with SAHA up-regulated p21WAF1 and p27KIP1 levels, increased the percentage of cells in G2-M phase of the cell cycle, as well as induced apoptosis in a dose-dependent manner.  This was assocd. with up-regulation of the pro-death Bak and Bim, as well as with attenuation of the levels of Her-2 and XIAP, survivin, Bcl-2, and Bcl-xL proteins.  SAHA treatment induced acetylation of hsp90.  This reduced the chaperone assocn. of Her-2 with hsp90, promoting polyubiquitylation and degrdn. of Her-2.  SAHA also attenuated the levels of c-Raf and AKT.  Cotreatment with SAHA significantly increased trastuzumab or docetaxel-induced apoptosis of BT-474 and SKBR-3 cells.  Addnl., median dose-effect anal. revealed that cotreatment with SAHA and trastuzumab or docetaxel induced synergistic cytotoxic effects against the breast cancer cells.  Conclusions: These preclin. findings support the development of SAHA in combination with docetaxel and/or trastuzumab against Her-2-amplified breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOxGcKxvQnOrVg90H21EOLACvtfcHk0lhecQGKGJidwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpslansbk%253D&md5=23d52dbf57795a4b78af8df220f84f5d</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-0344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-0344%26sid%3Dliteratum%253Aachs%26aulast%3DBali%26aufirst%3DP.%26aulast%3DPranpat%26aufirst%3DM.%26aulast%3DSwaby%26aufirst%3DR.%26aulast%3DFiskus%26aufirst%3DW.%26aulast%3DYamaguchi%26aufirst%3DH.%26aulast%3DBalasis%26aufirst%3DM.%26aulast%3DRocha%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DH.-G.%26aulast%3DVictoria%26aufirst%3DRichon%26aulast%3DKapil%26aufirst%3DBhalla%26atitle%3D.%2520Activity%2520of%2520Suberoylanilide%2520Hydroxamic%2520Acid%2520Against%2520Human%2520Breast%2520Cancer%2520Cells%2520with%2520Amplification%2520of%2520Her-2%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D6382%26epage%3D6389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Bali, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sigua, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vishvanath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scuto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Annavarapu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiskus, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moscinski, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atadja, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhalla, K.</span><span> </span><span class="NLM_article-title">Superior Activity of the Combination of Histone Deacetylase Inhibitor LAQ824 and the FLT-3 Kinase Inhibitor PKC412 Against Human Acute Myelogenous Leukemia Cells with Mutant FLT-3</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">4991</span><span class="NLM_x">–</span> <span class="NLM_lpage">4997</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm901453q&amp;key=10.1158%2F1078-0432.CCR-04-0210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm901453q&amp;key=15297399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm901453q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtlSitrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=4991-4997&author=P.+Baliauthor=P.+Georgeauthor=P.+Cohenauthor=J.+Taoauthor=F.+Guoauthor=C.+Siguaauthor=A.+Vishvanathauthor=A.+Scutoauthor=S.+Annavarapuauthor=W.+Fiskusauthor=L.+Moscinskiauthor=P.+Atadjaauthor=K.+Bhalla&title=Superior+Activity+of+the+Combination+of+Histone+Deacetylase+Inhibitor+LAQ824+and+the+FLT-3+Kinase+Inhibitor+PKC412+Against+Human+Acute+Myelogenous+Leukemia+Cells+with+Mutant+FLT-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 Kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3</span></div><div class="casAuthors">Bali, Purva; George, Prince; Cohen, Pamela; Tao, Jianguo; Guo, Fei; Sigua, Celia; Vishvanath, Anasuya; Scuto, Anna; Annavarapu, Srinivas; Fiskus, Warren; Moscinski, Lynn; Atadja, Peter; Bhalla, Kapil</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4991-4997</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mutant FLT-3 receptor tyrosine kinase is a client protein of the mol. chaperone heat shock protein 90 and is commonly present and contributes to the leukemia phenotype in acute myelogenous leukemia (AML).  LAQ824, a cinnamyl hydroxamate histone deacetylase inhibitor, is known to induce acetylation and inhibition of heat shock protein 90.  Here, we detd. the effects of LAQ824 and/or PKC412 (a FLT-3 kinase inhibitor) on the levels of mutant FLT-3 and its downstream signaling, as well as growth arrest and cell-death of cultured and primary human AML cells.  The effect of LAQ824 and/or PKC412 treatment was detd. on the levels of FLT-3 and phosphorylated (p)-FLT-3, on downstream pro-growth and pro-survival effectors, e.g., p-STAT5, p-AKT, and p-extracellular signal-regulated kinase (ERK) 1/2, and on the cell cycle status and apoptosis in the cultured MV4-11 and primary AML cells with mutant FLT-3.  Treatment with LAQ824 promoted proteasomal degrdn. and attenuation of the levels of FLT-3 and p-FLT-3, assocd. with cell cycle G1-phase accumulation and apoptosis of MV4-11 cells.  This was accompanied by attenuation of p-STAT5, p-AKT, and p-ERK1/2 levels.  STAT-5 DNA-binding activity and the levels of c-Myc and oncostatin M were also down-regulated.  Cotreatment with LAQ824 and PKC412 synergistically induced apoptosis of MV4-11 cells and induced more apoptosis of the primary AML cells expressing mutant FLT-3.  This was also assocd. with more attenuation of p-FLT-3, p-AKT, p-ERK1/2, and p-STAT5.  The combination of LAQ824 and PKC412 is highly active against human AML cells with mutant FLT-3, which merits in vivo studies of the combination against human AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPJeLfYNFiTbVg90H21EOLACvtfcHk0lhecQGKGJidwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtlSitrs%253D&md5=375c881c176bfec9a1ddf8b5616d576d</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-0210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-0210%26sid%3Dliteratum%253Aachs%26aulast%3DBali%26aufirst%3DP.%26aulast%3DGeorge%26aufirst%3DP.%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DTao%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DF.%26aulast%3DSigua%26aufirst%3DC.%26aulast%3DVishvanath%26aufirst%3DA.%26aulast%3DScuto%26aufirst%3DA.%26aulast%3DAnnavarapu%26aufirst%3DS.%26aulast%3DFiskus%26aufirst%3DW.%26aulast%3DMoscinski%26aufirst%3DL.%26aulast%3DAtadja%26aufirst%3DP.%26aulast%3DBhalla%26aufirst%3DK.%26atitle%3DSuperior%2520Activity%2520of%2520the%2520Combination%2520of%2520Histone%2520Deacetylase%2520Inhibitor%2520LAQ824%2520and%2520the%2520FLT-3%2520Kinase%2520Inhibitor%2520PKC412%2520Against%2520Human%2520Acute%2520Myelogenous%2520Leukemia%2520Cells%2520with%2520Mutant%2520FLT-3%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26spage%3D4991%26epage%3D4997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Edwards, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atadja, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhalla, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haura, E. B.</span><span> </span><span class="NLM_article-title">Effect of the Histone Deacetylase Inhibitor LBH589 Against Epidermal Growth Factor Receptor-dependent Human Lung Cancer Cells</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2515</span><span class="NLM_x">–</span> <span class="NLM_lpage">2524</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm901453q&amp;key=10.1158%2F1535-7163.MCT-06-0761" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm901453q&amp;key=17876048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm901453q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVCgur7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=2515-2524&author=A.+Edwardsauthor=J.+Liauthor=P.+Atadjaauthor=K.+Bhallaauthor=E.+B.+Haura&title=Effect+of+the+Histone+Deacetylase+Inhibitor+LBH589+Against+Epidermal+Growth+Factor+Receptor-dependent+Human+Lung+Cancer+Cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells</span></div><div class="casAuthors">Edwards, Arthur; Li, Jiannong; Atadja, Peter; Bhalla, Kapil; Haura, Eric B.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2515-2524</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Activating mutations in the epidermal growth factor receptor (EGFR) selectively activate signal transducers and activators of transcription (STAT) and Akt survival signaling pathways important in lung cancer cell growth and survival.  Many kinases, such as EGFR, rely on heat shock protein 90 (Hsp90) chaperone function for conformational maturation and proper function.  Histone deacetylase inhibitors (HDACi) have been suggested to regulate signaling protein interactions via modulation of protein chaperone function through Hsp90.  For these reasons, we evaluated the effect of a HDACi in lung cancer cells with defined EGFR status.  Cell lines with defined EGFR status and sensitivity to EGFR tyrosine kinase inhibitors were exposed to the HDACi LBH589, and the effects on cell survival, proliferation, and downstream signaling were evaluated.  LBH589 resulted in increased acetylation of Hsp90 and reduced assocn. of Hsp90 with EGFR, Akt, and STAT3.  LBH589 selectively depleted proteins important in signaling cascades in cell lines harboring EGFR kinase mutations, such as EGFR, STAT3, and Akt, and these cells underwent apoptosis following exposure to LBH589.  In addn., we found depletion of STAT3-dependent survival proteins, including Bcl-xL, Mcl-1, and Bcl-2.  Conversely, LBH589 had little effect on apoptosis in cells not dependent on EGFR for survival, no changes were identified in the expression of EGFR or other survival proteins, and the predominant effect was cell cycle arrest rather than apoptosis.  A 10-fold increase in LBH589 was necessary to observe durable depletion of EGFR and Akt in cells not harboring EGFR mutation.  Treatment of cells with erlotinib and LBH589 resulted in synergistic effects on lung cancer cells dependent on EGFR for growth and/or survival.  Based on these results, LBH589 can acetylate Hsp90, deplete EGFR and other key survival signaling proteins, and trigger apoptosis only in lung cancer cells harboring EGFR mutations.  Therefore, EGFR mutation status may be predictive of outcome with LBH589 and possibly other HDACi.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN5rKS34gOErVg90H21EOLACvtfcHk0ljBPhWKows8Vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVCgur7F&md5=79502c403a42e08255178e55b6f238b4</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0761%26sid%3Dliteratum%253Aachs%26aulast%3DEdwards%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DAtadja%26aufirst%3DP.%26aulast%3DBhalla%26aufirst%3DK.%26aulast%3DHaura%26aufirst%3DE.%2BB.%26atitle%3DEffect%2520of%2520the%2520Histone%2520Deacetylase%2520Inhibitor%2520LBH589%2520Against%2520Epidermal%2520Growth%2520Factor%2520Receptor-dependent%2520Human%2520Lung%2520Cancer%2520Cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D2515%26epage%3D2524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Fuino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bali, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donapaty, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atadja, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhalla, K.</span><span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitor LAQ824 Down-regulates Her-2 and Sensitizes Human Breast Cancer Cells to Trastuzumab, Taxotere, Gemcitabine, and Epothilone B</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">971</span><span class="NLM_x">–</span> <span class="NLM_lpage">984</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm901453q&amp;key=14578462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm901453q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosVCqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=971-984&author=L.+Fuinoauthor=P.+Baliauthor=S.+Wittmannauthor=S.+Donapatyauthor=F.+Guoauthor=H.+Yamaguchiauthor=H.-G.+Wangauthor=P.+Atadjaauthor=K.+Bhalla&title=Histone+Deacetylase+Inhibitor+LAQ824+Down-regulates+Her-2+and+Sensitizes+Human+Breast+Cancer+Cells+to+Trastuzumab%2C+Taxotere%2C+Gemcitabine%2C+and+Epothilone+B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B</span></div><div class="casAuthors">Fuino, Lianne; Bali, Purva; Wittmann, Sylvie; Donapaty, Sreenivas; Guo, Fei; Yamaguchi, Hirohito; Wang, Hong-Gang; Atadja, Peter; Bhalla, Kapil</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">971-984</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Histone deacetylase inhibitors induce hyperacetylation of the amino-terminal lysine residues of the core nucleosomal histones, which results in chromatin remodeling and altered gene expression.  Present studies demonstrate that exposure to a novel hydroxamic acid analog histone deacetylase inhibitor, LAQ824, induced p21WAF1 and p27KIP1 and caused growth arrest and apoptosis of human breast cancer SKBR-3 and BT-474 cells that possess amplification and overexpression of Her-2/neu.  Treatment with LAQ824 depleted the mRNA and protein levels of Her-2/neu-encoded Her-2, which was assocd. with attenuation of pAKT, c-Raf-1, and phosphorylated mitogen-activated protein kinase levels.  LAQ824 also induced the acetylation of heat shock protein (hsp) 90, resulting in inhibition of its binding to ATP, which has been shown to impair the chaperone assocn. of hsp 90 with its client proteins, Her-2, AKT, and c-Raf-1.  Consistent with this, treatment with LAQ824 shifted the binding of Her-2 from hsp 90 to hsp 70, promoting proteasomal degrdn. of Her-2.  Thus, LAQ824 depletes Her-2 through two mechanisms: attenuation of its mRNA levels and promotion of its degrdn. by the proteasome.  Following LAQ824 treatment, the cell membrane assocn., autotyrosine phosphorylation, and colocalization of Her-2 with HER-3 also declined.  Cotreatment with LAQ824 significantly increased trastuzumab-induced apoptosis of BT-474 and SKBR-3 cells.  This was assocd. with greater attenuation of Her-2, c-Raf-1, and pAKT levels.  LAQ824 also enhanced taxotere-induced, epothilone B-induced, and gemcitabine-induced apoptosis of BT-474 and SKBR-3 cells.  These findings suggest that LAQ824 is active against human breast cancer cells and has the potential to improve the efficacy of trastuzumab, taxotere, gemcitabine, and epothilone B against breast cancer with Her-2/neu amplification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7FPwt-FCSyLVg90H21EOLACvtfcHk0ljBPhWKows8Vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosVCqt7g%253D&md5=d7ba8ec62f9e1013ccbed795c8f1abf6</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFuino%26aufirst%3DL.%26aulast%3DBali%26aufirst%3DP.%26aulast%3DWittmann%26aufirst%3DS.%26aulast%3DDonapaty%26aufirst%3DS.%26aulast%3DGuo%26aufirst%3DF.%26aulast%3DYamaguchi%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DH.-G.%26aulast%3DAtadja%26aufirst%3DP.%26aulast%3DBhalla%26aufirst%3DK.%26atitle%3DHistone%2520Deacetylase%2520Inhibitor%2520LAQ824%2520Down-regulates%2520Her-2%2520and%2520Sensitizes%2520Human%2520Breast%2520Cancer%2520Cells%2520to%2520Trastuzumab%252C%2520Taxotere%252C%2520Gemcitabine%252C%2520and%2520Epothilone%2520B%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2003%26volume%3D2%26spage%3D971%26epage%3D984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Lai, C.-J.; Bao, R.; Tao, X; Wang, J.; Atoyan, R.; Qu, H; Wang, D.-G.; Yin, L; Samson, M; Forrester, J; Zifcak, B.; Xu, G.-X.; DellaRocca, S.; Zhai, H.-X.; Cai, X; Qian, C.</span><span> </span><span class="NLM_article-title">CUDC-101, a Multi-targeted Inhibitor of HDAC, EGFR and HER2, with Potent in vitro and in vivo Anti-cancer Activity</span>. Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Lai%2C+C.-J.%3B+Bao%2C+R.%3B+Tao%2C+X%3B+Wang%2C+J.%3B+Atoyan%2C+R.%3B+Qu%2C+H%3B+Wang%2C+D.-G.%3B+Yin%2C+L%3B+Samson%2C+M%3B+Forrester%2C+J%3B+Zifcak%2C+B.%3B+Xu%2C+G.-X.%3B+DellaRocca%2C+S.%3B+Zhai%2C+H.-X.%3B+Cai%2C+X%3B+Qian%2C+C.+CUDC-101%2C+a+Multi-targeted+Inhibitor+of+HDAC%2C+EGFR+and+HER2%2C+with+Potent+in+vitro+and+in+vivo+Anti-cancer+Activity.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DC.-J.%26atitle%3DCUDC-101%252C%2520a%2520Multi-targeted%2520Inhibitor%2520of%2520HDAC%252C%2520EGFR%2520and%2520HER2%252C%2520with%2520Potent%2520in%2520vitro%2520and%2520in%2520vivo%2520Anti-cancer%2520Activity" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Yu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friday, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCollum, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atadja, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, A. A.</span><span> </span><span class="NLM_article-title">Abrogation of MAPK and Akt Signaling by AEE788 Synergistically Potentiates Histone Deacetylase Inhibitor-Induced Apoptosis through Reactive Oxygen Species Generation</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1140</span><span class="NLM_x">–</span> <span class="NLM_lpage">1148</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm901453q&amp;key=10.1158%2F1078-0432.CCR-06-1751" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm901453q&amp;key=17317822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm901453q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvF2hsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=1140-1148&author=C.+Yuauthor=B.+B.+Fridayauthor=J.-P.+Laiauthor=A.+McCollumauthor=P.+Atadjaauthor=L.+R.+Robertsauthor=A.+A.+Adjei&title=Abrogation+of+MAPK+and+Akt+Signaling+by+AEE788+Synergistically+Potentiates+Histone+Deacetylase+Inhibitor-Induced+Apoptosis+through+Reactive+Oxygen+Species+Generation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Abrogation of MAPK and Akt Signaling by AEE788 Synergistically Potentiates Histone Deacetylase Inhibitor-Induced Apoptosis through Reactive Oxygen Species Generation</span></div><div class="casAuthors">Yu, Chunrong; Friday, Bret B.; Lai, Jin-Ping; McCollum, Andrea; Atadja, Peter; Roberts, Lewis R.; Adjei, Alex A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1140-1148</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: To evaluate the effects of combining the multiple receptor tyrosine kinase inhibitor AEE788 and histone deacetylase (HDAC) inhibitors on cytotoxicity in a broad spectrum of cancer cell lines, including cisplatin-resistant ovarian adenocarcinoma cells.  Exptl. Design: Multiple cancer cell lines were treated in vitro using AEE788 and HDAC inhibitors (LBH589, LAQ824, and trichostatin A), either alone or in combination.  Effects on cytotoxicity were detd. by growth and morphol. assays.  Effects of the combination on cell signaling pathways were detd. by Western blotting, and the results were confirmed using pathway-specific inhibitors and transfection of constitutively active proteins.  Results: Cell treatment with AEE788 and HDAC inhibitors (LBH589, LAQ824, and trichostatin A) in combination resulted in synergistic induction of apoptosis in non-small-cell lung cancer (MV522, A549), ovarian cancer (SKOV-3), and leukemia (K562, Jurkat, and ML-1) cells and in OV202hp cisplatin-resistant human ovarian cancer cells.  AEE788 alone or in combination with LBH589 inactivated mitogen-activated protein kinase (MAPK) and Akt cascades.  Inhibition of either MAPK and/or Akt enhanced LBH589-induced apoptosis.  In contrast, constitutively active MAPK or Akt attenuated LBH589 or LBH589 + AEE788-induced apoptosis.  Increased apoptosis was correlated with enhanced reactive oxygen species (ROS) generation.  The free radical scavenger N-acetyl-L-cysteine not only substantially suppressed the ROS accumulation but also blocked the induction of apoptosis mediated by cotreatment with AEE788 and LBH589.  Conclusions: Collectively, these results show that MAPK and Akt inactivation along with ROS generation contribute to the synergistic cytotoxicity of the combination of AEE788 and HDAC inhibitors in a variety of human cancer cell types.  This combination regimen warrants further preclin. and possible clin. study for a broad spectrum of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWUHPx_ds6mrVg90H21EOLACvtfcHk0lgO4I_U_vgbJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvF2hsLg%253D&md5=3348f1067262e46bb6ba8c8c3d2cb212</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-1751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-1751%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DC.%26aulast%3DFriday%26aufirst%3DB.%2BB.%26aulast%3DLai%26aufirst%3DJ.-P.%26aulast%3DMcCollum%26aufirst%3DA.%26aulast%3DAtadja%26aufirst%3DP.%26aulast%3DRoberts%26aufirst%3DL.%2BR.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DAbrogation%2520of%2520MAPK%2520and%2520Akt%2520Signaling%2520by%2520AEE788%2520Synergistically%2520Potentiates%2520Histone%2520Deacetylase%2520Inhibitor-Induced%2520Apoptosis%2520through%2520Reactive%2520Oxygen%2520Species%2520Generation%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D1140%26epage%3D1148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Chou, T. C</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talalay, P.</span><span> </span><span class="NLM_article-title">Quantitative Analysis of Dose-effect Relationships: the Combined Effects of Multiple Drugs or Enzyme Inhibitors</span> <span class="citation_source-journal">Adv. Enzyme Regul.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">55</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm901453q&amp;key=10.1016%2F0065-2571%2884%2990007-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm901453q&amp;key=6382953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm901453q&amp;key=1%3ACAS%3A528%3ADyaL2cXktlaksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1984&pages=27-55&author=T.+C+Chouauthor=P.+Talalay&title=Quantitative+Analysis+of+Dose-effect+Relationships%3A+the+Combined+Effects+of+Multiple+Drugs+or+Enzyme+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative analysis of dose-effect relationships:  the combined effects of multiple drugs or enzyme inhibitors</span></div><div class="casAuthors">Chou, Ting Chao; Talalay, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Enzyme Regulation</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">27-55</span>CODEN:
                <span class="NLM_cas:coden">AEZRA2</span>;
        ISSN:<span class="NLM_cas:issn">0065-2571</span>.
    </div><div class="casAbstract">A simplified exptl. design method for the anal. of multiple drug effects and for detg. summation, synergism, and antagonism is described.  The method is not limited by: whether the dose-effect relations are hyperbolic or sigmoidal, whether the effects are mutually exclusive or nonexclusive, whether the ligand interactions are competitive, noncompetitive, or uncompetitive, or whether the drugs are agonists or antagonists.  The method is independent of the no. of drugs involved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX4wNupCqgpbVg90H21EOLACvtfcHk0lgO4I_U_vgbJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXktlaksLk%253D&md5=055a2711b52dde49389c3f526352333d</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2F0065-2571%2884%2990007-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0065-2571%252884%252990007-4%26sid%3Dliteratum%253Aachs%26aulast%3DChou%26aufirst%3DT.%2BC%26aulast%3DTalalay%26aufirst%3DP.%26atitle%3DQuantitative%2520Analysis%2520of%2520Dose-effect%2520Relationships%253A%2520the%2520Combined%2520Effects%2520of%2520Multiple%2520Drugs%2520or%2520Enzyme%2520Inhibitors%26jtitle%3DAdv.%2520Enzyme%2520Regul.%26date%3D1984%26volume%3D22%26spage%3D27%26epage%3D55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Bolden, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peart, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnstone, R. E.</span><span> </span><span class="NLM_article-title">Anticancer Activities of Histone Deacetylase Inhibitors</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">769</span><span class="NLM_x">–</span> <span class="NLM_lpage">784</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm901453q&amp;key=10.1038%2Fnrd2133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm901453q&amp;key=16955068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm901453q&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVCltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=769-784&author=J.+E.+Boldenauthor=M.+J.+Peartauthor=R.+E.+Johnstone&title=Anticancer+Activities+of+Histone+Deacetylase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Anticancer activities of histone deacetylase inhibitors</span></div><div class="casAuthors">Bolden, Jessica E.; Peart, Melissa J.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">769-784</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) are enzymes involved in the remodelling of chromatin, and have a key role in the epigenetic regulation of gene expression.  In addn., the activity of non-histone proteins can be regulated through HDAC-mediated hypo-acetylation.  In recent years, inhibition of HDACs has emerged as a potential strategy to reverse aberrant epigenetic changes assocd. with cancer, and several classes of HDAC inhibitors have been found to have potent and specific anticancer activities in preclin. studies.  However, such studies have also indicated that the effects of HDAC inhibitors could be considerably broader and more complicated than originally understood.  Here we summarize recent advances in the understanding of the mol. events that underlie the anticancer effects of HDAC inhibitors, and discuss how such information could be used in optimizing the development and application of these agents in the clinic, either as monotherapies or in combination with other anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhfqS1awkOHbVg90H21EOLACvtfcHk0lgO4I_U_vgbJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVCltrY%253D&md5=91e55ee942fda3e4e2055ddf299fc866</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnrd2133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2133%26sid%3Dliteratum%253Aachs%26aulast%3DBolden%26aufirst%3DJ.%2BE.%26aulast%3DPeart%26aufirst%3DM.%2BJ.%26aulast%3DJohnstone%26aufirst%3DR.%2BE.%26atitle%3DAnticancer%2520Activities%2520of%2520Histone%2520Deacetylase%2520Inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D769%26epage%3D784" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Keri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orfi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eros, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hegymegi-Barakonyi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szantai-Kis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horvath, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waczek, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marosfalvi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabadkai, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pato, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greff, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hafenbradl, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daub, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klebl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span> </span><span class="NLM_article-title">Signal Transduction Therapy with Rationally Designed Kinase Inhibitors</span> <span class="citation_source-journal">Curr. Signal Transduction Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">67</span><span class="NLM_x">–</span> <span class="NLM_lpage">95</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm901453q&amp;key=10.2174%2F157436206775269190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm901453q&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhs1Gis7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=67-95&author=G.+Keriauthor=L.+Orfiauthor=D.+Erosauthor=B.+Hegymegi-Barakonyiauthor=C.+Szantai-Kisauthor=Z.+Horvathauthor=F.+Waczekauthor=J.+Marosfalviauthor=I.+Szabadkaiauthor=J.+Patoauthor=Z.+Greffauthor=D.+Hafenbradlauthor=H.+Daubauthor=G.+Mullerauthor=B.+Kleblauthor=A.+Ullrich&title=Signal+Transduction+Therapy+with+Rationally+Designed+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Signal transduction therapy with rationally designed kinase inhibitors</span></div><div class="casAuthors">Keri, Gyorgy; Orfi, Laszlo; Eros, Daniel; Hegymegi-Barakonyi, Balint; Szantai-Kis, Csaba; Horvath, Zoltan; Waczek, Frigyes; Marosfalvi, Jeno; Szabadkai, Istvan; Pato, Janos; Greff, Zoltan; Hafenbradl, Doris; Daub, Henrik; Muller, Gerhard; Klebl, Bert; Ullrich, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Current Signal Transduction Therapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-95</span>CODEN:
                <span class="NLM_cas:coden">CSTTBV</span>;
        ISSN:<span class="NLM_cas:issn">1574-3624</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Signal transduction therapy has become one of the most important areas of drug research.  Signaling disorders represent a major cause for the pathol. states and many of the recently identified validated target mols. of drug research are signal transduction related macromols., mostly kinases.  Rational drug design is aimed to achieve the selective inhibition of distinct pathol. relevant signaling enzymes or receptors.  In the previous years, the concept of rational drug design has been expanded for a complex process including pathomechanism-based target selection, target validation, structural biol., mol. modeling, structure-activity relationships, pharmacophore-based compd. selection and pharmacol. optimization.  The two main branches of the chem. rational drug design are structure-based design and ligand-based design.  Some important examples for the application of 3D structure-based rational drug design in the development of clin. relevant kinase inhibitors are presented.  The Nested Chem. Library (NCL) technol. is a ligand-based design approach and relies on a knowledge-based approach, where focused libraries around published leads and selected cores are used to generate extended pharmacophore models (Prediction Oriented QSAR).  NCL was designed on the platform of a diverse kinase inhibitor library, consisting of small mol. heterocycles, which are organized around 108 core structures.  Some examples for testing the library on various targets and Prediction Oriented QSAR models will also be presented.  The core elements of the kinase family-biased masterkey concept are the so-called privileged structures that emerge from a sophisticated mol. design and optimization process that encodes for a target family-wide structural commonality in ligand binding.  The combination of a kinase family-wide imprinted commonality with addnl. structural fragments in the mol. periphery of a once established privileged structure allows to synthesize highly active and selective kinase inhibitors.  In addn., several kinase inhibitors in preclin. or clin. development and application of 3D structure based rational drug design in the development of clin. relevant kinase inhibitors are reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrciqRCaicLB7Vg90H21EOLACvtfcHk0lgO4I_U_vgbJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhs1Gis7Y%253D&md5=2193e359dee7044ed8ecd873e76f0583</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.2174%2F157436206775269190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157436206775269190%26sid%3Dliteratum%253Aachs%26aulast%3DKeri%26aufirst%3DG.%26aulast%3DOrfi%26aufirst%3DL.%26aulast%3DEros%26aufirst%3DD.%26aulast%3DHegymegi-Barakonyi%26aufirst%3DB.%26aulast%3DSzantai-Kis%26aufirst%3DC.%26aulast%3DHorvath%26aufirst%3DZ.%26aulast%3DWaczek%26aufirst%3DF.%26aulast%3DMarosfalvi%26aufirst%3DJ.%26aulast%3DSzabadkai%26aufirst%3DI.%26aulast%3DPato%26aufirst%3DJ.%26aulast%3DGreff%26aufirst%3DZ.%26aulast%3DHafenbradl%26aufirst%3DD.%26aulast%3DDaub%26aufirst%3DH.%26aulast%3DMuller%26aufirst%3DG.%26aulast%3DKlebl%26aufirst%3DB.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DSignal%2520Transduction%2520Therapy%2520with%2520Rationally%2520Designed%2520Kinase%2520Inhibitors%26jtitle%3DCurr.%2520Signal%2520Transduction%2520Ther.%26date%3D2006%26volume%3D1%26spage%3D67%26epage%3D95" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Acharya, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sparreboom, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venitz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Figg, W. D.</span><span> </span><span class="NLM_article-title">Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">917</span><span class="NLM_x">–</span> <span class="NLM_lpage">932</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2005&pages=917-932&author=M.+R.+Acharyaauthor=A.+Sparreboomauthor=J.+Venitzauthor=W.+D.+Figg&title=Rational+Development+of+Histone+Deacetylase+Inhibitors+as+Anticancer+Agents%3A+A+Review"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAcharya%26aufirst%3DM.%2BR.%26aulast%3DSparreboom%26aufirst%3DA.%26aulast%3DVenitz%26aufirst%3DJ.%26aulast%3DFigg%26aufirst%3DW.%2BD.%26atitle%3DRational%2520Development%2520of%2520Histone%2520Deacetylase%2520Inhibitors%2520as%2520Anticancer%2520Agents%253A%2520A%2520Review%26jtitle%3DMol.%2520Pharmacol.%26date%3D2005%26volume%3D68%26spage%3D917%26epage%3D932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Collins, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span> </span><span class="NLM_article-title">Design and Development of Signal Transduction Inhibitors for Cancer Treatment: Experience and Challenges with Kinase Targets</span> <span class="citation_source-journal">Curr. Signal Transduction Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">13</span><span class="NLM_x">–</span> <span class="NLM_lpage">23</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm901453q&amp;key=10.2174%2F157436206775269181" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm901453q&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhs1Gis7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=13-23&author=I.+Collinsauthor=P.+Workman&title=Design+and+Development+of+Signal+Transduction+Inhibitors+for+Cancer+Treatment%3A+Experience+and+Challenges+with+Kinase+Targets"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Design and development of signal transduction inhibitors for cancer treatment: experience and challenges with kinase targets</span></div><div class="casAuthors">Collins, Ian; Workman, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Current Signal Transduction Therapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-23</span>CODEN:
                <span class="NLM_cas:coden">CSTTBV</span>;
        ISSN:<span class="NLM_cas:issn">1574-3624</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The last several years have seen major progress towards the goal of translating our growing understanding of the mol. basis of cancer into drugs with improved therapeutic activity and selectivity.  Tremendous advances have been made but significant obstacles remain.  In this review we assess our experience in the design and development of signal transduction drugs for cancer treatment, with a specific focus on small mol. kinase inhibitors.  The druggability of cancer kinome targets is exemplified by imatinib, gefitinib, erlotinib and many other emerging agents.  We assess the current status of the design of potent and selective kinase inhibitors, which has benefited greatly from high throughput screening and structure-based approaches.  A diverse range of kinase inhibitory scaffolds is now available based on these methods.  Multi-parameter optimization now focuses as much on pharmacokinetic and metabolic properties as it does on target potency and selectivity.  Development of a 'mol. audit trail' requiring assays to demonstrate mechanism of action in vitro and in vivo is essential.  Current issues include our relatively poor ability to predict the level of kinase selectivity in the intact cell, uncertainties around the most desirable selectivity profile, and the emergence of drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4PMWClBEM9rVg90H21EOLACvtfcHk0lg5qrb3TQuydA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhs1Gis7s%253D&md5=02782d829d340091081de5f8d72c31fb</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.2174%2F157436206775269181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157436206775269181%26sid%3Dliteratum%253Aachs%26aulast%3DCollins%26aufirst%3DI.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DDesign%2520and%2520Development%2520of%2520Signal%2520Transduction%2520Inhibitors%2520for%2520Cancer%2520Treatment%253A%2520Experience%2520and%2520Challenges%2520with%2520Kinase%2520Targets%26jtitle%3DCurr.%2520Signal%2520Transduction%2520Ther.%26date%3D2006%26volume%3D1%26spage%3D13%26epage%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Stamos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span> </span><span class="NLM_article-title">Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">46265</span><span class="NLM_x">–</span> <span class="NLM_lpage">46272</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2002&pages=46265-46272&author=J.+Stamosauthor=M.+X.+Sliwkowskiauthor=C.+Eigenbrot&title=Structure+of+the+Epidermal+Growth+Factor+Receptor+Kinase+Domain+Alone+and+in+Complex+with+a+4-Anilinoquinazoline+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStamos%26aufirst%3DJ.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DEigenbrot%26aufirst%3DC.%26atitle%3DStructure%2520of%2520the%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Kinase%2520Domain%2520Alone%2520and%2520in%2520Complex%2520with%2520a%25204-Anilinoquinazoline%2520Inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D48%26spage%3D46265%26epage%3D46272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Wang, D.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helquist, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiech, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiest†, O.</span><span> </span><span class="NLM_article-title">Toward Selective Histone Deacetylase Inhibitor Design: Homology Modeling, Docking Studies, and Molecular Dynamics Simulations of Human Class I Histone Deacetylases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">6936</span><span class="NLM_x">–</span> <span class="NLM_lpage">6947</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0505011" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm901453q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtV2jsLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6936-6947&author=D.-F.+Wangauthor=P.+Helquistauthor=N.+L.+Wiechauthor=O.+Wiest%E2%80%A0&title=Toward+Selective+Histone+Deacetylase+Inhibitor+Design%3A+Homology+Modeling%2C+Docking+Studies%2C+and+Molecular+Dynamics+Simulations+of+Human+Class+I+Histone+Deacetylases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Toward Selective Histone Deacetylase Inhibitor Design: Homology Modeling, Docking Studies, and Molecular Dynamics Simulations of Human Class I Histone Deacetylases</span></div><div class="casAuthors">Wang, Di-Fei; Helquist, Paul; Wiech, Norbert L.; Wiest, Olaf</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6936-6947</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) play an important role in gene transcription.  Inhibitors of HDACs induce cell differentiation and suppress cell proliferation in tumor cells.  Although many HDAC inhibitors have been designed and synthesized, selective inhibition for class I HDAC isoforms is a goal that has yet to be achieved.  To understand the difference between class I HDAC isoforms that could be exploited for the design of isoform-specific HDAC inhibitors, the authors have built three-dimensional models of four class I histone deacetylases, HDAC1, HDAC2, HDAC3, and HDAC8.  Comparison of the homol. model of HDAC8 with the recently published x-ray structure shows excellent agreement and validates the approach.  A series of HDAC inhibitors were docked to the homol. models to understand the similarities and differences between the binding modes.  Mol. dynamic simulations of these HDAC-inhibitor complexes indicate that the interaction between the protein surface and inhibitor is playing an important role; also some active site residues show some flexibility, which is usually not included in routine docking protocols.  The implications of these results for the design of isoform-selective HDAC inhibitors are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqb6SYJC1ObVLVg90H21EOLACvtfcHk0lg5qrb3TQuydA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtV2jsLnL&md5=0b59815173df7f16feb9ba66c8b4da83</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm0505011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0505011%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DD.-F.%26aulast%3DHelquist%26aufirst%3DP.%26aulast%3DWiech%26aufirst%3DN.%2BL.%26aulast%3DWiest%25E2%2580%25A0%26aufirst%3DO.%26atitle%3DToward%2520Selective%2520Histone%2520Deacetylase%2520Inhibitor%2520Design%253A%2520Homology%2520Modeling%252C%2520Docking%2520Studies%252C%2520and%2520Molecular%2520Dynamics%2520Simulations%2520of%2520Human%2520Class%2520I%2520Histone%2520Deacetylases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6936%26epage%3D6947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Finnin, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donigian, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richon, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rifkind, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marks, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslow, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavletich, N. P.</span><span> </span><span class="NLM_article-title">Structures of a Histone Deacetylase Homologue Bound to the TSA and SAHA Inhibitors</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">401</span><span class="NLM_x">, </span> <span class="NLM_fpage">188</span><span class="NLM_x">–</span> <span class="NLM_lpage">193</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm901453q&amp;key=10.1038%2F43710" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm901453q&amp;key=10490031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm901453q&amp;key=1%3ACAS%3A528%3ADyaK1MXlvFKgtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=401&publication_year=1999&pages=188-193&author=M.+S.+Finninauthor=J.+R.+Donigianauthor=A.+Cohenauthor=V.+M.+Richonauthor=R.+A.+Rifkindauthor=P.+A.+Marksauthor=R.+Breslowauthor=N.+P.+Pavletich&title=Structures+of+a+Histone+Deacetylase+Homologue+Bound+to+the+TSA+and+SAHA+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors</span></div><div class="casAuthors">Finnin, Michael S.; Donigian, Jill R.; Cohen, Alona; Richon, Victoria M.; Rifkind, Richard A.; Marks, Paul A.; Breslow, Ronald; Pavletich, Nikola P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">401</span>
        (<span class="NLM_cas:issue">6749</span>),
    <span class="NLM_cas:pages">188-193</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) mediate changes in nucleosome conformation and are important in the regulation of gene expression.  HDACs are involved in cell-cycle progression and differentiation, and their deregulation is assocd. with several cancers.  HDAC inhibitors, such as trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA), have anti-tumor effects, as they can inhibit cell growth, induce terminal differentiation and prevent the formation of tumors in mice models, and they are effective in the treatment of promyelocytic leukemia.  Here we describe the structure of the histone deacetylase catalytic core, as revealed by the crystal structure of a homolog from the hyperthermophilic bacterium Aquifex aeolicus, that shares 35.2% identity with human HDAC1 over 375 residues, deacetylates histones in vitro and is inhibited by TSA and SAHA.  The deacetylase, deacetylase-TSA and deacetylase-SAHA structures reveal an active site consisting of a tubular pocket, a zinc-binding site and two Asp-His charge-relay systems, and establish the mechanism of HDAC inhibition.  The residues that make up the active site and contact the inhibitors are conserved across the HDAC family.  These structures also suggest a mechanism for the deacetylation reaction and provide a framework for the further development of HDAC inhibitors as antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrG0lsZMMo37Vg90H21EOLACvtfcHk0lg7Te4xTL9rHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvFKgtrc%253D&md5=29bbc6d3ba9a9d2a8c330349ae8199a8</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2F43710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F43710%26sid%3Dliteratum%253Aachs%26aulast%3DFinnin%26aufirst%3DM.%2BS.%26aulast%3DDonigian%26aufirst%3DJ.%2BR.%26aulast%3DCohen%26aufirst%3DA.%26aulast%3DRichon%26aufirst%3DV.%2BM.%26aulast%3DRifkind%26aufirst%3DR.%2BA.%26aulast%3DMarks%26aufirst%3DP.%2BA.%26aulast%3DBreslow%26aufirst%3DR.%26aulast%3DPavletich%26aufirst%3DN.%2BP.%26atitle%3DStructures%2520of%2520a%2520Histone%2520Deacetylase%2520Homologue%2520Bound%2520to%2520the%2520TSA%2520and%2520SAHA%2520Inhibitors%26jtitle%3DNature%26date%3D1999%26volume%3D401%26spage%3D188%26epage%3D193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Gibson, K. H.</span><span> </span><span class="NLM_article-title">Quinazoline Derivatives</span>. U.S. Patent 5,770,599,<span class="NLM_x"> </span><span class="NLM_year">1998</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1998&author=K.+H.+Gibson&title=Quinazoline+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGibson%26aufirst%3DK.%2BH.%26atitle%3DQuinazoline%2520Derivatives%26date%3D1998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Barker, A. J.</span><span> </span><span class="NLM_article-title">Quinazoline Derivatives Useful for Treatment of Neoplastic Disease</span>. U.S. Patent5,457,105,<span class="NLM_x"> </span><span class="NLM_year">1995</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1995&author=A.+J.+Barker&title=Quinazoline+Derivatives+Useful+for+Treatment+of+Neoplastic+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBarker%26aufirst%3DA.%2BJ.%26atitle%3DQuinazoline%2520Derivatives%2520Useful%2520for%2520Treatment%2520of%2520Neoplastic%2520Disease%26date%3D1995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Alley, M. C.; Hollingshead, M. D.; Dykes, D.</span><span> </span><span class="NLM_article-title">Human Tumor Xenograft Models in NCI Drug Development</span>. In  <span class="citation_source-book">Anticancer drug development guide</span>; <span class="NLM_contrib-group">Teicher, B. A.; Andrews, P. A.</span>, Eds.; <span class="NLM_publisher-name">Humana Press Inc.</span>: <span class="NLM_publisher-loc">Totowa, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2004</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">125</span>− <span class="NLM_lpage">152</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&pages=125-152&author=M.+C.+Alley&author=M.+D.+Hollingshead&author=D.+Dykesauthor=B.+A.+Teicher&author=P.+A.+Andrews&title=Anticancer+drug+development+guide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DAlley%26aufirst%3DM.%2BC.%26atitle%3DHuman%2520Tumor%2520Xenograft%2520Models%2520in%2520NCI%2520Drug%2520Development%26btitle%3DAnticancer%2520drug%2520development%2520guide%26aulast%3DTeicher%26aufirst%3DB.%2BA.%26pub%3DHumana%2520Press%2520Inc%26date%3D2004%26spage%3D125%26epage%3D152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 164 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Nilanjan Adhikari, Tarun Jha, <span class="NLM_string-name hlFld-ContribAuthor">Balaram Ghosh</span>. </span><span class="cited-content_cbyCitation_article-title">Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (13)
                                     , 8827-8869. <a href="https://doi.org/10.1021/acs.jmedchem.0c01676" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01676</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01676&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01676%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDissecting%252BHistone%252BDeacetylase%252B3%252Bin%252BMultiple%252BDisease%252BConditions%25253A%252BSelective%252BInhibition%252Bas%252Ba%252BPromising%252BTherapeutic%252BStrategy%26aulast%3DAdhikari%26aufirst%3DNilanjan%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D24092020%26date%3D23062021%26volume%3D64%26issue%3D13%26spage%3D8827%26epage%3D8869" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaopeng Peng, Jingxuan Chen, Ling Li, Zhiqiang Sun, Jin Liu, Yichang Ren, Junli Huang, <span class="NLM_string-name hlFld-ContribAuthor">Jianjun Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Efficient Synthesis and Bioevaluation of Novel Dual Tubulin/Histone Deacetylase 3 Inhibitors as Potential Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 8447-8473. <a href="https://doi.org/10.1021/acs.jmedchem.1c00413" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00413</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00413%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DEfficient%252BSynthesis%252Band%252BBioevaluation%252Bof%252BNovel%252BDual%252BTubulin%25252FHistone%252BDeacetylase%252B3%252BInhibitors%252Bas%252BPotential%252BAnticancer%252BAgents%26aulast%3DPeng%26aufirst%3DXiaopeng%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D08032021%26date%3D07062021%26volume%3D64%26issue%3D12%26spage%3D8447%26epage%3D8473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yuhao Ren, Shanshan Li, Ren Zhu, Chengying Wan, Dongmei Song, Jiawen Zhu, Guiping Cai, Sihui Long, Lingyi Kong, <span class="NLM_string-name hlFld-ContribAuthor">Wenying Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (11)
                                     , 7468-7482. <a href="https://doi.org/10.1021/acs.jmedchem.1c00136" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00136</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00136%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BSTAT3%252Band%252BHistone%252BDeacetylase%252B%252528HDAC%252529%252BDual-Pathway%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BSolid%252BCancer%26aulast%3DRen%26aufirst%3DYuhao%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D24012021%26date%3D27052021%26volume%3D64%26issue%3D11%26spage%3D7468%26epage%3D7482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Tamer A. Elwaie, Safinaz E. Abbas, Enayat I. Aly, Riham F. George, Hamdy Ali, Nikolai Kraiouchkine, Khaldoun S. Abdelwahed, Tamer E. Fandy, Khalid A. El Sayed, Zakaria Y. Abd Elmageed, <span class="NLM_string-name hlFld-ContribAuthor">Hamed I. Ali</span>. </span><span class="cited-content_cbyCitation_article-title">HER2 Kinase-Targeted Breast Cancer Therapy: Design, Synthesis, and In Vitro and In Vivo Evaluation of Novel Lapatinib Congeners as Selective and Potent HER2 Inhibitors with Favorable Metabolic Stability. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (24)
                                     , 15906-15945. <a href="https://doi.org/10.1021/acs.jmedchem.0c01647" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01647</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01647%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHER2%252BKinase-Targeted%252BBreast%252BCancer%252BTherapy%25253A%252BDesign%25252C%252BSynthesis%25252C%252Band%252BIn%252BVitro%252Band%252BIn%252BVivo%252BEvaluation%252Bof%252BNovel%252BLapatinib%252BCongeners%252Bas%252BSelective%252Band%252BPotent%252BHER2%252BInhibitors%252Bwith%252BFavorable%252BMetabolic%252BStability%26aulast%3DElwaie%26aufirst%3DTamer%2BA.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D21092020%26date%3D14122020%26volume%3D63%26issue%3D24%26spage%3D15906%26epage%3D15945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Terence C. S. Ho, Alex H. Y. Chan, <span class="NLM_string-name hlFld-ContribAuthor">A. Ganesan</span>. </span><span class="cited-content_cbyCitation_article-title">Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (21)
                                     , 12460-12484. <a href="https://doi.org/10.1021/acs.jmedchem.0c00830" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00830</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00830%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThirty%252BYears%252Bof%252BHDAC%252BInhibitors%25253A%252B2020%252BInsight%252Band%252BHindsight%26aulast%3DHo%26aufirst%3DTerence%2BC.%2BS.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D15052020%26date%3D16072020%26date%3D01072020%26volume%3D63%26issue%3D21%26spage%3D12460%26epage%3D12484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Atamjit Singh, Jatinder Vir Singh, Abhineet Rana, Kavita Bhagat, Harmandeep Kaur Gulati, Raman Kumar, Rajan Salwan, Kajal Bhagat, Gurinder Kaur, Navjot Singh, Randeep Kumar, Harbinder Singh, Sahil Sharma, <span class="NLM_string-name hlFld-ContribAuthor">Preet Mohinder Singh Bedi</span>. </span><span class="cited-content_cbyCitation_article-title">Monocarbonyl Curcumin-Based Molecular Hybrids as Potent Antibacterial Agents. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2019,</strong> <em>4 </em>
                                    (7)
                                     , 11673-11684. <a href="https://doi.org/10.1021/acsomega.9b01109" title="DOI URL">https://doi.org/10.1021/acsomega.9b01109</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.9b01109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.9b01109%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DMonocarbonyl%252BCurcumin-Based%252BMolecular%252BHybrids%252Bas%252BPotent%252BAntibacterial%252BAgents%26aulast%3DSingh%26aufirst%3DAtamjit%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D17042019%26date%3D14062019%26volume%3D4%26issue%3D7%26spage%3D11673%26epage%3D11684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yepeng Luan, Jerry Li, Jean A. Bernatchez, <span class="NLM_string-name hlFld-ContribAuthor">Rongshi Li</span>. </span><span class="cited-content_cbyCitation_article-title">Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (7)
                                     , 3171-3183. <a href="https://doi.org/10.1021/acs.jmedchem.8b00189" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00189</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00189%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DKinase%252Band%252BHistone%252BDeacetylase%252BHybrid%252BInhibitors%252Bfor%252BCancer%252BTherapy%26aulast%3DLuan%26aufirst%3DYepeng%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D05022018%26date%3D16112018%26date%3D12112018%26volume%3D62%26issue%3D7%26spage%3D3171%26epage%3D3183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lianbin  Yao</span>, <span class="hlFld-ContribAuthor ">Nurulhuda  Mustafa</span>, <span class="hlFld-ContribAuthor ">Eng Chong  Tan</span>, <span class="hlFld-ContribAuthor ">Anders  Poulsen</span>, <span class="hlFld-ContribAuthor ">Prachi  Singh</span>, <span class="hlFld-ContribAuthor ">Minh-Dao  Duong-Thi</span>, <span class="hlFld-ContribAuthor ">Jeannie X. T.  Lee</span>, <span class="hlFld-ContribAuthor ">Pondy Murugappan  Ramanujulu</span>, <span class="hlFld-ContribAuthor ">Wee Joo  Chng</span>, <span class="hlFld-ContribAuthor ">Jeffrey J. Y.  Yen</span>, <span class="hlFld-ContribAuthor ">Sten  Ohlson</span>, and <span class="hlFld-ContribAuthor ">Brian W.  Dymock</span>  . </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (20)
                                     , 8336-8357. <a href="https://doi.org/10.1021/acs.jmedchem.7b00678" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00678</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00678%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BLigand%252BEfficient%252BDual%252BInhibitors%252Bof%252BJanus%252BKinase%252B%252528JAK%252529%252Band%252BHistone%252BDeacetylase%252B%252528HDAC%252529%252BBased%252Bon%252BRuxolitinib%252Band%252BVorinostat%26aulast%3DYao%26aufirst%3DLianbin%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D11052017%26date%3D10102017%26date%3D26102017%26date%3D27092017%26volume%3D60%26issue%3D20%26spage%3D8336%26epage%3D8357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dong  Lu</span>, <span class="hlFld-ContribAuthor ">Juan  Yan</span>, <span class="hlFld-ContribAuthor ">Lang  Wang</span>, <span class="hlFld-ContribAuthor ">Hongchun  Liu</span>, <span class="hlFld-ContribAuthor ">Limin  Zeng</span>, <span class="hlFld-ContribAuthor ">Minmin  Zhang</span>, <span class="hlFld-ContribAuthor ">Wenwen  Duan</span>, <span class="hlFld-ContribAuthor ">Yinchun  Ji</span>, <span class="hlFld-ContribAuthor ">Jingchen  Cao</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, <span class="hlFld-ContribAuthor ">Aijun  Shen</span>, and <span class="hlFld-ContribAuthor ">Youhong  Hu</span>  . </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of the First c-Met/HDAC Inhibitors Based on Pyridazinone Derivatives. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>8 </em>
                                    (8)
                                     , 830-834. <a href="https://doi.org/10.1021/acsmedchemlett.7b00172" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.7b00172</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.7b00172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.7b00172%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252Bthe%252BFirst%252Bc-Met%25252FHDAC%252BInhibitors%252BBased%252Bon%252BPyridazinone%252BDerivatives%26aulast%3DLu%26aufirst%3DDong%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D22042017%26date%3D18072017%26date%3D19072017%26date%3D10082017%26date%3D18072017%26volume%3D8%26issue%3D8%26spage%3D830%26epage%3D834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Weiqiang  Lu</span>, <span class="hlFld-ContribAuthor ">Xue  Yao</span>, <span class="hlFld-ContribAuthor ">Ping  Ouyang</span>, <span class="hlFld-ContribAuthor ">Ningning  Dong</span>, <span class="hlFld-ContribAuthor ">Dang  Wu</span>, <span class="hlFld-ContribAuthor ">Xingwu  Jiang</span>, <span class="hlFld-ContribAuthor ">Zengrui  Wu</span>, <span class="hlFld-ContribAuthor ">Chen  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhongyu  Xu</span>, <span class="hlFld-ContribAuthor ">Yun  Tang</span>, <span class="hlFld-ContribAuthor ">Shien  Zou</span>, <span class="hlFld-ContribAuthor ">Mingyao  Liu</span>, <span class="hlFld-ContribAuthor ">Jian  Li</span>, <span class="hlFld-ContribAuthor ">Minghua  Zeng</span>, <span class="hlFld-ContribAuthor ">Ping  Lin</span>, <span class="hlFld-ContribAuthor ">Feixiong  Cheng</span>, and <span class="hlFld-ContribAuthor ">Jin  Huang</span>  . </span><span class="cited-content_cbyCitation_article-title">Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (5)
                                     , 1817-1828. <a href="https://doi.org/10.1021/acs.jmedchem.6b01507" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01507</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01507%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDrug%252BRepurposing%252Bof%252BHistone%252BDeacetylase%252BInhibitors%252BThat%252BAlleviate%252BNeutrophilic%252BInflammation%252Bin%252BAcute%252BLung%252BInjury%252Band%252BIdiopathic%252BPulmonary%252BFibrosis%252Bvia%252BInhibiting%252BLeukotriene%252BA4%252BHydrolase%252Band%252BBlocking%252BLTB4%252BBiosynthesis%26aulast%3DLu%26aufirst%3DWeiqiang%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D17102016%26date%3D28022017%26date%3D09032017%26date%3D20022017%26volume%3D60%26issue%3D5%26spage%3D1817%26epage%3D1828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Timothy P.  Heffron</span>  . </span><span class="cited-content_cbyCitation_article-title">Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (22)
                                     , 10030-10066. <a href="https://doi.org/10.1021/acs.jmedchem.6b00618" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00618</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00618%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall%252BMolecule%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BBrain%252BCancer%26aulast%3DHeffron%26aufirst%3DTimothy%2BP.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D21042016%26date%3D03082016%26date%3D23112016%26date%3D14072016%26volume%3D59%26issue%3D22%26spage%3D10030%26epage%3D10066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eugene Guorong  Yang</span>, <span class="hlFld-ContribAuthor ">Nurulhuda  Mustafa</span>, <span class="hlFld-ContribAuthor ">Eng Chong  Tan</span>, <span class="hlFld-ContribAuthor ">Anders  Poulsen</span>, <span class="hlFld-ContribAuthor ">Pondy Murugappan  Ramanujulu</span>, <span class="hlFld-ContribAuthor ">Wee Joo  Chng</span>, <span class="hlFld-ContribAuthor ">Jeffrey J. Y.  Yen</span>, and <span class="hlFld-ContribAuthor ">Brian W.  Dymock</span>  . </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (18)
                                     , 8233-8262. <a href="https://doi.org/10.1021/acs.jmedchem.6b00157" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00157</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00157%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BJanus%252BKinase%252B2%252B%252528JAK2%252529%252Band%252BHistone%252BDeacetlyase%252B%252528HDAC%252529%252BBispecific%252BInhibitors%252BBased%252Bon%252BPacritinib%252Band%252BEvidence%252Bof%252BDual%252BPathway%252BInhibition%252Bin%252BHematological%252BCell%252BLines%26aulast%3DYang%26aufirst%3DEugene%2BGuorong%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D03022016%26date%3D08092016%26date%3D22092016%26date%3D19082016%26volume%3D59%26issue%3D18%26spage%3D8233%26epage%3D8262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhuang  Yang</span>, <span class="hlFld-ContribAuthor ">Taijin  Wang</span>, <span class="hlFld-ContribAuthor ">Fang  Wang</span>, <span class="hlFld-ContribAuthor ">Ting  Niu</span>, <span class="hlFld-ContribAuthor ">Zhuowei  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaoxin  Chen</span>, <span class="hlFld-ContribAuthor ">Chaofeng  Long</span>, <span class="hlFld-ContribAuthor ">Minghai  Tang</span>, <span class="hlFld-ContribAuthor ">Dong  Cao</span>, <span class="hlFld-ContribAuthor ">Xiaoyan  Wang</span>, <span class="hlFld-ContribAuthor ">Wei  Xiang</span>, <span class="hlFld-ContribAuthor ">Yuyao  Yi</span>, <span class="hlFld-ContribAuthor ">Liang  Ma</span>, <span class="hlFld-ContribAuthor ">Jingsong  You</span>, and <span class="hlFld-ContribAuthor ">Lijuan  Chen</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (4)
                                     , 1455-1470. <a href="https://doi.org/10.1021/acs.jmedchem.5b01342" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01342</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01342%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BSelective%252BHistone%252BDeacetylase%252B6%252BInhibitors%252BUsing%252Bthe%252BQuinazoline%252Bas%252Bthe%252BCap%252Bfor%252Bthe%252BTreatment%252Bof%252BCancer%26aulast%3DYang%26aufirst%3DZhuang%26date%3D2016%26date%3D2015%26date%3D2015%26date%3D20062015%26date%3D13102015%26date%3D25022016%26date%3D06102015%26volume%3D59%26issue%3D4%26spage%3D1455%26epage%3D1470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mark P.  Thomas</span> and <span class="hlFld-ContribAuthor ">Barry V. L.  Potter</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery and Development of the Aryl O-Sulfamate Pharmacophore for Oncology and Women’s Health. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (19)
                                     , 7634-7658. <a href="https://doi.org/10.1021/acs.jmedchem.5b00386" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00386</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00386%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BDevelopment%252Bof%252Bthe%252BAryl%252BO-Sulfamate%252BPharmacophore%252Bfor%252BOncology%252Band%252BWomen%2525E2%252580%252599s%252BHealth%26aulast%3DThomas%26aufirst%3DMark%2BP.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D10032015%26date%3D12062015%26date%3D08102015%26date%3D20052015%26volume%3D58%26issue%3D19%26spage%3D7634%26epage%3D7658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shinichi  Sato</span>, <span class="hlFld-ContribAuthor ">Kohei  Morita</span>, and <span class="hlFld-ContribAuthor ">Hiroyuki  Nakamura</span>  . </span><span class="cited-content_cbyCitation_article-title">Regulation of Target Protein Knockdown and Labeling Using Ligand-Directed Ru(bpy)3 Photocatalyst. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2015,</strong> <em>26 </em>
                                    (2)
                                     , 250-256. <a href="https://doi.org/10.1021/bc500518t" title="DOI URL">https://doi.org/10.1021/bc500518t</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/bc500518t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fbc500518t%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DRegulation%252Bof%252BTarget%252BProtein%252BKnockdown%252Band%252BLabeling%252BUsing%252BLigand-Directed%252BRu%252528bpy%2525293%252BPhotocatalyst%26aulast%3DSato%26aufirst%3DShinichi%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D2014%26date%3D11112014%26date%3D06122014%26date%3D15012015%26date%3D18022015%26date%3D30122014%26volume%3D26%26issue%3D2%26spage%3D250%26epage%3D256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qingqing  Meng</span>, <span class="hlFld-ContribAuthor ">Feng  Li</span>, <span class="hlFld-ContribAuthor ">Sheng  Jiang</span>, and <span class="hlFld-ContribAuthor ">Zheng  Li</span>  . </span><span class="cited-content_cbyCitation_article-title">Novel 64Cu-Labeled CUDC-101 for in Vivo PET Imaging of Histone Deacetylases. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2013,</strong> <em>4 </em>
                                    (9)
                                     , 858-862. <a href="https://doi.org/10.1021/ml400191z" title="DOI URL">https://doi.org/10.1021/ml400191z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ml400191z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fml400191z%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DNovel%252B64Cu-Labeled%252BCUDC-101%252Bfor%252Bin%252BVivo%252BPET%252BImaging%252Bof%252BHistone%252BDeacetylases%26aulast%3DMeng%26aufirst%3DQingqing%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D17052013%26date%3D25072013%26date%3D06082013%26date%3D12092013%26date%3D25072013%26volume%3D4%26issue%3D9%26spage%3D858%26epage%3D862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kristin S.  Ko</span>, <span class="hlFld-ContribAuthor ">Michael E.  Steffey</span>, <span class="hlFld-ContribAuthor ">Kristoffer R.  Brandvold</span>, and <span class="hlFld-ContribAuthor ">Matthew B.  Soellner</span>  . </span><span class="cited-content_cbyCitation_article-title">Development of a Chimeric c-Src Kinase and HDAC Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2013,</strong> <em>4 </em>
                                    (8)
                                     , 779-783. <a href="https://doi.org/10.1021/ml400175d" title="DOI URL">https://doi.org/10.1021/ml400175d</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ml400175d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fml400175d%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDevelopment%252Bof%252Ba%252BChimeric%252Bc-Src%252BKinase%252Band%252BHDAC%252BInhibitor%26aulast%3DKo%26aufirst%3DKristin%2BS.%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D10052013%26date%3D03072013%26date%3D11072013%26date%3D08082013%26date%3D03072013%26volume%3D4%26issue%3D8%26spage%3D779%26epage%3D783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gautam  Patel</span>, <span class="hlFld-ContribAuthor ">Caitlin E.  Karver</span>, <span class="hlFld-ContribAuthor ">Ranjan  Behera</span>, <span class="hlFld-ContribAuthor ">Paul J.  Guyett</span>, <span class="hlFld-ContribAuthor ">Catherine  Sullenberger</span>, <span class="hlFld-ContribAuthor ">Peter  Edwards</span>, <span class="hlFld-ContribAuthor ">Norma E.  Roncal</span>, <span class="hlFld-ContribAuthor ">Kojo  Mensa-Wilmot</span>, and <span class="hlFld-ContribAuthor ">Michael P.  Pollastri</span>  . </span><span class="cited-content_cbyCitation_article-title">Kinase Scaffold Repurposing for Neglected Disease Drug Discovery: Discovery of an Efficacious, Lapatanib-Derived Lead Compound for Trypanosomiasis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (10)
                                     , 3820-3832. <a href="https://doi.org/10.1021/jm400349k" title="DOI URL">https://doi.org/10.1021/jm400349k</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm400349k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm400349k%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DKinase%252BScaffold%252BRepurposing%252Bfor%252BNeglected%252BDisease%252BDrug%252BDiscovery%25253A%252BDiscovery%252Bof%252Ban%252BEfficacious%25252C%252BLapatanib-Derived%252BLead%252BCompound%252Bfor%252BTrypanosomiasis%26aulast%3DPatel%26aufirst%3DGautam%26date%3D2013%26date%3D2013%26date%3D2012%26date%3D27112012%26date%3D03052013%26date%3D23052013%26date%3D18042013%26volume%3D56%26issue%3D10%26spage%3D3820%26epage%3D3832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jhih-Bin  Chen</span>, <span class="hlFld-ContribAuthor ">Ting-Rong  Chern</span>, <span class="hlFld-ContribAuthor ">Tzu-Tang  Wei</span>, <span class="hlFld-ContribAuthor ">Ching-Chow  Chen</span>, <span class="hlFld-ContribAuthor ">Jung-Hsin  Lin</span>, and <span class="hlFld-ContribAuthor ">Jim-Min  Fang</span>  . </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Dual-Action Inhibitors Targeting Histone Deacetylases and 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase for Cancer Treatment. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (9)
                                     , 3645-3655. <a href="https://doi.org/10.1021/jm400179b" title="DOI URL">https://doi.org/10.1021/jm400179b</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm400179b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm400179b%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BDual-Action%252BInhibitors%252BTargeting%252BHistone%252BDeacetylases%252Band%252B3-Hydroxy-3-methylglutaryl%252BCoenzyme%252BA%252BReductase%252Bfor%252BCancer%252BTreatment%26aulast%3DChen%26aufirst%3DJhih-Bin%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D03022013%26date%3D22042013%26date%3D09052013%26date%3D09042013%26volume%3D56%26issue%3D9%26spage%3D3645%26epage%3D3655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">William  Guerrant</span>, <span class="hlFld-ContribAuthor ">Vishal  Patil</span>, <span class="hlFld-ContribAuthor ">Joshua C.  Canzoneri</span>, and <span class="hlFld-ContribAuthor ">Adegboyega K.  Oyelere</span>  . </span><span class="cited-content_cbyCitation_article-title">Dual Targeting of Histone Deacetylase and Topoisomerase II with Novel Bifunctional Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>55 </em>
                                    (4)
                                     , 1465-1477. <a href="https://doi.org/10.1021/jm200799p" title="DOI URL">https://doi.org/10.1021/jm200799p</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm200799p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm200799p%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDual%252BTargeting%252Bof%252BHistone%252BDeacetylase%252Band%252BTopoisomerase%252BII%252Bwith%252BNovel%252BBifunctional%252BInhibitors%26aulast%3DGuerrant%26aufirst%3DWilliam%26date%3D2012%26date%3D2012%26date%3D2011%26date%3D25032011%26date%3D13022012%26date%3D23022012%26date%3D19012012%26volume%3D55%26issue%3D4%26spage%3D1465%26epage%3D1477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Avineesh  Singh</span>, <span class="hlFld-ContribAuthor ">Vijay K.  Patel</span>, <span class="hlFld-ContribAuthor ">Harish  Rajak</span>. </span><span class="cited-content_cbyCitation_article-title">Appraisal of pyrrole as connecting unit in hydroxamic acid based histone deacetylase inhibitors: Synthesis, anticancer evaluation and molecular docking studies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2021,</strong> <em>1240 </em>, 130590. <a href="https://doi.org/10.1016/j.molstruc.2021.130590" title="DOI URL">https://doi.org/10.1016/j.molstruc.2021.130590</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2021.130590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2021.130590%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3DAppraisal%252Bof%252Bpyrrole%252Bas%252Bconnecting%252Bunit%252Bin%252Bhydroxamic%252Bacid%252Bbased%252Bhistone%252Bdeacetylase%252Binhibitors%25253A%252BSynthesis%25252C%252Banticancer%252Bevaluation%252Band%252Bmolecular%252Bdocking%252Bstudies%26aulast%3DSingh%26aufirst%3DAvineesh%26date%3D2021%26volume%3D1240%26spage%3D130590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hongyan  Li</span>, <span class="hlFld-ContribAuthor ">Rihua  Cui</span>, <span class="hlFld-ContribAuthor ">Meiying  Ji</span>, <span class="hlFld-ContribAuthor ">Sheng-Yu  Jin</span>. </span><span class="cited-content_cbyCitation_article-title">CUDC-101 enhances the chemosensitivity of gemcitabine-treated lymphoma cells. </span><span class="cited-content_cbyCitation_journal-name">Leukemia Research</span><span> <strong>2021,</strong> <em>106 </em>, 106575. <a href="https://doi.org/10.1016/j.leukres.2021.106575" title="DOI URL">https://doi.org/10.1016/j.leukres.2021.106575</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.leukres.2021.106575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.leukres.2021.106575%26sid%3Dliteratum%253Aachs%26jtitle%3DLeukemia%2520Research%26atitle%3DCUDC-101%252Benhances%252Bthe%252Bchemosensitivity%252Bof%252Bgemcitabine-treated%252Blymphoma%252Bcells%26aulast%3DLi%26aufirst%3DHongyan%26date%3D2021%26volume%3D106%26spage%3D106575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ammar D.  Elmezayen</span>, <span class="hlFld-ContribAuthor ">Anas  Al-Obaidi</span>, <span class="hlFld-ContribAuthor ">Kemal  Yelekçi</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel isoform-selective histone deacetylases 5 and 9 inhibitors through combined ligand-based pharmacophore modeling, molecular mocking, and molecular dynamics simulations for cancer treatment. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Graphics and Modelling</span><span> <strong>2021,</strong> <em>106 </em>, 107937. <a href="https://doi.org/10.1016/j.jmgm.2021.107937" title="DOI URL">https://doi.org/10.1016/j.jmgm.2021.107937</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jmgm.2021.107937&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jmgm.2021.107937%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Graphics%2520and%2520Modelling%26atitle%3DDiscovery%252Bof%252Bnovel%252Bisoform-selective%252Bhistone%252Bdeacetylases%252B5%252Band%252B9%252Binhibitors%252Bthrough%252Bcombined%252Bligand-based%252Bpharmacophore%252Bmodeling%25252C%252Bmolecular%252Bmocking%25252C%252Band%252Bmolecular%252Bdynamics%252Bsimulations%252Bfor%252Bcancer%252Btreatment%26aulast%3DElmezayen%26aufirst%3DAmmar%2BD.%26date%3D2021%26volume%3D106%26spage%3D107937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marta  Szumilak</span>, <span class="hlFld-ContribAuthor ">Anna  Wiktorowska-Owczarek</span>, <span class="hlFld-ContribAuthor ">Andrzej  Stanczak</span>. </span><span class="cited-content_cbyCitation_article-title">Hybrid Drugs—A Strategy for Overcoming Anticancer Drug Resistance?. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (9)
                                     , 2601. <a href="https://doi.org/10.3390/molecules26092601" title="DOI URL">https://doi.org/10.3390/molecules26092601</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26092601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26092601%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DHybrid%252BDrugs%2525E2%252580%252594A%252BStrategy%252Bfor%252BOvercoming%252BAnticancer%252BDrug%252BResistance%25253F%26aulast%3DSzumilak%26aufirst%3DMarta%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D9%26spage%3D2601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lei  Zhao</span>, <span class="hlFld-ContribAuthor ">Tingting  Fan</span>, <span class="hlFld-ContribAuthor ">Zhichao  Shi</span>, <span class="hlFld-ContribAuthor ">Chao  Ding</span>, <span class="hlFld-ContribAuthor ">Cunlong  Zhang</span>, <span class="hlFld-ContribAuthor ">Zigao  Yuan</span>, <span class="hlFld-ContribAuthor ">Qinsheng  Sun</span>, <span class="hlFld-ContribAuthor ">Chunyan  Tan</span>, <span class="hlFld-ContribAuthor ">Bizhu  Chu</span>, <span class="hlFld-ContribAuthor ">Yuyang  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFRT790M mutant cell lines. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>213 </em>, 113173. <a href="https://doi.org/10.1016/j.ejmech.2021.113173" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113173</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113173%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bevaluation%252Bof%252Bnovel%252BErbB%25252FHDAC%252Bmultitargeted%252Binhibitors%252Bwith%252Bselectivity%252Bin%252BEGFRT790M%252Bmutant%252Bcell%252Blines%26aulast%3DZhao%26aufirst%3DLei%26date%3D2021%26volume%3D213%26spage%3D113173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert  Jenke</span>, <span class="hlFld-ContribAuthor ">Nina  Reßing</span>, <span class="hlFld-ContribAuthor ">Finn K.  Hansen</span>, <span class="hlFld-ContribAuthor ">Achim  Aigner</span>, <span class="hlFld-ContribAuthor ">Thomas  Büch</span>. </span><span class="cited-content_cbyCitation_article-title">Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (4)
                                     , 634. <a href="https://doi.org/10.3390/cancers13040634" title="DOI URL">https://doi.org/10.3390/cancers13040634</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13040634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13040634%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DAnticancer%252BTherapy%252Bwith%252BHDAC%252BInhibitors%25253A%252BMechanism-Based%252BCombination%252BStrategies%252Band%252BFuture%252BPerspectives%26aulast%3DJenke%26aufirst%3DRobert%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D4%26spage%3D634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gargi Nikhil  Vaidya</span>, <span class="hlFld-ContribAuthor ">Pooja  Rana</span>, <span class="hlFld-ContribAuthor ">Ashwini  Venkatesh</span>, <span class="hlFld-ContribAuthor ">Deep Rohan  Chatterjee</span>, <span class="hlFld-ContribAuthor ">Darshan  Contractor</span>, <span class="hlFld-ContribAuthor ">Dinesh Parshuram  Satpute</span>, <span class="hlFld-ContribAuthor ">Mithilesh  Nagpure</span>, <span class="hlFld-ContribAuthor ">Alok  Jain</span>, <span class="hlFld-ContribAuthor ">Dinesh  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Paradigm shift of “classical” HDAC inhibitors to “hybrid” HDAC inhibitors in therapeutic interventions. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>209 </em>, 112844. <a href="https://doi.org/10.1016/j.ejmech.2020.112844" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112844</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112844&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112844%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DParadigm%252Bshift%252Bof%252B%2525E2%252580%25259Cclassical%2525E2%252580%25259D%252BHDAC%252Binhibitors%252Bto%252B%2525E2%252580%25259Chybrid%2525E2%252580%25259D%252BHDAC%252Binhibitors%252Bin%252Btherapeutic%252Binterventions%26aulast%3DVaidya%26aufirst%3DGargi%2BNikhil%26date%3D2021%26volume%3D209%26spage%3D112844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amr K.A.  Bass</span>, <span class="hlFld-ContribAuthor ">Mona S.  El-Zoghbi</span>, <span class="hlFld-ContribAuthor ">El-Shimaa M.  Nageeb</span>, <span class="hlFld-ContribAuthor ">Mamdouh F.A.  Mohamed</span>, <span class="hlFld-ContribAuthor ">Mohamed  Badr</span>, <span class="hlFld-ContribAuthor ">Gamal El-Din A.  Abuo-Rahma</span>. </span><span class="cited-content_cbyCitation_article-title">Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>209 </em>, 112904. <a href="https://doi.org/10.1016/j.ejmech.2020.112904" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112904</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112904%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DComprehensive%252Breview%252Bfor%252Banticancer%252Bhybridized%252Bmultitargeting%252BHDAC%252Binhibitors%26aulast%3DBass%26aufirst%3DAmr%2BK.A.%26date%3D2021%26volume%3D209%26spage%3D112904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vinayak  Palve</span>, <span class="hlFld-ContribAuthor ">Yi  Liao</span>, <span class="hlFld-ContribAuthor ">Lily L.  Remsing Rix</span>, <span class="hlFld-ContribAuthor ">Uwe  Rix</span>. </span><span class="cited-content_cbyCitation_article-title">Turning liabilities into opportunities: Off-target based drug repurposing in cancer. </span><span class="cited-content_cbyCitation_journal-name">Seminars in Cancer Biology</span><span> <strong>2021,</strong> <em>68 </em>, 209-229. <a href="https://doi.org/10.1016/j.semcancer.2020.02.003" title="DOI URL">https://doi.org/10.1016/j.semcancer.2020.02.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.semcancer.2020.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.semcancer.2020.02.003%26sid%3Dliteratum%253Aachs%26jtitle%3DSeminars%2520in%2520Cancer%2520Biology%26atitle%3DTurning%252Bliabilities%252Binto%252Bopportunities%25253A%252BOff-target%252Bbased%252Bdrug%252Brepurposing%252Bin%252Bcancer%26aulast%3DPalve%26aufirst%3DVinayak%26date%3D2021%26volume%3D68%26spage%3D209%26epage%3D229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Colleen E.  Quaas</span>, <span class="hlFld-ContribAuthor ">David T.  Long</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting (de)acetylation: A Diversity of Mechanism and Disease. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/B978-0-12-820472-6.00076-1" title="DOI URL">https://doi.org/10.1016/B978-0-12-820472-6.00076-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-820472-6.00076-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-820472-6.00076-1%26sid%3Dliteratum%253Aachs%26atitle%3DTargeting%252B%252528de%252529acetylation%25253A%252BA%252BDiversity%252Bof%252BMechanism%252Band%252BDisease%26aulast%3DQuaas%26aufirst%3DColleen%2BE.%26date%3D2021%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BBiomedical%252BSciences%26date%3D2021%26volume%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mona M.  Abdel-Atty</span>, <span class="hlFld-ContribAuthor ">Nahla A.  Farag</span>, <span class="hlFld-ContribAuthor ">Rabah A. T.  Serya</span>, <span class="hlFld-ContribAuthor ">Khaled A. M.  Abouzid</span>, <span class="hlFld-ContribAuthor ">Samar  Mowafy</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular design, synthesis and
              in vitro
              biological evaluation of thienopyrimidine–hydroxamic acids as chimeric kinase HDAC inhibitors: a challenging approach to combat cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2021,</strong> <em>36 </em>
                                    (1)
                                     , 1290-1312. <a href="https://doi.org/10.1080/14756366.2021.1933465" title="DOI URL">https://doi.org/10.1080/14756366.2021.1933465</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2021.1933465&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2021.1933465%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DMolecular%252Bdesign%25252C%252Bsynthesis%252Band%252Bin%252Bvitro%252Bbiological%252Bevaluation%252Bof%252Bthienopyrimidine%2525E2%252580%252593hydroxamic%252Bacids%252Bas%252Bchimeric%252Bkinase%252BHDAC%252Binhibitors%25253A%252Ba%252Bchallenging%252Bapproach%252Bto%252Bcombat%252Bcancer%26aulast%3DAbdel-Atty%26aufirst%3DMona%2BM.%26date%3D2021%26date%3D2021%26volume%3D36%26issue%3D1%26spage%3D1290%26epage%3D1312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Halmuthur M.  Sampath Kumar</span>, <span class="hlFld-ContribAuthor ">Lars  Herrmann</span>, <span class="hlFld-ContribAuthor ">Svetlana B.  Tsogoeva</span>. </span><span class="cited-content_cbyCitation_article-title">Structural hybridization as a facile approach to new drug candidates. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (23)
                                     , 127514. <a href="https://doi.org/10.1016/j.bmcl.2020.127514" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127514</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127514%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DStructural%252Bhybridization%252Bas%252Ba%252Bfacile%252Bapproach%252Bto%252Bnew%252Bdrug%252Bcandidates%26aulast%3DSampath%2BKumar%26aufirst%3DHalmuthur%2BM.%26date%3D2020%26volume%3D30%26issue%3D23%26spage%3D127514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaopeng  Peng</span>, <span class="hlFld-ContribAuthor ">Zhiqiang  Sun</span>, <span class="hlFld-ContribAuthor ">Peihua  Kuang</span>, <span class="hlFld-ContribAuthor ">Jianjun  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>208 </em>, 112831. <a href="https://doi.org/10.1016/j.ejmech.2020.112831" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112831</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112831%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bprogress%252Bon%252BHDAC%252Binhibitors%252Bwith%252Bdual%252Btargeting%252Bcapabilities%252Bfor%252Bcancer%252Btreatment%26aulast%3DPeng%26aufirst%3DXiaopeng%26date%3D2020%26volume%3D208%26spage%3D112831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rui  Chen</span>, <span class="hlFld-ContribAuthor ">Mengxian  Zhang</span>, <span class="hlFld-ContribAuthor ">Yangmei  Zhou</span>, <span class="hlFld-ContribAuthor ">Wenjing  Guo</span>, <span class="hlFld-ContribAuthor ">Ming  Yi</span>, <span class="hlFld-ContribAuthor ">Ziyan  Zhang</span>, <span class="hlFld-ContribAuthor ">Yanpeng  Ding</span>, <span class="hlFld-ContribAuthor ">Yali  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">The application of histone deacetylases inhibitors in glioblastoma. </span><span class="cited-content_cbyCitation_journal-name">Journal of Experimental & Clinical Cancer Research</span><span> <strong>2020,</strong> <em>39 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13046-020-01643-6" title="DOI URL">https://doi.org/10.1186/s13046-020-01643-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13046-020-01643-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13046-020-01643-6%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Experimental%2520%2526%2520Clinical%2520Cancer%2520Research%26atitle%3DThe%252Bapplication%252Bof%252Bhistone%252Bdeacetylases%252Binhibitors%252Bin%252Bglioblastoma%26aulast%3DChen%26aufirst%3DRui%26date%3D2020%26date%3D2020%26volume%3D39%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bernhard  Biersack</span>, <span class="hlFld-ContribAuthor ">Sibel  Polat</span>, <span class="hlFld-ContribAuthor ">Michael  Höpfner</span>. </span><span class="cited-content_cbyCitation_article-title">Anticancer properties of chimeric HDAC and kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Seminars in Cancer Biology</span><span> <strong>2020,</strong> <em>184 </em><a href="https://doi.org/10.1016/j.semcancer.2020.11.005" title="DOI URL">https://doi.org/10.1016/j.semcancer.2020.11.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.semcancer.2020.11.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.semcancer.2020.11.005%26sid%3Dliteratum%253Aachs%26jtitle%3DSeminars%2520in%2520Cancer%2520Biology%26atitle%3DAnticancer%252Bproperties%252Bof%252Bchimeric%252BHDAC%252Band%252Bkinase%252Binhibitors%26aulast%3DBiersack%26aufirst%3DBernhard%26date%3D2020%26volume%3D184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joshua P.  Smalley</span>, <span class="hlFld-ContribAuthor ">Shaun M.  Cowley</span>, <span class="hlFld-ContribAuthor ">James T.  Hodgkinson</span>. </span><span class="cited-content_cbyCitation_article-title">Bifunctional HDAC Therapeutics: One Drug to Rule Them All?. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (19)
                                     , 4394. <a href="https://doi.org/10.3390/molecules25194394" title="DOI URL">https://doi.org/10.3390/molecules25194394</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25194394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25194394%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DBifunctional%252BHDAC%252BTherapeutics%25253A%252BOne%252BDrug%252Bto%252BRule%252BThem%252BAll%25253F%26aulast%3DSmalley%26aufirst%3DJoshua%2BP.%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D19%26spage%3D4394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kun  Xing</span>, <span class="hlFld-ContribAuthor ">Jian  Zhang</span>, <span class="hlFld-ContribAuthor ">Yu  Han</span>, <span class="hlFld-ContribAuthor ">Tong  Tong</span>, <span class="hlFld-ContribAuthor ">Dan  Liu</span>, <span class="hlFld-ContribAuthor ">Linxiang  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis and Bioactivity Evaluation of 4,6-Disubstituted Pyrido[3,2-d]pyrimidine Derivatives as Mnk and HDAC Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (18)
                                     , 4318. <a href="https://doi.org/10.3390/molecules25184318" title="DOI URL">https://doi.org/10.3390/molecules25184318</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25184318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25184318%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DDesign%25252C%252BSynthesis%252Band%252BBioactivity%252BEvaluation%252Bof%252B4%25252C6-Disubstituted%252BPyrido%25255B3%25252C2-d%25255Dpyrimidine%252BDerivatives%252Bas%252BMnk%252Band%252BHDAC%252BInhibitors%26aulast%3DXing%26aufirst%3DKun%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D18%26spage%3D4318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao  Hu</span>, <span class="hlFld-ContribAuthor ">Fei  Chen</span>, <span class="hlFld-ContribAuthor ">Yuhong  Dong</span>, <span class="hlFld-ContribAuthor ">Yajing  Liu</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel dual c-Met/HDAC inhibitors as a promising strategy for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>101 </em>, 103970. <a href="https://doi.org/10.1016/j.bioorg.2020.103970" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103970</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103970&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103970%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Bdual%252Bc-Met%25252FHDAC%252Binhibitors%252Bas%252Ba%252Bpromising%252Bstrategy%252Bfor%252Bcancer%252Btherapy%26aulast%3DHu%26aufirst%3DHao%26date%3D2020%26volume%3D101%26spage%3D103970" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Angel R.  de Lera</span>, <span class="hlFld-ContribAuthor ">A.  Ganesan</span>. </span><span class="cited-content_cbyCitation_article-title">Two-hit wonders: The expanding universe of multitargeting epigenetic agents. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Chemical Biology</span><span> <strong>2020,</strong> <em>57 </em>, 135-154. <a href="https://doi.org/10.1016/j.cbpa.2020.05.009" title="DOI URL">https://doi.org/10.1016/j.cbpa.2020.05.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cbpa.2020.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cbpa.2020.05.009%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Chemical%2520Biology%26atitle%3DTwo-hit%252Bwonders%25253A%252BThe%252Bexpanding%252Buniverse%252Bof%252Bmultitargeting%252Bepigenetic%252Bagents%26aulast%3Dde%2BLera%26aufirst%3DAngel%2BR.%26date%3D2020%26volume%3D57%26spage%3D135%26epage%3D154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ammar D.  Elmezayen</span>, <span class="hlFld-ContribAuthor ">Kemal  Yelekçi</span>. </span><span class="cited-content_cbyCitation_article-title">Homology modeling and
              in silico
              design of novel and potential dual-acting inhibitors of human histone deacetylases HDAC5 and HDAC9 isozymes. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2020,</strong> <em>55 </em>, 1-19. <a href="https://doi.org/10.1080/07391102.2020.1798812" title="DOI URL">https://doi.org/10.1080/07391102.2020.1798812</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2020.1798812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2020.1798812%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DHomology%252Bmodeling%252Band%252Bin%252Bsilico%252Bdesign%252Bof%252Bnovel%252Band%252Bpotential%252Bdual-acting%252Binhibitors%252Bof%252Bhuman%252Bhistone%252Bdeacetylases%252BHDAC5%252Band%252BHDAC9%252Bisozymes%26aulast%3DElmezayen%26aufirst%3DAmmar%2BD.%26date%3D2020%26date%3D2020%26volume%3D55%26spage%3D1%26epage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Koji  Fukuda</span>, <span class="hlFld-ContribAuthor ">Shinji  Takeuchi</span>, <span class="hlFld-ContribAuthor ">Sachiko  Arai</span>, <span class="hlFld-ContribAuthor ">Kenji  Kita</span>, <span class="hlFld-ContribAuthor ">Azusa  Tanimoto</span>, <span class="hlFld-ContribAuthor ">Akihiro  Nishiyama</span>, <span class="hlFld-ContribAuthor ">Seiji  Yano</span>. </span><span class="cited-content_cbyCitation_article-title">Glycogen synthase kinase‐3 inhibition overcomes epithelial‐mesenchymal transition‐associated resistance to osimertinib in
              EGFR
              ‐mutant lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Cancer Science</span><span> <strong>2020,</strong> <em>111 </em>
                                    (7)
                                     , 2374-2384. <a href="https://doi.org/10.1111/cas.14454" title="DOI URL">https://doi.org/10.1111/cas.14454</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cas.14454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcas.14454%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Science%26atitle%3DGlycogen%252Bsynthase%252Bkinase%2525E2%252580%2525903%252Binhibition%252Bovercomes%252Bepithelial%2525E2%252580%252590mesenchymal%252Btransition%2525E2%252580%252590associated%252Bresistance%252Bto%252Bosimertinib%252Bin%252BEGFR%252B%2525E2%252580%252590mutant%252Blung%252Bcancer%26aulast%3DFukuda%26aufirst%3DKoji%26date%3D2020%26date%3D2020%26volume%3D111%26issue%3D7%26spage%3D2374%26epage%3D2384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Loredana  Cappellacci</span>, <span class="hlFld-ContribAuthor ">Diego R.  Perinelli</span>, <span class="hlFld-ContribAuthor ">Filippo  Maggi</span>, <span class="hlFld-ContribAuthor ">Mario  Grifantini</span>, <span class="hlFld-ContribAuthor ">Riccardo  Petrelli</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">Current Medicinal Chemistry</span><span> <strong>2020,</strong> <em>27 </em>
                                    (15)
                                     , 2449-2493. <a href="https://doi.org/10.2174/0929867325666181016163110" title="DOI URL">https://doi.org/10.2174/0929867325666181016163110</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/0929867325666181016163110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F0929867325666181016163110%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Medicinal%2520Chemistry%26atitle%3DRecent%252BProgress%252Bin%252BHistone%252BDeacetylase%252BInhibitors%252Bas%252BAnticancer%252BAgents%26aulast%3DCappellacci%26aufirst%3DLoredana%26date%3D2020%26volume%3D27%26issue%3D15%26spage%3D2449%26epage%3D2493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adileh  Ayati</span>, <span class="hlFld-ContribAuthor ">Setareh  Moghimi</span>, <span class="hlFld-ContribAuthor ">Somayeh  Salarinejad</span>, <span class="hlFld-ContribAuthor ">Maliheh  Safavi</span>, <span class="hlFld-ContribAuthor ">Behjat  Pouramiri</span>, <span class="hlFld-ContribAuthor ">Alireza  Foroumadi</span>. </span><span class="cited-content_cbyCitation_article-title">A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>99 </em>, 103811. <a href="https://doi.org/10.1016/j.bioorg.2020.103811" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103811</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103811%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DA%252Breview%252Bon%252Bprogression%252Bof%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252B%252528EGFR%252529%252Binhibitors%252Bas%252Ban%252Befficient%252Bapproach%252Bin%252Bcancer%252Btargeted%252Btherapy%26aulast%3DAyati%26aufirst%3DAdileh%26date%3D2020%26volume%3D99%26spage%3D103811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dang Thi  Tuyet Anh</span>, <span class="hlFld-ContribAuthor ">Dinh Thi  Cuc</span>, <span class="hlFld-ContribAuthor ">Le Nhat  Thuy Giang</span>, <span class="hlFld-ContribAuthor ">Nguyen Thi  Hien</span>, <span class="hlFld-ContribAuthor ">Vu Ngoc  Doan</span>, <span class="hlFld-ContribAuthor ">Nguyen Ha  Thanh</span>, <span class="hlFld-ContribAuthor ">Nguyen Van  Tuyen</span>, <span class="hlFld-ContribAuthor ">Phan  Van Kiem</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Cytotoxic Evaluation of Novel Lupane Triterpenoid Derived Hydroxamates. </span><span class="cited-content_cbyCitation_journal-name">Natural Product Communications</span><span> <strong>2020,</strong> <em>15 </em>
                                    (6)
                                     , 1934578X2093196. <a href="https://doi.org/10.1177/1934578X20931967" title="DOI URL">https://doi.org/10.1177/1934578X20931967</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/1934578X20931967&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F1934578X20931967%26sid%3Dliteratum%253Aachs%26jtitle%3DNatural%2520Product%2520Communications%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BCytotoxic%252BEvaluation%252Bof%252BNovel%252BLupane%252BTriterpenoid%252BDerived%252BHydroxamates%26aulast%3DTuyet%2BAnh%26aufirst%3DDang%2BThi%26date%3D2020%26date%3D2020%26volume%3D15%26issue%3D6%26spage%3D1934578X2093196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Manvendra  Kumar</span>, <span class="hlFld-ContribAuthor ">Gaurav  Joshi</span>, <span class="hlFld-ContribAuthor ">Joydeep  Chatterjee</span>, <span class="hlFld-ContribAuthor ">Raj  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Epidermal Growth Factor Receptor and its Trafficking Regulation by Acetylation: Implication in Resistance and Exploring the Newer Therapeutic Avenues in Cancer. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2020,</strong> <em>20 </em>
                                    (12)
                                     , 1105-1123. <a href="https://doi.org/10.2174/1568026620666200207100227" title="DOI URL">https://doi.org/10.2174/1568026620666200207100227</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026620666200207100227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026620666200207100227%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DEpidermal%252BGrowth%252BFactor%252BReceptor%252Band%252Bits%252BTrafficking%252BRegulation%252Bby%252BAcetylation%25253A%252BImplication%252Bin%252BResistance%252Band%252BExploring%252Bthe%252BNewer%252BTherapeutic%252BAvenues%252Bin%252BCancer%26aulast%3DKumar%26aufirst%3DManvendra%26date%3D2020%26volume%3D20%26issue%3D12%26spage%3D1105%26epage%3D1123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bernard  Staumont</span>, <span class="hlFld-ContribAuthor ">Majeed  Jamakhani</span>, <span class="hlFld-ContribAuthor ">Chrisostome  Costa</span>, <span class="hlFld-ContribAuthor ">Fabian  Vandermeers</span>, <span class="hlFld-ContribAuthor ">Sathya Neelature  Sriramareddy</span>, <span class="hlFld-ContribAuthor ">Gaëlle  Redouté</span>, <span class="hlFld-ContribAuthor ">Céline  Mascaux</span>, <span class="hlFld-ContribAuthor ">Philippe  Delvenne</span>, <span class="hlFld-ContribAuthor ">Pascale  Hubert</span>, <span class="hlFld-ContribAuthor ">Roghaiyeh  Safari</span>, <span class="hlFld-ContribAuthor ">Luc  Willems</span>. </span><span class="cited-content_cbyCitation_article-title">TGFα Promotes Chemoresistance of Malignant Pleural Mesothelioma. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2020,</strong> <em>12 </em>
                                    (6)
                                     , 1484. <a href="https://doi.org/10.3390/cancers12061484" title="DOI URL">https://doi.org/10.3390/cancers12061484</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers12061484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers12061484%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DTGF%2525CE%2525B1%252BPromotes%252BChemoresistance%252Bof%252BMalignant%252BPleural%252BMesothelioma%26aulast%3DStaumont%26aufirst%3DBernard%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D6%26spage%3D1484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Regina  Martínez</span>, <span class="hlFld-ContribAuthor ">Bruno  Di Geronimo</span>, <span class="hlFld-ContribAuthor ">Miryam  Pastor</span>, <span class="hlFld-ContribAuthor ">José María  Zapico</span>, <span class="hlFld-ContribAuthor ">Claire  Coderch</span>, <span class="hlFld-ContribAuthor ">Rostyslav  Panchuk</span>, <span class="hlFld-ContribAuthor ">Nadia  Skorokhyd</span>, <span class="hlFld-ContribAuthor ">Maciej  Maslyk</span>, <span class="hlFld-ContribAuthor ">Ana  Ramos</span>, <span class="hlFld-ContribAuthor ">Beatriz  de Pascual-Teresa</span>. </span><span class="cited-content_cbyCitation_article-title">Multitarget Anticancer Agents Based on Histone Deacetylase and Protein Kinase CK2 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (7)
                                     , 1497. <a href="https://doi.org/10.3390/molecules25071497" title="DOI URL">https://doi.org/10.3390/molecules25071497</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25071497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25071497%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DMultitarget%252BAnticancer%252BAgents%252BBased%252Bon%252BHistone%252BDeacetylase%252Band%252BProtein%252BKinase%252BCK2%252BInhibitors%26aulast%3DMart%25C3%25ADnez%26aufirst%3DRegina%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D7%26spage%3D1497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Min  Huang</span>, <span class="hlFld-ContribAuthor ">Xiaorui  Xie</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>, <span class="hlFld-ContribAuthor ">Yunfei  Wei</span>, <span class="hlFld-ContribAuthor ">Heliang  Du</span>, <span class="hlFld-ContribAuthor ">Yuanbo  Xu</span>, <span class="hlFld-ContribAuthor ">Qihao  Xu</span>, <span class="hlFld-ContribAuthor ">Yongkui  Jing</span>, <span class="hlFld-ContribAuthor ">Linxiang  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">A 18β-glycyrrhetinic acid conjugate with Vorinostat degrades HDAC3 and HDAC6 with improved antitumor effects. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>188 </em>, 111991. <a href="https://doi.org/10.1016/j.ejmech.2019.111991" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111991</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111991&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111991%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252B18%2525CE%2525B2-glycyrrhetinic%252Bacid%252Bconjugate%252Bwith%252BVorinostat%252Bdegrades%252BHDAC3%252Band%252BHDAC6%252Bwith%252Bimproved%252Bantitumor%252Beffects%26aulast%3DHuang%26aufirst%3DMin%26date%3D2020%26volume%3D188%26spage%3D111991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tianzhuo  Zhang</span>, <span class="hlFld-ContribAuthor ">Dan  Ma</span>, <span class="hlFld-ContribAuthor ">Danna  Wei</span>, <span class="hlFld-ContribAuthor ">Tingting  Lu</span>, <span class="hlFld-ContribAuthor ">Kunlin  Yu</span>, <span class="hlFld-ContribAuthor ">Zhaoyuan  Zhang</span>, <span class="hlFld-ContribAuthor ">Weili  Wang</span>, <span class="hlFld-ContribAuthor ">Qin  Fang</span>, <span class="hlFld-ContribAuthor ">Jishi  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">CUDC-101 overcomes arsenic trioxide resistance via caspase-dependent promyelocytic leukemia-retinoic acid receptor alpha degradation in acute promyelocytic leukemia. </span><span class="cited-content_cbyCitation_journal-name">Anti-Cancer Drugs</span><span> <strong>2020,</strong> <em>31 </em>
                                    (2)
                                     , 158-168. <a href="https://doi.org/10.1097/CAD.0000000000000847" title="DOI URL">https://doi.org/10.1097/CAD.0000000000000847</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1097/CAD.0000000000000847&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1097%2FCAD.0000000000000847%26sid%3Dliteratum%253Aachs%26jtitle%3DAnti-Cancer%2520Drugs%26atitle%3DCUDC-101%252Bovercomes%252Barsenic%252Btrioxide%252Bresistance%252Bvia%252Bcaspase-dependent%252Bpromyelocytic%252Bleukemia-retinoic%252Bacid%252Breceptor%252Balpha%252Bdegradation%252Bin%252Bacute%252Bpromyelocytic%252Bleukemia%26aulast%3DZhang%26aufirst%3DTianzhuo%26date%3D2020%26volume%3D31%26issue%3D2%26spage%3D158%26epage%3D168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniela  Tomaselli</span>, <span class="hlFld-ContribAuthor ">Alessia  Lucidi</span>, <span class="hlFld-ContribAuthor ">Dante  Rotili</span>, <span class="hlFld-ContribAuthor ">Antonello  Mai</span>. </span><span class="cited-content_cbyCitation_article-title">Epigenetic polypharmacology: A new frontier for epi‐drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2020,</strong> <em>40 </em>
                                    (1)
                                     , 190-244. <a href="https://doi.org/10.1002/med.21600" title="DOI URL">https://doi.org/10.1002/med.21600</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21600%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DEpigenetic%252Bpolypharmacology%25253A%252BA%252Bnew%252Bfrontier%252Bfor%252Bepi%2525E2%252580%252590drug%252Bdiscovery%26aulast%3DTomaselli%26aufirst%3DDaniela%26date%3D2020%26date%3D2019%26volume%3D40%26issue%3D1%26spage%3D190%26epage%3D244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A.  Ganesan</span>. </span><span class="cited-content_cbyCitation_article-title">HDAC inhibitors in cancer therapy. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 19-49. <a href="https://doi.org/10.1016/B978-0-12-816422-8.00002-7" title="DOI URL">https://doi.org/10.1016/B978-0-12-816422-8.00002-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-816422-8.00002-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-816422-8.00002-7%26sid%3Dliteratum%253Aachs%26atitle%3DHDAC%252Binhibitors%252Bin%252Bcancer%252Btherapy%26aulast%3DGanesan%26aufirst%3DA.%26date%3D2020%26spage%3D19%26epage%3D49%26pub%3DElsevier%26atitle%3DHistone%252BModifications%252Bin%252BTherapy%26date%3D2020%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vânia  Camilo</span>, <span class="hlFld-ContribAuthor ">Carmen  Jerónimo</span>. </span><span class="cited-content_cbyCitation_article-title">Present and future perspectives for targeting histone modifications in therapy. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 415-457. <a href="https://doi.org/10.1016/B978-0-12-816422-8.00018-0" title="DOI URL">https://doi.org/10.1016/B978-0-12-816422-8.00018-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-816422-8.00018-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-816422-8.00018-0%26sid%3Dliteratum%253Aachs%26atitle%3DPresent%252Band%252Bfuture%252Bperspectives%252Bfor%252Btargeting%252Bhistone%252Bmodifications%252Bin%252Btherapy%26aulast%3DCamilo%26aufirst%3DV%25C3%25A2nia%26date%3D2020%26spage%3D415%26epage%3D457%26pub%3DElsevier%26atitle%3DHistone%252BModifications%252Bin%252BTherapy%26date%3D2020%26volume%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Samir  Mehndiratta</span>, <span class="hlFld-ContribAuthor ">Mei-Hsiang  Lin</span>, <span class="hlFld-ContribAuthor ">Yi-Wen  Wu</span>, <span class="hlFld-ContribAuthor ">Chun-Han  Chen</span>, <span class="hlFld-ContribAuthor ">Tung-Yun  Wu</span>, <span class="hlFld-ContribAuthor ">Kuo-Hsiang  Chuang</span>, <span class="hlFld-ContribAuthor ">Min-Wu  Chao</span>, <span class="hlFld-ContribAuthor ">Yi-Ying  Chen</span>, <span class="hlFld-ContribAuthor ">Shiow-Lin  Pan</span>, <span class="hlFld-ContribAuthor ">Mei-Chuan  Chen</span>, <span class="hlFld-ContribAuthor ">Jing-Ping  Liou</span>. </span><span class="cited-content_cbyCitation_article-title">N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>185 </em>, 111725. <a href="https://doi.org/10.1016/j.ejmech.2019.111725" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111725</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111725%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DN-alkyl-hydroxybenzoyl%252Banilide%252Bhydroxamates%252Bas%252Bdual%252Binhibitors%252Bof%252BHDAC%252Band%252BHSP90%25252C%252Bdownregulating%252BIFN-%2525CE%2525B3%252Binduced%252BPD-L1%252Bexpression%26aulast%3DMehndiratta%26aufirst%3DSamir%26date%3D2020%26volume%3D185%26spage%3D111725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nguyen V.  Minh</span>, <span class="hlFld-ContribAuthor ">Nguyen T.  Thanh</span>, <span class="hlFld-ContribAuthor ">Hoang T.  Lien</span>, <span class="hlFld-ContribAuthor ">Dinh T.P.  Anh</span>, <span class="hlFld-ContribAuthor ">Ho D.  Cuong</span>, <span class="hlFld-ContribAuthor ">Nguyen H.  Nam</span>, <span class="hlFld-ContribAuthor ">Pham T.  Hai</span>, <span class="hlFld-ContribAuthor ">Le  Minh-Ngoc</span>, <span class="hlFld-ContribAuthor ">Huong  Le-Thi-Thu</span>, <span class="hlFld-ContribAuthor ">Luu V.  Chinh</span>, <span class="hlFld-ContribAuthor ">Tran K.  Vu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis and Biological Evaluation of Novel N-hydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Cytotoxic Agents. </span><span class="cited-content_cbyCitation_journal-name">Anti-Cancer Agents in Medicinal Chemistry</span><span> <strong>2019,</strong> <em>19 </em>
                                    (12)
                                     , 1543-1557. <a href="https://doi.org/10.2174/1871520619666190702142654" title="DOI URL">https://doi.org/10.2174/1871520619666190702142654</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1871520619666190702142654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1871520619666190702142654%26sid%3Dliteratum%253Aachs%26jtitle%3DAnti-Cancer%2520Agents%2520in%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BNovel%252BN-hydroxyheptanamides%252BIncorporating%252B6-hydroxy-2-methylquinazolin-4%2525283H%252529-ones%252Bas%252BHistone%252BDeacetylase%252BInhibitors%252Band%252BCytotoxic%252BAgents%26aulast%3DMinh%26aufirst%3DNguyen%2BV.%26date%3D2019%26volume%3D19%26issue%3D12%26spage%3D1543%26epage%3D1557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Silvina E.  Fioressi</span>, <span class="hlFld-ContribAuthor ">Daniel E.  Bacelo</span>, <span class="hlFld-ContribAuthor ">Pablo R.  Duchowicz</span>. </span><span class="cited-content_cbyCitation_article-title">QSAR study of human epidermal growth factor receptor (EGFR) inhibitors: conformation-independent models. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2019,</strong> <em>28 </em>
                                    (11)
                                     , 2079-2087. <a href="https://doi.org/10.1007/s00044-019-02437-y" title="DOI URL">https://doi.org/10.1007/s00044-019-02437-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-019-02437-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-019-02437-y%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3DQSAR%252Bstudy%252Bof%252Bhuman%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252B%252528EGFR%252529%252Binhibitors%25253A%252Bconformation-independent%252Bmodels%26aulast%3DFioressi%26aufirst%3DSilvina%2BE.%26date%3D2019%26date%3D2019%26volume%3D28%26issue%3D11%26spage%3D2079%26epage%3D2087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuo  Yuan</span>, <span class="hlFld-ContribAuthor ">Bin  Yu</span>, <span class="hlFld-ContribAuthor ">Hong‐Min  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">“On‐Water” Palladium‐Catalyzed Tandem Cyclization Reaction for the Synthesis of Biologically Relevant 4‐Arylquinazolines. </span><span class="cited-content_cbyCitation_journal-name">Chemistry – A European Journal</span><span> <strong>2019,</strong> <em>25 </em>
                                    (57)
                                     , 13109-13113. <a href="https://doi.org/10.1002/chem.201903464" title="DOI URL">https://doi.org/10.1002/chem.201903464</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.201903464&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.201903464%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520A%2520European%2520Journal%26atitle%3D%2525E2%252580%25259COn%2525E2%252580%252590Water%2525E2%252580%25259D%252BPalladium%2525E2%252580%252590Catalyzed%252BTandem%252BCyclization%252BReaction%252Bfor%252Bthe%252BSynthesis%252Bof%252BBiologically%252BRelevant%252B4%2525E2%252580%252590Arylquinazolines%26aulast%3DYuan%26aufirst%3DShuo%26date%3D2019%26date%3D2019%26volume%3D25%26issue%3D57%26spage%3D13109%26epage%3D13113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sevim  Dalva-Aydemir</span>, <span class="hlFld-ContribAuthor ">Cemaliye Boylu  Akyerli</span>, <span class="hlFld-ContribAuthor ">Şirin Kılıçturgay  Yüksel</span>, <span class="hlFld-ContribAuthor ">Hilal  Keskin</span>, <span class="hlFld-ContribAuthor ">Mustafa Cengiz  Yakıcıer</span>. </span><span class="cited-content_cbyCitation_article-title">Toward
              In Vitro
              Epigenetic Drug Design for Thyroid Cancer: The Promise of PF-03814735, an Aurora Kinase Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">OMICS: A Journal of Integrative Biology</span><span> <strong>2019,</strong> <em>23 </em>
                                    (10)
                                     , 486-495. <a href="https://doi.org/10.1089/omi.2019.0050" title="DOI URL">https://doi.org/10.1089/omi.2019.0050</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1089/omi.2019.0050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1089%2Fomi.2019.0050%26sid%3Dliteratum%253Aachs%26jtitle%3DOMICS%253A%2520A%2520Journal%2520of%2520Integrative%2520Biology%26atitle%3DToward%252BIn%252BVitro%252BEpigenetic%252BDrug%252BDesign%252Bfor%252BThyroid%252BCancer%25253A%252BThe%252BPromise%252Bof%252BPF-03814735%25252C%252Ban%252BAurora%252BKinase%252BInhibitor%26aulast%3DDalva-Aydemir%26aufirst%3DSevim%26date%3D2019%26volume%3D23%26issue%3D10%26spage%3D486%26epage%3D495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lilian  Zsákai</span>, <span class="hlFld-ContribAuthor ">Anna  Sipos</span>, <span class="hlFld-ContribAuthor ">Judit  Dobos</span>, <span class="hlFld-ContribAuthor ">Dániel  Erős</span>, <span class="hlFld-ContribAuthor ">Csaba  Szántai-Kis</span>, <span class="hlFld-ContribAuthor ">Péter  Bánhegyi</span>, <span class="hlFld-ContribAuthor ">János  Pató</span>, <span class="hlFld-ContribAuthor ">László  Őrfi</span>, <span class="hlFld-ContribAuthor ">Zsolt  Matula</span>, <span class="hlFld-ContribAuthor ">Gábor  Mikala</span>, <span class="hlFld-ContribAuthor ">György  Kéri</span>, <span class="hlFld-ContribAuthor ">István  Peták</span>, <span class="hlFld-ContribAuthor ">István  Vályi-Nagy</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted drug combination therapy design based on driver genes. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2019,</strong> <em>10 </em>
                                    (51)
                                     , 5255-5266. <a href="https://doi.org/10.18632/oncotarget.26985" title="DOI URL">https://doi.org/10.18632/oncotarget.26985</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.26985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.26985%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DTargeted%252Bdrug%252Bcombination%252Btherapy%252Bdesign%252Bbased%252Bon%252Bdriver%252Bgenes%26aulast%3DZs%25C3%25A1kai%26aufirst%3DLilian%26date%3D2019%26date%3D2019%26volume%3D10%26issue%3D51%26spage%3D5255%26epage%3D5266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Harbinder  Singh</span>, <span class="hlFld-ContribAuthor ">Jatinder Vir  Singh</span>, <span class="hlFld-ContribAuthor ">Kavita  Bhagat</span>, <span class="hlFld-ContribAuthor ">Harmandeep Kaur  Gulati</span>, <span class="hlFld-ContribAuthor ">Mohit  Sanduja</span>, <span class="hlFld-ContribAuthor ">Nitish  Kumar</span>, <span class="hlFld-ContribAuthor ">Nihar  Kinarivala</span>, <span class="hlFld-ContribAuthor ">Sahil  Sharma</span>. </span><span class="cited-content_cbyCitation_article-title">Rational approaches, design strategies, structure activity relationship and mechanistic insights for therapeutic coumarin hybrids. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (16)
                                     , 3477-3510. <a href="https://doi.org/10.1016/j.bmc.2019.06.033" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.06.033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.06.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.06.033%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DRational%252Bapproaches%25252C%252Bdesign%252Bstrategies%25252C%252Bstructure%252Bactivity%252Brelationship%252Band%252Bmechanistic%252Binsights%252Bfor%252Btherapeutic%252Bcoumarin%252Bhybrids%26aulast%3DSingh%26aufirst%3DHarbinder%26date%3D2019%26volume%3D27%26issue%3D16%26spage%3D3477%26epage%3D3510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohammad A.  Alam</span>. </span><span class="cited-content_cbyCitation_article-title">Methods for Hydroxamic Acid Synthesis. </span><span class="cited-content_cbyCitation_journal-name">Current Organic Chemistry</span><span> <strong>2019,</strong> <em>23 </em>
                                    (9)
                                     , 978-993. <a href="https://doi.org/10.2174/1385272823666190424142821" title="DOI URL">https://doi.org/10.2174/1385272823666190424142821</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1385272823666190424142821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1385272823666190424142821%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Organic%2520Chemistry%26atitle%3DMethods%252Bfor%252BHydroxamic%252BAcid%252BSynthesis%26aulast%3DAlam%26aufirst%3DMohammad%2BA.%26date%3D2019%26volume%3D23%26issue%3D9%26spage%3D978%26epage%3D993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Harbinder  Singh</span>, <span class="hlFld-ContribAuthor ">Nihar  Kinarivala</span>, <span class="hlFld-ContribAuthor ">Sahil  Sharma</span>. </span><span class="cited-content_cbyCitation_article-title">Multi-Targeting Anticancer Agents: Rational Approaches, Synthetic Routes and Structure Activity Relationship. </span><span class="cited-content_cbyCitation_journal-name">Anti-Cancer Agents in Medicinal Chemistry</span><span> <strong>2019,</strong> <em>19 </em>
                                    (7)
                                     , 842-874. <a href="https://doi.org/10.2174/1871520619666190118120708" title="DOI URL">https://doi.org/10.2174/1871520619666190118120708</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1871520619666190118120708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1871520619666190118120708%26sid%3Dliteratum%253Aachs%26jtitle%3DAnti-Cancer%2520Agents%2520in%2520Medicinal%2520Chemistry%26atitle%3DMulti-Targeting%252BAnticancer%252BAgents%25253A%252BRational%252BApproaches%25252C%252BSynthetic%252BRoutes%252Band%252BStructure%252BActivity%252BRelationship%26aulast%3DSingh%26aufirst%3DHarbinder%26date%3D2019%26volume%3D19%26issue%3D7%26spage%3D842%26epage%3D874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Simone  Moertl</span>, <span class="hlFld-ContribAuthor ">Sarah  Payer</span>, <span class="hlFld-ContribAuthor ">Rosemarie  Kell</span>, <span class="hlFld-ContribAuthor ">Klaudia  Winkler</span>, <span class="hlFld-ContribAuthor ">Natasa  Anastasov</span>, <span class="hlFld-ContribAuthor ">Michael J.  Atkinson</span>. </span><span class="cited-content_cbyCitation_article-title">Comparison of Radiosensitization by HDAC Inhibitors CUDC-101 and SAHA in Pancreatic Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2019,</strong> <em>20 </em>
                                    (13)
                                     , 3259. <a href="https://doi.org/10.3390/ijms20133259" title="DOI URL">https://doi.org/10.3390/ijms20133259</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms20133259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms20133259%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DComparison%252Bof%252BRadiosensitization%252Bby%252BHDAC%252BInhibitors%252BCUDC-101%252Band%252BSAHA%252Bin%252BPancreatic%252BCancer%252BCells%26aulast%3DMoertl%26aufirst%3DSimone%26date%3D2019%26date%3D2019%26volume%3D20%26issue%3D13%26spage%3D3259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hang  Dong</span>, <span class="hlFld-ContribAuthor ">Hao  Yin</span>, <span class="hlFld-ContribAuthor ">Chunlong  Zhao</span>, <span class="hlFld-ContribAuthor ">Jiangying  Cao</span>, <span class="hlFld-ContribAuthor ">Wenfang  Xu</span>, <span class="hlFld-ContribAuthor ">Yingjie  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis and Biological Evaluation of Novel Osimertinib-Based HDAC and EGFR Dual Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (13)
                                     , 2407. <a href="https://doi.org/10.3390/molecules24132407" title="DOI URL">https://doi.org/10.3390/molecules24132407</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24132407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24132407%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DDesign%25252C%252BSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BNovel%252BOsimertinib-Based%252BHDAC%252Band%252BEGFR%252BDual%252BInhibitors%26aulast%3DDong%26aufirst%3DHang%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D13%26spage%3D2407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Debasis  Das</span>, <span class="hlFld-ContribAuthor ">Jian  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>170 </em>, 55-72. <a href="https://doi.org/10.1016/j.ejmech.2019.03.004" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.03.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.03.004%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvancements%252Bof%252B4-aminoquinazoline%252Bderivatives%252Bas%252Bkinase%252Binhibitors%252Band%252Btheir%252Bapplications%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DDas%26aufirst%3DDebasis%26date%3D2019%26volume%3D170%26spage%3D55%26epage%3D72" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Frida S.  Herrera-Vázquez</span>, <span class="hlFld-ContribAuthor ">Francisco  Hernández-Luis</span>, <span class="hlFld-ContribAuthor ">José L.  Medina Franco</span>. </span><span class="cited-content_cbyCitation_article-title">Quinazolines as inhibitors of chromatin-associated proteins in histones. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2019,</strong> <em>28 </em>
                                    (4)
                                     , 395-416. <a href="https://doi.org/10.1007/s00044-019-02300-0" title="DOI URL">https://doi.org/10.1007/s00044-019-02300-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-019-02300-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-019-02300-0%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3DQuinazolines%252Bas%252Binhibitors%252Bof%252Bchromatin-associated%252Bproteins%252Bin%252Bhistones%26aulast%3DHerrera-V%25C3%25A1zquez%26aufirst%3DFrida%2BS.%26date%3D2019%26date%3D2019%26volume%3D28%26issue%3D4%26spage%3D395%26epage%3D416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Koji  Fukuda</span>, <span class="hlFld-ContribAuthor ">Shinji  Takeuchi</span>, <span class="hlFld-ContribAuthor ">Sachiko  Arai</span>, <span class="hlFld-ContribAuthor ">Ryohei  Katayama</span>, <span class="hlFld-ContribAuthor ">Shigeki  Nanjo</span>, <span class="hlFld-ContribAuthor ">Azusa  Tanimoto</span>, <span class="hlFld-ContribAuthor ">Akihiro  Nishiyama</span>, <span class="hlFld-ContribAuthor ">Takayuki  Nakagawa</span>, <span class="hlFld-ContribAuthor ">Hirokazu  Taniguchi</span>, <span class="hlFld-ContribAuthor ">Takeshi  Suzuki</span>, <span class="hlFld-ContribAuthor ">Tadaaki  Yamada</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Nishihara</span>, <span class="hlFld-ContribAuthor ">Hironori  Ninomiya</span>, <span class="hlFld-ContribAuthor ">Yuichi  Ishikawa</span>, <span class="hlFld-ContribAuthor ">Satoko  Baba</span>, <span class="hlFld-ContribAuthor ">Kengo  Takeuchi</span>, <span class="hlFld-ContribAuthor ">Atsushi  Horiike</span>, <span class="hlFld-ContribAuthor ">Noriko  Yanagitani</span>, <span class="hlFld-ContribAuthor ">Makoto  Nishio</span>, <span class="hlFld-ContribAuthor ">Seiji  Yano</span>. </span><span class="cited-content_cbyCitation_article-title">Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of
              ALK
              Mutation Status. </span><span class="cited-content_cbyCitation_journal-name">Cancer Research</span><span> <strong>2019,</strong> <em>79 </em>
                                    (7)
                                     , 1658-1670. <a href="https://doi.org/10.1158/0008-5472.CAN-18-2052" title="DOI URL">https://doi.org/10.1158/0008-5472.CAN-18-2052</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/0008-5472.CAN-18-2052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F0008-5472.CAN-18-2052%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Research%26atitle%3DEpithelial-to-Mesenchymal%252BTransition%252BIs%252Ba%252BMechanism%252Bof%252BALK%252BInhibitor%252BResistance%252Bin%252BLung%252BCancer%252BIndependent%252Bof%252BALK%252BMutation%252BStatus%26aulast%3DFukuda%26aufirst%3DKoji%26date%3D2019%26date%3D2019%26volume%3D79%26issue%3D7%26spage%3D1658%26epage%3D1670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Md. Maqusood  Alam</span>, <span class="hlFld-ContribAuthor ">Ahmed H.E.  Hassan</span>, <span class="hlFld-ContribAuthor ">Kun Won  Lee</span>, <span class="hlFld-ContribAuthor ">Min Chang  Cho</span>, <span class="hlFld-ContribAuthor ">Ji Seul  Yang</span>, <span class="hlFld-ContribAuthor ">Jiho  Song</span>, <span class="hlFld-ContribAuthor ">Kyung Hoon  Min</span>, <span class="hlFld-ContribAuthor ">Jongki  Hong</span>, <span class="hlFld-ContribAuthor ">Dong-Hyun  Kim</span>, <span class="hlFld-ContribAuthor ">Yong Sup  Lee</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and cytotoxicity of chimeric erlotinib-alkylphospholipid hybrids. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>84 </em>, 51-62. <a href="https://doi.org/10.1016/j.bioorg.2018.11.021" title="DOI URL">https://doi.org/10.1016/j.bioorg.2018.11.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2018.11.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2018.11.021%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bcytotoxicity%252Bof%252Bchimeric%252Berlotinib-alkylphospholipid%252Bhybrids%26aulast%3DAlam%26aufirst%3DMd.%2BMaqusood%26date%3D2019%26volume%3D84%26spage%3D51%26epage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yang  Li</span>, <span class="hlFld-ContribAuthor ">Jie  Xiao</span>, <span class="hlFld-ContribAuthor ">Qizhi  Zhang</span>, <span class="hlFld-ContribAuthor ">Wenmei  Yu</span>, <span class="hlFld-ContribAuthor ">Mengqin  Liu</span>, <span class="hlFld-ContribAuthor ">Yu  Guo</span>, <span class="hlFld-ContribAuthor ">Jun  He</span>, <span class="hlFld-ContribAuthor ">Yunmei  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">The association between anti-tumor potency and structure-activity of protein-kinases inhibitors based on quinazoline molecular skeleton. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (3)
                                     , 568-577. <a href="https://doi.org/10.1016/j.bmc.2018.12.032" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.12.032</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.12.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.12.032%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DThe%252Bassociation%252Bbetween%252Banti-tumor%252Bpotency%252Band%252Bstructure-activity%252Bof%252Bprotein-kinases%252Binhibitors%252Bbased%252Bon%252Bquinazoline%252Bmolecular%252Bskeleton%26aulast%3DLi%26aufirst%3DYang%26date%3D2019%26volume%3D27%26issue%3D3%26spage%3D568%26epage%3D577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A.  Ganesan</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the Zinc-Dependent Histone Deacetylases (HDACs) for Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 1-27. <a href="https://doi.org/10.1007/7355_2019_68" title="DOI URL">https://doi.org/10.1007/7355_2019_68</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2019_68&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2019_68%26sid%3Dliteratum%253Aachs%26atitle%3DTargeting%252Bthe%252BZinc-Dependent%252BHistone%252BDeacetylases%252B%252528HDACs%252529%252Bfor%252BDrug%252BDiscovery%26aulast%3DGanesan%26aufirst%3DA.%26date%3D2019%26date%3D2020%26spage%3D1%26epage%3D27%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DChemical%252BEpigenetics%26aulast%3DMai%26aufirst%3DAntonello%26date%3D2020%26volume%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mei-Jung  Lai</span>, <span class="hlFld-ContribAuthor ">Ritu  Ojha</span>, <span class="hlFld-ContribAuthor ">Mei-Hsiang  Lin</span>, <span class="hlFld-ContribAuthor ">Yi-Min  Liu</span>, <span class="hlFld-ContribAuthor ">Hsueh-Yun  Lee</span>, <span class="hlFld-ContribAuthor ">Tony Eight  Lin</span>, <span class="hlFld-ContribAuthor ">Kai-Cheng  Hsu</span>, <span class="hlFld-ContribAuthor ">Chi-Yen  Chang</span>, <span class="hlFld-ContribAuthor ">Mei-Chuan  Chen</span>, <span class="hlFld-ContribAuthor ">Kunal  Nepali</span>, <span class="hlFld-ContribAuthor ">Jang-Yang  Chang</span>, <span class="hlFld-ContribAuthor ">Jing-Ping  Liou</span>. </span><span class="cited-content_cbyCitation_article-title">1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>162 </em>, 612-630. <a href="https://doi.org/10.1016/j.ejmech.2018.10.066" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.10.066</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.10.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.10.066%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3D1-Arylsulfonyl%252Bindoline-benzamides%252Bas%252Ba%252Bnew%252Bantitubulin%252Bagents%25252C%252Bwith%252Binhibition%252Bof%252Bhistone%252Bdeacetylase%26aulast%3DLai%26aufirst%3DMei-Jung%26date%3D2019%26volume%3D162%26spage%3D612%26epage%3D630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rekha  Sangwan</span>, <span class="hlFld-ContribAuthor ">Remya  Rajan</span>, <span class="hlFld-ContribAuthor ">Pintu Kumar  Mandal</span>. </span><span class="cited-content_cbyCitation_article-title">HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>158 </em>, 620-706. <a href="https://doi.org/10.1016/j.ejmech.2018.08.073" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.08.073</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.08.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.08.073%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHDAC%252Bas%252Bonco%252Btarget%25253A%252BReviewing%252Bthe%252Bsynthetic%252Bapproaches%252Bwith%252BSAR%252Bstudy%252Bof%252Btheir%252Binhibitors%26aulast%3DSangwan%26aufirst%3DRekha%26date%3D2018%26volume%3D158%26spage%3D620%26epage%3D706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Heba M.  Hesham</span>, <span class="hlFld-ContribAuthor ">Deena S.  Lasheen</span>, <span class="hlFld-ContribAuthor ">Khaled A.M.  Abouzid</span>. </span><span class="cited-content_cbyCitation_article-title">Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2018,</strong> <em>38 </em>
                                    (6)
                                     , 2058-2109. <a href="https://doi.org/10.1002/med.21505" title="DOI URL">https://doi.org/10.1002/med.21505</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21505%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DChimeric%252BHDAC%252Binhibitors%25253A%252BComprehensive%252Breview%252Bon%252Bthe%252BHDAC-based%252Bstrategies%252Bdeveloped%252Bto%252Bcombat%252Bcancer%26aulast%3DHesham%26aufirst%3DHeba%2BM.%26date%3D2018%26date%3D2018%26volume%3D38%26issue%3D6%26spage%3D2058%26epage%3D2109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qiwen  Zhu</span>, <span class="hlFld-ContribAuthor ">Xumeng  Yu</span>, <span class="hlFld-ContribAuthor ">Qianqian  Shen</span>, <span class="hlFld-ContribAuthor ">Qiumeng  Zhang</span>, <span class="hlFld-ContribAuthor ">Mingbo  Su</span>, <span class="hlFld-ContribAuthor ">Yubo  Zhou</span>, <span class="hlFld-ContribAuthor ">Jia  Li</span>, <span class="hlFld-ContribAuthor ">Yi  Chen</span>, <span class="hlFld-ContribAuthor ">Wei  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">A series of camptothecin prodrugs exhibit HDAC inhibition activity. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (16)
                                     , 4706-4715. <a href="https://doi.org/10.1016/j.bmc.2018.08.008" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.08.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.08.008%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DA%252Bseries%252Bof%252Bcamptothecin%252Bprodrugs%252Bexhibit%252BHDAC%252Binhibition%252Bactivity%26aulast%3DZhu%26aufirst%3DQiwen%26date%3D2018%26volume%3D26%26issue%3D16%26spage%3D4706%26epage%3D4715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ni  Sima</span>, <span class="hlFld-ContribAuthor ">Wei  Sun</span>, <span class="hlFld-ContribAuthor ">Kirill  Gorshkov</span>, <span class="hlFld-ContribAuthor ">Min  Shen</span>, <span class="hlFld-ContribAuthor ">Wei  Huang</span>, <span class="hlFld-ContribAuthor ">Wenge  Zhu</span>, <span class="hlFld-ContribAuthor ">Xing  Xie</span>, <span class="hlFld-ContribAuthor ">Wei  Zheng</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Cheng</span>. </span><span class="cited-content_cbyCitation_article-title">Small Molecules Identified from a Quantitative Drug Combinational Screen Resensitize Cisplatin's Response in Drug-Resistant Ovarian Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">Translational Oncology</span><span> <strong>2018,</strong> <em>11 </em>
                                    (4)
                                     , 1053-1064. <a href="https://doi.org/10.1016/j.tranon.2018.06.002" title="DOI URL">https://doi.org/10.1016/j.tranon.2018.06.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tranon.2018.06.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tranon.2018.06.002%26sid%3Dliteratum%253Aachs%26jtitle%3DTranslational%2520Oncology%26atitle%3DSmall%252BMolecules%252BIdentified%252Bfrom%252Ba%252BQuantitative%252BDrug%252BCombinational%252BScreen%252BResensitize%252BCisplatin%252527s%252BResponse%252Bin%252BDrug-Resistant%252BOvarian%252BCancer%252BCells%26aulast%3DSima%26aufirst%3DNi%26date%3D2018%26volume%3D11%26issue%3D4%26spage%3D1053%26epage%3D1064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mahmud  Hasan</span>, <span class="hlFld-ContribAuthor ">Rehana K.  Leak</span>, <span class="hlFld-ContribAuthor ">Robert E.  Stratford</span>, <span class="hlFld-ContribAuthor ">Darius P.  Zlotos</span>, <span class="hlFld-ContribAuthor ">Paula A.  Witt-Enderby</span>. </span><span class="cited-content_cbyCitation_article-title">Drug conjugates-an emerging approach to treat breast cancer. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology Research & Perspectives</span><span> <strong>2018,</strong> <em>6 </em>
                                    (4)
                                     , e00417. <a href="https://doi.org/10.1002/prp2.417" title="DOI URL">https://doi.org/10.1002/prp2.417</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/prp2.417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fprp2.417%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520Research%2520%2526%2520Perspectives%26atitle%3DDrug%252Bconjugates-an%252Bemerging%252Bapproach%252Bto%252Btreat%252Bbreast%252Bcancer%26aulast%3DHasan%26aufirst%3DMahmud%26date%3D2018%26date%3D2018%26volume%3D6%26issue%3D4%26spage%3De00417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A.  Ganesan</span>. </span><span class="cited-content_cbyCitation_article-title">Epigenetic drug discovery: a success story for cofactor interference. </span><span class="cited-content_cbyCitation_journal-name">Philosophical Transactions of the Royal Society B: Biological Sciences</span><span> <strong>2018,</strong> <em>373 </em>
                                    (1748)
                                     , 20170069. <a href="https://doi.org/10.1098/rstb.2017.0069" title="DOI URL">https://doi.org/10.1098/rstb.2017.0069</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1098/rstb.2017.0069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1098%2Frstb.2017.0069%26sid%3Dliteratum%253Aachs%26jtitle%3DPhilosophical%2520Transactions%2520of%2520the%2520Royal%2520Society%2520B%253A%2520Biological%2520Sciences%26atitle%3DEpigenetic%252Bdrug%252Bdiscovery%25253A%252Ba%252Bsuccess%252Bstory%252Bfor%252Bcofactor%252Binterference%26aulast%3DGanesan%26aufirst%3DA.%26date%3D2018%26date%3D2018%26volume%3D373%26issue%3D1748%26spage%3D20170069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ritu  Ojha</span>, <span class="hlFld-ContribAuthor ">Han-Li  Huang</span>, <span class="hlFld-ContribAuthor ">Wei-Chun  HuangFu</span>, <span class="hlFld-ContribAuthor ">Yi-Wen  Wu</span>, <span class="hlFld-ContribAuthor ">Kunal  Nepali</span>, <span class="hlFld-ContribAuthor ">Mei-Jung  Lai</span>, <span class="hlFld-ContribAuthor ">Chih-Jou  Su</span>, <span class="hlFld-ContribAuthor ">Ting-Yi  Sung</span>, <span class="hlFld-ContribAuthor ">Yi-Lin  Chen</span>, <span class="hlFld-ContribAuthor ">Shiow-Lin  Pan</span>, <span class="hlFld-ContribAuthor ">Jing-Ping  Liou</span>. </span><span class="cited-content_cbyCitation_article-title">1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>150 </em>, 667-677. <a href="https://doi.org/10.1016/j.ejmech.2018.03.006" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.03.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.03.006%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3D1-Aroylindoline-hydroxamic%252Bacids%252Bas%252Banticancer%252Bagents%25252C%252Binhibitors%252Bof%252BHSP90%252Band%252BHDAC%26aulast%3DOjha%26aufirst%3DRitu%26date%3D2018%26volume%3D150%26spage%3D667%26epage%3D677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ella  Lineham</span>, <span class="hlFld-ContribAuthor ">Graham J.  Tizzard</span>, <span class="hlFld-ContribAuthor ">Simon J.  Coles</span>, <span class="hlFld-ContribAuthor ">John  Spencer</span>, <span class="hlFld-ContribAuthor ">Simon J.  Morley</span>. </span><span class="cited-content_cbyCitation_article-title">Synergistic effects of inhibiting the MNK-eIF4E and PI3K/AKT/ mTOR pathways on cell migration in MDA-MB-231 cells. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2018,</strong> <em>9 </em>
                                    (18)
                                     , 14148-14159. <a href="https://doi.org/10.18632/oncotarget.24354" title="DOI URL">https://doi.org/10.18632/oncotarget.24354</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.24354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.24354%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DSynergistic%252Beffects%252Bof%252Binhibiting%252Bthe%252BMNK-eIF4E%252Band%252BPI3K%25252FAKT%25252F%252BmTOR%252Bpathways%252Bon%252Bcell%252Bmigration%252Bin%252BMDA-MB-231%252Bcells%26aulast%3DLineham%26aufirst%3DElla%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D18%26spage%3D14148%26epage%3D14159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tetsuro  Tago</span>, <span class="hlFld-ContribAuthor ">Jun  Toyohara</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in the Development of PET Ligands Targeting Histone Deacetylases for the Assessment of Neurodegenerative Diseases. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2018,</strong> <em>23 </em>
                                    (2)
                                     , 300. <a href="https://doi.org/10.3390/molecules23020300" title="DOI URL">https://doi.org/10.3390/molecules23020300</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules23020300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules23020300%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DAdvances%252Bin%252Bthe%252BDevelopment%252Bof%252BPET%252BLigands%252BTargeting%252BHistone%252BDeacetylases%252Bfor%252Bthe%252BAssessment%252Bof%252BNeurodegenerative%252BDiseases%26aulast%3DTago%26aufirst%3DTetsuro%26date%3D2018%26date%3D2018%26volume%3D23%26issue%3D2%26spage%3D300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna  Kiseleva</span>, <span class="hlFld-ContribAuthor ">Tim N.  Beck</span>, <span class="hlFld-ContribAuthor ">Ilya G.  Serebriiskii</span>, <span class="hlFld-ContribAuthor ">Hanqing  Liu</span>, <span class="hlFld-ContribAuthor ">Barbara  Burtness</span>, <span class="hlFld-ContribAuthor ">Erica A.  Golemis</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the ErbB Family in Head and Neck Cancer. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 7-61. <a href="https://doi.org/10.1007/978-3-319-78762-6_2" title="DOI URL">https://doi.org/10.1007/978-3-319-78762-6_2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-78762-6_2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-78762-6_2%26sid%3Dliteratum%253Aachs%26atitle%3DTargeting%252Bthe%252BErbB%252BFamily%252Bin%252BHead%252Band%252BNeck%252BCancer%26aulast%3DKiseleva%26aufirst%3DAnna%26date%3D2018%26date%3D2018%26spage%3D7%26epage%3D61%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DMolecular%252BDeterminants%252Bof%252BHead%252Band%252BNeck%252BCancer%26aulast%3DBurtness%26aufirst%3DBarbara%26date%3D2018%26volume%3D53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pankaj K.  Singh</span>, <span class="hlFld-ContribAuthor ">Om  Silakari</span>. </span><span class="cited-content_cbyCitation_article-title">Multitargeting Heterocycles. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 1-29. <a href="https://doi.org/10.1016/B978-0-08-102083-8.00001-7" title="DOI URL">https://doi.org/10.1016/B978-0-08-102083-8.00001-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-102083-8.00001-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-102083-8.00001-7%26sid%3Dliteratum%253Aachs%26atitle%3DMultitargeting%252BHeterocycles%26aulast%3DSingh%26aufirst%3DPankaj%2BK.%26date%3D2018%26spage%3D1%26epage%3D29%26pub%3DElsevier%26atitle%3DKey%252BHeterocycle%252BCores%252Bfor%252BDesigning%252BMultitargeting%252BMolecules%26date%3D2018%26volume%3D103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>, <span class="hlFld-ContribAuthor ">Xiaoqing  Lv</span>, <span class="hlFld-ContribAuthor ">Jiankang  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Exploiting polypharmacology for improving therapeutic outcome of kinase inhibitors (KIs): An update of recent medicinal chemistry efforts. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>143 </em>, 449-463. <a href="https://doi.org/10.1016/j.ejmech.2017.11.049" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.11.049</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.11.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.11.049%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DExploiting%252Bpolypharmacology%252Bfor%252Bimproving%252Btherapeutic%252Boutcome%252Bof%252Bkinase%252Binhibitors%252B%252528KIs%252529%25253A%252BAn%252Bupdate%252Bof%252Brecent%252Bmedicinal%252Bchemistry%252Befforts%26aulast%3DMa%26aufirst%3DXiaodong%26date%3D2018%26volume%3D143%26spage%3D449%26epage%3D463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amna  Ghith</span>, <span class="hlFld-ContribAuthor ">Nasser S.M.  Ismail</span>, <span class="hlFld-ContribAuthor ">Khairia  Youssef</span>, <span class="hlFld-ContribAuthor ">Khaled A.M.  Abouzid</span>. </span><span class="cited-content_cbyCitation_article-title">Medicinal Attributes of Thienopyrimidine Based Scaffold Targeting Tyrosine Kinases and Their Potential Anticancer Activities. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2017,</strong> <em>350 </em>
                                    (11)
                                     , 1700242. <a href="https://doi.org/10.1002/ardp.201700242" title="DOI URL">https://doi.org/10.1002/ardp.201700242</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.201700242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.201700242%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3DMedicinal%252BAttributes%252Bof%252BThienopyrimidine%252BBased%252BScaffold%252BTargeting%252BTyrosine%252BKinases%252Band%252BTheir%252BPotential%252BAnticancer%252BActivities%26aulast%3DGhith%26aufirst%3DAmna%26date%3D2017%26date%3D2017%26volume%3D350%26issue%3D11%26spage%3D1700242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Huiping  Shi</span>, <span class="hlFld-ContribAuthor ">Bonan  Lai</span>, <span class="hlFld-ContribAuthor ">Shizhen  Chen</span>, <span class="hlFld-ContribAuthor ">Xin  Zhou</span>, <span class="hlFld-ContribAuthor ">Jing  Nie</span>, <span class="hlFld-ContribAuthor ">Jun-An  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Facile Synthesis of Novel Perfluorocarbon-Modulated 4-Anilinoquinazoline Analogues. </span><span class="cited-content_cbyCitation_journal-name">Chinese Journal of Chemistry</span><span> <strong>2017,</strong> <em>35 </em>
                                    (11)
                                     , 1693-1700. <a href="https://doi.org/10.1002/cjoc.201700240" title="DOI URL">https://doi.org/10.1002/cjoc.201700240</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cjoc.201700240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcjoc.201700240%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Journal%2520of%2520Chemistry%26atitle%3DFacile%252BSynthesis%252Bof%252BNovel%252BPerfluorocarbon-Modulated%252B4-Anilinoquinazoline%252BAnalogues%26aulast%3DShi%26aufirst%3DHuiping%26date%3D2017%26date%3D2017%26volume%3D35%26issue%3D11%26spage%3D1693%26epage%3D1700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chiara  Zagni</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Floresta</span>, <span class="hlFld-ContribAuthor ">Giulia  Monciino</span>, <span class="hlFld-ContribAuthor ">Antonio  Rescifina</span>. </span><span class="cited-content_cbyCitation_article-title">The Search for Potent, Small-Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2017,</strong> <em>37 </em>
                                    (6)
                                     , 1373-1428. <a href="https://doi.org/10.1002/med.21437" title="DOI URL">https://doi.org/10.1002/med.21437</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21437%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DThe%252BSearch%252Bfor%252BPotent%25252C%252BSmall-Molecule%252BHDACIs%252Bin%252BCancer%252BTreatment%25253A%252BA%252BDecade%252BAfter%252BVorinostat%26aulast%3DZagni%26aufirst%3DChiara%26date%3D2017%26date%3D2017%26volume%3D37%26issue%3D6%26spage%3D1373%26epage%3D1428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lanlan  Zang</span>, <span class="hlFld-ContribAuthor ">Shukkoor M.  Kondengaden</span>, <span class="hlFld-ContribAuthor ">Qing  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaobo  Li</span>, <span class="hlFld-ContribAuthor ">Dilep K.  Sigalapalli</span>, <span class="hlFld-ContribAuthor ">Shameer M.  Kondengadan</span>, <span class="hlFld-ContribAuthor ">Kenneth  Huang</span>, <span class="hlFld-ContribAuthor ">Keqin Kathy  Li</span>, <span class="hlFld-ContribAuthor ">Shanshan  Li</span>, <span class="hlFld-ContribAuthor ">Zhongying  Xiao</span>, <span class="hlFld-ContribAuthor ">Liuqing  Wen</span>, <span class="hlFld-ContribAuthor ">Hailiang  Zhu</span>, <span class="hlFld-ContribAuthor ">Bathini N.  Babu</span>, <span class="hlFld-ContribAuthor ">Lijuan  Wang</span>, <span class="hlFld-ContribAuthor ">Fengyuan  Che</span>, <span class="hlFld-ContribAuthor ">Peng George  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Structure based design, synthesis and activity studies of small hybrid molecules as HDAC and G9a dual inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2017,</strong> <em>8 </em>
                                    (38)
                                     , 63187-63207. <a href="https://doi.org/10.18632/oncotarget.18730" title="DOI URL">https://doi.org/10.18632/oncotarget.18730</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.18730&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.18730%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DStructure%252Bbased%252Bdesign%25252C%252Bsynthesis%252Band%252Bactivity%252Bstudies%252Bof%252Bsmall%252Bhybrid%252Bmolecules%252Bas%252BHDAC%252Band%252BG9a%252Bdual%252Binhibitors%26aulast%3DZang%26aufirst%3DLanlan%26date%3D2017%26date%3D2017%26volume%3D8%26issue%3D38%26spage%3D63187%26epage%3D63207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rong-geng  Fu</span>, <span class="hlFld-ContribAuthor ">Yuan  Sun</span>, <span class="hlFld-ContribAuthor ">Wen-bing  Sheng</span>, <span class="hlFld-ContribAuthor ">Duan-fang  Liao</span>. </span><span class="cited-content_cbyCitation_article-title">Designing multi-targeted agents: An emerging anticancer drug discovery paradigm. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>136 </em>, 195-211. <a href="https://doi.org/10.1016/j.ejmech.2017.05.016" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.05.016</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.05.016%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesigning%252Bmulti-targeted%252Bagents%25253A%252BAn%252Bemerging%252Banticancer%252Bdrug%252Bdiscovery%252Bparadigm%26aulast%3DFu%26aufirst%3DRong-geng%26date%3D2017%26volume%3D136%26spage%3D195%26epage%3D211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chao  Ding</span>, <span class="hlFld-ContribAuthor ">Dan  Li</span>, <span class="hlFld-ContribAuthor ">Yan-Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Sai-Sai  Han</span>, <span class="hlFld-ContribAuthor ">Chun-Mei  Gao</span>, <span class="hlFld-ContribAuthor ">Chun-Yan  Tan</span>, <span class="hlFld-ContribAuthor ">Yu-Yang  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of ErbB/HDAC inhibitors by combining the core pharmacophores of HDAC inhibitor vorinostat and kinase inhibitors vandetanib, BMS-690514, neratinib, and TAK-285. </span><span class="cited-content_cbyCitation_journal-name">Chinese Chemical Letters</span><span> <strong>2017,</strong> <em>28 </em>
                                    (6)
                                     , 1220-1227. <a href="https://doi.org/10.1016/j.cclet.2017.01.003" title="DOI URL">https://doi.org/10.1016/j.cclet.2017.01.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cclet.2017.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cclet.2017.01.003%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Chemical%2520Letters%26atitle%3DDiscovery%252Bof%252BErbB%25252FHDAC%252Binhibitors%252Bby%252Bcombining%252Bthe%252Bcore%252Bpharmacophores%252Bof%252BHDAC%252Binhibitor%252Bvorinostat%252Band%252Bkinase%252Binhibitors%252Bvandetanib%25252C%252BBMS-690514%25252C%252Bneratinib%25252C%252Band%252BTAK-285%26aulast%3DDing%26aufirst%3DChao%26date%3D2017%26volume%3D28%26issue%3D6%26spage%3D1220%26epage%3D1227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pablo R.  Duchowicz</span>, <span class="hlFld-ContribAuthor ">Silvina E.  Fioressi</span>, <span class="hlFld-ContribAuthor ">Eduardo  Castro</span>, <span class="hlFld-ContribAuthor ">Karolina  Wróbel</span>, <span class="hlFld-ContribAuthor ">Nnenna E.  Ibezim</span>, <span class="hlFld-ContribAuthor ">Daniel E.  Bacelo</span>. </span><span class="cited-content_cbyCitation_article-title">Conformation-Independent QSAR Study on Human Epidermal Growth Factor Receptor-2 (HER2) Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2017,</strong> <em>2 </em>
                                    (13)
                                     , 3725-3731. <a href="https://doi.org/10.1002/slct.201700436" title="DOI URL">https://doi.org/10.1002/slct.201700436</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.201700436&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.201700436%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DConformation-Independent%252BQSAR%252BStudy%252Bon%252BHuman%252BEpidermal%252BGrowth%252BFactor%252BReceptor-2%252B%252528HER2%252529%252BInhibitors%26aulast%3DDuchowicz%26aufirst%3DPablo%2BR.%26date%3D2017%26date%3D2017%26volume%3D2%26issue%3D13%26spage%3D3725%26epage%3D3731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ramalingam  Boobalan</span>, <span class="hlFld-ContribAuthor ">Kuang-Kai  Liu</span>, <span class="hlFld-ContribAuthor ">Jui-I.  Chao</span>, <span class="hlFld-ContribAuthor ">Chinpiao  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological assay of erlotinib analogues and BSA-conjugated erlotinib analogue. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (8)
                                     , 1784-1788. <a href="https://doi.org/10.1016/j.bmcl.2017.02.059" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.02.059</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.02.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.02.059%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Bbiological%252Bassay%252Bof%252Berlotinib%252Banalogues%252Band%252BBSA-conjugated%252Berlotinib%252Banalogue%26aulast%3DBoobalan%26aufirst%3DRamalingam%26date%3D2017%26volume%3D27%26issue%3D8%26spage%3D1784%26epage%3D1788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiang  Wang</span>, <span class="hlFld-ContribAuthor ">Mingbo  Su</span>, <span class="hlFld-ContribAuthor ">Tingting  Li</span>, <span class="hlFld-ContribAuthor ">Anhui  Gao</span>, <span class="hlFld-ContribAuthor ">Wei  Yang</span>, <span class="hlFld-ContribAuthor ">Li  Sheng</span>, <span class="hlFld-ContribAuthor ">Yi  Zang</span>, <span class="hlFld-ContribAuthor ">Jia  Li</span>, <span class="hlFld-ContribAuthor ">Hong  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of thienopyrimidine hydroxamic acid based derivatives as structurally novel histone deacetylase (HDAC) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>128 </em>, 293-299. <a href="https://doi.org/10.1016/j.ejmech.2017.01.035" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.01.035</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.01.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.01.035%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bthienopyrimidine%252Bhydroxamic%252Bacid%252Bbased%252Bderivatives%252Bas%252Bstructurally%252Bnovel%252Bhistone%252Bdeacetylase%252B%252528HDAC%252529%252Binhibitors%26aulast%3DWang%26aufirst%3DJiang%26date%3D2017%26volume%3D128%26spage%3D293%26epage%3D299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Siavosh  Mahboobi</span>, <span class="hlFld-ContribAuthor ">Bernadette  Pilsl</span>, <span class="hlFld-ContribAuthor ">Andreas  Sellmer</span>. </span><span class="cited-content_cbyCitation_article-title">Generation and Assessment of Fusions Between HDACi and TKi. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 405-412. <a href="https://doi.org/10.1007/978-1-4939-6527-4_31" title="DOI URL">https://doi.org/10.1007/978-1-4939-6527-4_31</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-1-4939-6527-4_31&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-1-4939-6527-4_31%26sid%3Dliteratum%253Aachs%26atitle%3DGeneration%252Band%252BAssessment%252Bof%252BFusions%252BBetween%252BHDACi%252Band%252BTKi%26aulast%3DMahboobi%26aufirst%3DSiavosh%26date%3D2017%26date%3D2016%26spage%3D405%26epage%3D412%26pub%3DSpringer%2520New%2520York%26atitle%3DHDAC%25252FHAT%252BFunction%252BAssessment%252Band%252BInhibitor%252BDevelopment%26aulast%3DKr%25C3%25A4mer%26aufirst%3DOliver%2BH.%26date%3D2017%26volume%3D1510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qingjie  Zhao</span>, <span class="hlFld-ContribAuthor ">Guozheng  Huang</span>. </span><span class="cited-content_cbyCitation_article-title">Anticancer Hybrids. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 193-218. <a href="https://doi.org/10.1016/B978-0-08-101011-2.00007-6" title="DOI URL">https://doi.org/10.1016/B978-0-08-101011-2.00007-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-101011-2.00007-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-101011-2.00007-6%26sid%3Dliteratum%253Aachs%26atitle%3DAnticancer%252BHybrids%26aulast%3DZhao%26aufirst%3DQingjie%26date%3D2017%26spage%3D193%26epage%3D218%26pub%3DElsevier%26atitle%3DDesign%252Bof%252BHybrid%252BMolecules%252Bfor%252BDrug%252BDevelopment%26date%3D2017%26volume%3D66" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chao  Ding</span>, <span class="hlFld-ContribAuthor ">Shaopeng  Chen</span>, <span class="hlFld-ContribAuthor ">Cunlong  Zhang</span>, <span class="hlFld-ContribAuthor ">Guangnan  Hu</span>, <span class="hlFld-ContribAuthor ">Wei  Zhang</span>, <span class="hlFld-ContribAuthor ">Lulu  Li</span>, <span class="hlFld-ContribAuthor ">Yu Zong  Chen</span>, <span class="hlFld-ContribAuthor ">Chunyan  Tan</span>, <span class="hlFld-ContribAuthor ">Yuyang  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2017,</strong> <em>25 </em>
                                    (1)
                                     , 27-37. <a href="https://doi.org/10.1016/j.bmc.2016.10.006" title="DOI URL">https://doi.org/10.1016/j.bmc.2016.10.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2016.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2016.10.006%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Binvestigation%252Bof%252Bnovel%252B6-%2525281%25252C2%25252C3-triazol-4-yl%252529-4-aminoquinazolin%252Bderivatives%252Bpossessing%252Bhydroxamic%252Bacid%252Bmoiety%252Bfor%252Bcancer%252Btherapy%26aulast%3DDing%26aufirst%3DChao%26date%3D2017%26volume%3D25%26issue%3D1%26spage%3D27%26epage%3D37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Inês  Graça</span>, <span class="hlFld-ContribAuthor ">Eva  Pereira-Silva</span>, <span class="hlFld-ContribAuthor ">Rui  Henrique</span>, <span class="hlFld-ContribAuthor ">Graham  Packham</span>, <span class="hlFld-ContribAuthor ">Simon J.  Crabb</span>, <span class="hlFld-ContribAuthor ">Carmen  Jerónimo</span>. </span><span class="cited-content_cbyCitation_article-title">Epigenetic modulators as therapeutic targets in prostate cancer. </span><span class="cited-content_cbyCitation_journal-name">Clinical Epigenetics</span><span> <strong>2016,</strong> <em>8 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13148-016-0264-8" title="DOI URL">https://doi.org/10.1186/s13148-016-0264-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13148-016-0264-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13148-016-0264-8%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Epigenetics%26atitle%3DEpigenetic%252Bmodulators%252Bas%252Btherapeutic%252Btargets%252Bin%252Bprostate%252Bcancer%26aulast%3DGra%25C3%25A7a%26aufirst%3DIn%25C3%25AAs%26date%3D2016%26date%3D2016%26volume%3D8%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Angel R.  de Lera</span>, <span class="hlFld-ContribAuthor ">A.  Ganesan</span>. </span><span class="cited-content_cbyCitation_article-title">Epigenetic polypharmacology: from combination therapy to multitargeted drugs. </span><span class="cited-content_cbyCitation_journal-name">Clinical Epigenetics</span><span> <strong>2016,</strong> <em>8 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13148-016-0271-9" title="DOI URL">https://doi.org/10.1186/s13148-016-0271-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13148-016-0271-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13148-016-0271-9%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Epigenetics%26atitle%3DEpigenetic%252Bpolypharmacology%25253A%252Bfrom%252Bcombination%252Btherapy%252Bto%252Bmultitargeted%252Bdrugs%26aulast%3Dde%2BLera%26aufirst%3DAngel%2BR.%26date%3D2016%26date%3D2016%26volume%3D8%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arpit Kumar  Pathak</span>, <span class="hlFld-ContribAuthor ">Chetna  Ameta</span>, <span class="hlFld-ContribAuthor ">Rakshit  Ameta</span>, <span class="hlFld-ContribAuthor ">Pinki B.  Punjabi</span>. </span><span class="cited-content_cbyCitation_article-title">Microwave-Assisted Organic Synthesis in Ionic Liquids. </span><span class="cited-content_cbyCitation_journal-name">Journal of Heterocyclic Chemistry</span><span> <strong>2016,</strong> <em>53 </em>
                                    (6)
                                     , 1697-1705. <a href="https://doi.org/10.1002/jhet.2515" title="DOI URL">https://doi.org/10.1002/jhet.2515</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jhet.2515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjhet.2515%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Heterocyclic%2520Chemistry%26atitle%3DMicrowave-Assisted%252BOrganic%252BSynthesis%252Bin%252BIonic%252BLiquids%26aulast%3DPathak%26aufirst%3DArpit%2BKumar%26date%3D2016%26date%3D2015%26volume%3D53%26issue%3D6%26spage%3D1697%26epage%3D1705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jung Hun  Kim</span>, <span class="hlFld-ContribAuthor ">Yeonui  Kwak</span>, <span class="hlFld-ContribAuthor ">Chiman  Song</span>, <span class="hlFld-ContribAuthor ">Eun Joo  Roh</span>, <span class="hlFld-ContribAuthor ">Chang-Hyun  Oh</span>, <span class="hlFld-ContribAuthor ">So Ha  Lee</span>, <span class="hlFld-ContribAuthor ">Taebo  Sim</span>, <span class="hlFld-ContribAuthor ">Jung Hoon  Choi</span>, <span class="hlFld-ContribAuthor ">Kyung Ho  Yoo</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of novel arylaminoquinazolinylurea derivatives and their antiproliferative activities against bladder cancer cell line. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (20)
                                     , 5082-5086. <a href="https://doi.org/10.1016/j.bmcl.2016.08.076" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.08.076</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.08.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.08.076%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Bof%252Bnovel%252Barylaminoquinazolinylurea%252Bderivatives%252Band%252Btheir%252Bantiproliferative%252Bactivities%252Bagainst%252Bbladder%252Bcancer%252Bcell%252Bline%26aulast%3DKim%26aufirst%3DJung%2BHun%26date%3D2016%26volume%3D26%26issue%3D20%26spage%3D5082%26epage%3D5086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joëlle  Roche</span>, <span class="hlFld-ContribAuthor ">Philippe  Bertrand</span>. </span><span class="cited-content_cbyCitation_article-title">Inside HDACs with more selective HDAC inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>121 </em>, 451-483. <a href="https://doi.org/10.1016/j.ejmech.2016.05.047" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.05.047</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.05.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.05.047%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DInside%252BHDACs%252Bwith%252Bmore%252Bselective%252BHDAC%252Binhibitors%26aulast%3DRoche%26aufirst%3DJo%25C3%25ABlle%26date%3D2016%26volume%3D121%26spage%3D451%26epage%3D483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yixuan  Li</span>, <span class="hlFld-ContribAuthor ">Edward  Seto</span>. </span><span class="cited-content_cbyCitation_article-title">HDACs and HDAC Inhibitors in Cancer Development and Therapy. </span><span class="cited-content_cbyCitation_journal-name">Cold Spring Harbor Perspectives in Medicine</span><span> <strong>2016,</strong> <em>6 </em>
                                    (10)
                                     , a026831. <a href="https://doi.org/10.1101/cshperspect.a026831" title="DOI URL">https://doi.org/10.1101/cshperspect.a026831</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1101/cshperspect.a026831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1101%2Fcshperspect.a026831%26sid%3Dliteratum%253Aachs%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspectives%2520in%2520Medicine%26atitle%3DHDACs%252Band%252BHDAC%252BInhibitors%252Bin%252BCancer%252BDevelopment%252Band%252BTherapy%26aulast%3DLi%26aufirst%3DYixuan%26date%3D2016%26date%3D2016%26volume%3D6%26issue%3D10%26spage%3Da026831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div><a href="#" data-source="/pb/widgets/cited-by?doi=10.1021%2Fjm901453q&amp;widgetId=9cf770f4-a9a2-46e0-bd29-3da15bcf4ae0&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Fjm901453q%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2010.53.issue-5%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text&amp;citedByCount=164&amp;pagesCount=2&amp;pageNumber=-1" title="Load all citations" class="button_primary float-right cited-by__see-more mb-5"><i aria-hidden="”true”" class="icon-angle-double-down"></i><span>Load all citations</span></a></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/medium/jm-2009-01453q_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901453q&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/medium/jm-2009-01453q_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Structure of Known Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901453q&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/medium/jm-2009-01453q_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Design of multitargeted EGFR/HER2/HDAC inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901453q&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/medium/jm-2009-01453q_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901453q&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) Isopropanol, reflux; (b) LiOH, CH<sub>3</sub>OH, H<sub>2</sub>O; (c) ethyl or methyl bromoalkanoate, K<sub>2</sub>CO<sub>3</sub>, 40 °C; (d) NH<sub>2</sub>OH, CH<sub>3</sub>OH, 0 °C to rt.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/medium/jm-2009-01453q_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901453q&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) CH<sub>3</sub>I or 2-methyoxyethyl-4-methylbenzenesulfonate, K<sub>2</sub>CO<sub>3</sub>, DMF; (b) ethyl 7-bromoheptanoate, K<sub>2</sub>CO<sub>3</sub>, DMF, 60 °C; (c) HNO<sub>3</sub>, HOAc, 20 °C; (d) Fe, HCl, EtOH, H<sub>2</sub>O, reflux; (e) HCONH<sub>2</sub>, HCOONH<sub>4</sub>, 180 °C; (f) PCl<sub>3</sub>, reflux; (g) <b>27</b> or <b>28</b>, isopropanol, reflux; (h) NH<sub>2</sub>OH, CH<sub>3</sub>OH, 0 °C to rt.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/medium/jm-2009-01453q_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901453q&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) Na, CH<sub>3</sub>OH, sealed tube; (b) POCl<sub>3</sub>, reflux; (c) <b>27</b>, isopropanol, reflux; (d) Fe, HCl, EtOH, H<sub>2</sub>O, reflux; (e) methyl 5-chloro-5-oxopentanoate, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>; (f) NH<sub>2</sub>OH, CH<sub>3</sub>OH, 0 °C to rt.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/medium/jm-2009-01453q_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901453q&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) NaNO<sub>2</sub>, H<sub>2</sub>SO<sub>4</sub>, AcOH, KI; (b) thiobenzoic acid, 1,10-phenathroline, CuI, DIPEA, toluene, 110 °C; (c) ethyl 7-bromoheptanoate, K<sub>2</sub>CO<sub>3</sub>, DMF, 50 °C; (d) KMnO<sub>4</sub>, CH<sub>3</sub>CN, H<sub>2</sub>O, 65 °C; (e) NH<sub>2</sub>OH, CH<sub>3</sub>OH, 0 °C to rt.</p></p></figure><figure data-id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/medium/jm-2009-01453q_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901453q&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) Isopropanol, 60 °C; (b) ethyl 7-bromoheptanoate, K<sub>2</sub>CO<sub>3</sub>, DMF, 60 °C; (c) NH<sub>2</sub>OH, CH<sub>3</sub>OH, 0 °C to rt.</p></p></figure><figure data-id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/medium/jm-2009-01453q_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901453q&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) Ethyl 7-bromoheptanoate, K<sub>2</sub>CO<sub>3</sub>, DMF; (b) CH<sub>3</sub>I, K<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C; (c) HNO<sub>3</sub>, AcOH, 20 °C; (d) Fe, HCl, EtOH, reflux; (e) HCONH<sub>2</sub>, HCOONH<sub>4</sub>, 180 °C; (f) POCl<sub>3</sub>, reflux; (g) <b>27</b> or <b>28</b>, isopropanol, reflux; (h) NH<sub>2</sub>OH, CH<sub>3</sub>OH, 0 °C to rt.</p></p></figure><figure data-id="fig2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/medium/jm-2009-01453q_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. <b>8</b>, dosed at 120 mg/kg, iv, daily, induced tumor regression in the Hep-G2 liver cancer model and was more efficacious than erlotinib at its maximum tolerated dose (MTD, 25 mg/kg, po, daily) and vorinostat at an equimolar concentration (72 mg/kg, iv, daily).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901453q/production/images/large/jm-2009-01453q_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901453q&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i40">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88868" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88868" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 32 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Sergina, N. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moasser, M. M.</span><span> </span><span class="NLM_article-title">The HER Family and Cancer: Emerging Molecular Mechanisms and Therapeutic Targets</span> <span class="citation_source-journal">Trends Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">527</span><span class="NLM_x">–</span> <span class="NLM_lpage">534</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=527-534&author=N.+V.+Serginaauthor=M.+M.+Moasser&title=The+HER+Family+and+Cancer%3A+Emerging+Molecular+Mechanisms+and+Therapeutic+Targets"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSergina%26aufirst%3DN.%2BV.%26aulast%3DMoasser%26aufirst%3DM.%2BM.%26atitle%3DThe%2520HER%2520Family%2520and%2520Cancer%253A%2520Emerging%2520Molecular%2520Mechanisms%2520and%2520Therapeutic%2520Targets%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2007%26volume%3D13%26spage%3D527%26epage%3D534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Hynes, N. E</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H. A.</span><span> </span><span class="NLM_article-title">ERBB Receptors and Cancer: the Complexity of Targeted Inhibitors</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">341</span><span class="NLM_x">–</span> <span class="NLM_lpage">354</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm901453q&amp;key=10.1038%2Fnrc1609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm901453q&amp;key=15864276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm901453q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=341-354&author=N.+E+Hynesauthor=H.+A.+Lane&title=ERBB+Receptors+and+Cancer%3A+the+Complexity+of+Targeted+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">ERBB receptors and cancer: the complexity of targeted inhibitors</span></div><div class="casAuthors">Hynes, Nancy E.; Lane, Heidi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">341-354</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  ERBB receptor tyrosine kinases have important roles in human cancer.  In particular, the expression or activation of epidermal growth factor receptor and ERBB2 are altered in many epithelial tumors, and clin. studies indicate that they have important roles in tumor etiol. and progression.  Accordingly, these receptors have been intensely studied to understand their importance in cancer biol. and as therapeutic targets, and many ERBB inhibitors are now used in the clinic.  We will discuss the significance of these receptors as clin. targets, in particular the mol. mechanisms underlying response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrimBiy4bn4LrVg90H21EOLACvtfcHk0ljQEGrUaQgaNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D&md5=54a45e004711da7017ee0f016696a36e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc1609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1609%26sid%3Dliteratum%253Aachs%26aulast%3DHynes%26aufirst%3DN.%2BE%26aulast%3DLane%26aufirst%3DH.%2BA.%26atitle%3DERBB%2520Receptors%2520and%2520Cancer%253A%2520the%2520Complexity%2520of%2520Targeted%2520Inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D341%26epage%3D354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Moasser, M. M.</span><span> </span><span class="NLM_article-title">Targeting the Function of the HER2 Oncogene in Human Cancer Therapeutics</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">6577</span><span class="NLM_x">–</span> <span class="NLM_lpage">6592</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm901453q&amp;key=10.1038%2Fsj.onc.1210478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm901453q&amp;key=17486079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm901453q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFCkt7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=6577-6592&author=M.+M.+Moasser&title=Targeting+the+Function+of+the+HER2+Oncogene+in+Human+Cancer+Therapeutics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the function of the HER2 oncogene in human cancer therapeutics</span></div><div class="casAuthors">Moasser, M. M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">6577-6592</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The year 2007 marks exactly two decades since human epidermal growth factor receptor-2 (HER2) was functionally implicated in the pathogenesis of human breast cancer.  This finding established the HER2 oncogene hypothesis for the development of some human cancers.  An abundance of exptl. evidence compiled over the past two decades now solidly supports the HER2 oncogene hypothesis.  A direct consequence of this hypothesis was the promise that inhibitors of oncogenic HER2 would be highly effective treatments for HER2-driven cancers.  This treatment hypothesis has led to the development and widespread use of anti-HER2 antibodies (trastuzumab) in clin. management resulting in significantly improved clin. antitumor efficacies that have transformed the clin. practice of oncol.  In the shadows of this irrefutable clin. success, scientific studies have not yet been able to mechanistically validate that trastuzumab inhibits oncogenic HER2 function and it remains possible that the current clin. advances are a consequence of the oncogene hypothesis, but not a translation of it.  These looming scientific uncertainties suggest that the full promise of the treatment hypothesis may not yet have been realized.  The coming decade will see a second generation of HER2-targeting agents brought into clin. testing and a renewed attempt to treat HER2-driven cancers through the inactivation of HER2.  Here, I review the development of treatments that target HER2 in the context of the HER2 oncogene hypothesis, and where we stand with regards to the clin. translation of the HER2 oncogene hypothesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXXzfJk2kvX7Vg90H21EOLACvtfcHk0ljQEGrUaQgaNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFCkt7vK&md5=4c585356ad9ede3a85a774ad772b8ba6</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210478%26sid%3Dliteratum%253Aachs%26aulast%3DMoasser%26aufirst%3DM.%2BM.%26atitle%3DTargeting%2520the%2520Function%2520of%2520the%2520HER2%2520Oncogene%2520in%2520Human%2520Cancer%2520Therapeutics%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D6577%26epage%3D6592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Moasser, M. M.</span><span> </span><span class="NLM_article-title">The Oncogene HER2: Its Signaling and Transforming Functions and Its Role in Human Cancer Pathogenesis</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">6469</span><span class="NLM_x">–</span> <span class="NLM_lpage">6487</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm901453q&amp;key=10.1038%2Fsj.onc.1210477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm901453q&amp;key=17471238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm901453q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFagsbnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=6469-6487&author=M.+M.+Moasser&title=The+Oncogene+HER2%3A+Its+Signaling+and+Transforming+Functions+and+Its+Role+in+Human+Cancer+Pathogenesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis</span></div><div class="casAuthors">Moasser, M. M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">6469-6487</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The year 2007 marks exactly two decades since Human Epidermal Growth Factor Receptor-2 (HER2) was functionally implicated in the pathogenesis of human breast cancer.  This finding established the HER2 oncogene hypothesis for the development of some human cancers.  The subsequent two decades have brought about an explosion of information about the biol. of HER2 and the HER family.  An abundance of exptl. evidence now solidly supports the HER2 oncogene hypothesis and etiol. links amplification of the HER2 gene locus with human cancer pathogenesis.  The mol. mechanisms underlying HER2 tumorigenesis appear to be complex and a unified mechanistic model of HER2-induced transformation has not emerged.  Numerous hypotheses implicating diverse transforming pathways have been proposed and are individually supported by exptl. models and HER2 may indeed induce cell transformation through multiple mechanisms.  Here I review the evidence supporting the oncogenic function of HER2, the mechanisms that are felt to mediate its oncogenic functions, and the evidence that links the exptl. evidence with human cancer pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoP3J_STszvOrVg90H21EOLACvtfcHk0ljQEGrUaQgaNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFagsbnN&md5=1ca26e99dc27692105e2751c90ccdb45</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210477%26sid%3Dliteratum%253Aachs%26aulast%3DMoasser%26aufirst%3DM.%2BM.%26atitle%3DThe%2520Oncogene%2520HER2%253A%2520Its%2520Signaling%2520and%2520Transforming%2520Functions%2520and%2520Its%2520Role%2520in%2520Human%2520Cancer%2520Pathogenesis%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D6469%26epage%3D6487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Burgess, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, H.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, T. P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leahy, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemmon, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokoyama, S.</span><span> </span><span class="NLM_article-title">An Open-and-shut Case? Recent Insights Into the Activation of EGF/ErbB Receptors</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">541</span><span class="NLM_x">–</span> <span class="NLM_lpage">552</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2003&pages=541-552&author=A.+W.+Burgessauthor=H.-S.+Choauthor=C.+Eigenbrotauthor=K.+M.+Fergusonauthor=T.+P.+J.+Garrettauthor=D.+J.+Leahyauthor=M.+A.+Lemmonauthor=M.+X.+Sliwkowskiauthor=C.+W.+Wardauthor=S.+Yokoyama&title=An+Open-and-shut+Case%3F+Recent+Insights+Into+the+Activation+of+EGF%2FErbB+Receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBurgess%26aufirst%3DA.%2BW.%26aulast%3DCho%26aufirst%3DH.-S.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DFerguson%26aufirst%3DK.%2BM.%26aulast%3DGarrett%26aufirst%3DT.%2BP.%2BJ.%26aulast%3DLeahy%26aufirst%3DD.%2BJ.%26aulast%3DLemmon%26aufirst%3DM.%2BA.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DWard%26aufirst%3DC.%2BW.%26aulast%3DYokoyama%26aufirst%3DS.%26atitle%3DAn%2520Open-and-shut%2520Case%253F%2520Recent%2520Insights%2520Into%2520the%2520Activation%2520of%2520EGF%252FErbB%2520Receptors%26jtitle%3DMol.%2520Cell%26date%3D2003%26volume%3D12%26spage%3D541%26epage%3D552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Press, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, H.-J.</span><span> </span><span class="NLM_article-title">EGFR, HER2 and VEGF Pathways: Validated Targets for Cancer Treatment</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">2045</span><span class="NLM_x">–</span> <span class="NLM_lpage">2075</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=2045-2075&author=M.+F.+Pressauthor=H.-J.+Lenz&title=EGFR%2C+HER2+and+VEGF+Pathways%3A+Validated+Targets+for+Cancer+Treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPress%26aufirst%3DM.%2BF.%26aulast%3DLenz%26aufirst%3DH.-J.%26atitle%3DEGFR%252C%2520HER2%2520and%2520VEGF%2520Pathways%253A%2520Validated%2520Targets%2520for%2520Cancer%2520Treatment%26jtitle%3DDrugs%26date%3D2007%26volume%3D67%26spage%3D2045%26epage%3D2075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Epidermal Growth Factor Receptor Mutations in Lung Cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm901453q&amp;key=10.1038%2Fnrc2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm901453q&amp;key=17318210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm901453q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=169-181&author=S.+V.+Sharmaauthor=D.+W.+Bellauthor=J.+Settlemanauthor=D.+A.+Haber&title=Epidermal+Growth+Factor+Receptor+Mutations+in+Lung+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Sharma, Sreenath V.; Bell, Daphne W.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-181</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The development and clin. application of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the broader field of targeted cancer therapies.  We review the results of genetic, biochem. and clin. studies focused on somatic mutations of EGFR that are assocd. with the phenomenon of oncogene addiction, describing 'oncogenic shock' as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors.  Understanding the genetic heterogeneity of epithelial tumors and devising strategies to circumvent their rapid acquisition of resistance to targeted kinase inhibitors are essential to the successful use of targeted therapies in common epithelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKw7Y4FUFM7Vg90H21EOLACvtfcHk0lieRHQuM3m51g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D&md5=46219ea3ae7b9f0977e4a4b7243fd875</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrc2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2088%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DEpidermal%2520Growth%2520Factor%2520Receptor%2520Mutations%2520in%2520Lung%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D169%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berezov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drebin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murali, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, M. I.</span><span> </span><span class="NLM_article-title">ErbB Receptors: from Oncogenes to Targeted Cancer Therapies</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">2051</span><span class="NLM_x">–</span> <span class="NLM_lpage">2058</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2007&pages=2051-2058&author=H.+Zhangauthor=A.+Berezovauthor=Q.+Wangauthor=G.+Zhangauthor=J.+Drebinauthor=R.+Muraliauthor=M.+I.+Greene&title=ErbB+Receptors%3A+from+Oncogenes+to+Targeted+Cancer+Therapies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DBerezov%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DDrebin%26aufirst%3DJ.%26aulast%3DMurali%26aufirst%3DR.%26aulast%3DGreene%26aufirst%3DM.%2BI.%26atitle%3DErbB%2520Receptors%253A%2520from%2520Oncogenes%2520to%2520Targeted%2520Cancer%2520Therapies%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2007%26volume%3D117%26spage%3D2051%26epage%3D2058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib is Associated with a Second Mutation in the EGFR Kinase Domain</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e73</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=e73&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=Acquired+Resistance+of+Lung+Adenocarcinomas+to+Gefitinib+or+Erlotinib+is+Associated+with+a+Second+Mutation+in+the+EGFR+Kinase+Domain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520Resistance%2520of%2520Lung%2520Adenocarcinomas%2520to%2520Gefitinib%2520or%2520Erlotinib%2520is%2520Associated%2520with%2520a%2520Second%2520Mutation%2520in%2520the%2520EGFR%2520Kinase%2520Domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3De73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Avizienyte, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garner, A. P.</span><span> </span><span class="NLM_article-title">Comparison of the EGFR Resistance Mutation Profiles Generated by EGFR-targeted Tyrosine Kinase Inhibitors and the Impact of Drug Combinations</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">415</span><span class="NLM_x">, </span> <span class="NLM_fpage">197</span><span class="NLM_x">–</span> <span class="NLM_lpage">206</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=415&publication_year=2008&pages=197-206&author=E.+Avizienyteauthor=R.+A.+Wardauthor=A.+P.+Garner&title=Comparison+of+the+EGFR+Resistance+Mutation+Profiles+Generated+by+EGFR-targeted+Tyrosine+Kinase+Inhibitors+and+the+Impact+of+Drug+Combinations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAvizienyte%26aufirst%3DE.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DGarner%26aufirst%3DA.%2BP.%26atitle%3DComparison%2520of%2520the%2520EGFR%2520Resistance%2520Mutation%2520Profiles%2520Generated%2520by%2520EGFR-targeted%2520Tyrosine%2520Kinase%2520Inhibitors%2520and%2520the%2520Impact%2520of%2520Drug%2520Combinations%26jtitle%3DBiochem.%2520J.%26date%3D2008%26volume%3D415%26spage%3D197%26epage%3D206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Rubin, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duensing, A.</span><span> </span><span class="NLM_article-title">Mechanisms of Resistance to Small Molecule Kinase Inhibition in the Treatment of Solid Tumors</span> <span class="citation_source-journal">Lab. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">981</span><span class="NLM_x">–</span> <span class="NLM_lpage">986</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2006&pages=981-986&author=B.+P.+Rubinauthor=A.+Duensing&title=Mechanisms+of+Resistance+to+Small+Molecule+Kinase+Inhibition+in+the+Treatment+of+Solid+Tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRubin%26aufirst%3DB.%2BP.%26aulast%3DDuensing%26aufirst%3DA.%26atitle%3DMechanisms%2520of%2520Resistance%2520to%2520Small%2520Molecule%2520Kinase%2520Inhibition%2520in%2520the%2520Treatment%2520of%2520Solid%2520Tumors%26jtitle%3DLab.%2520Invest.%26date%3D2006%26volume%3D86%26spage%3D981%26epage%3D986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Marks, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.-S.</span><span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitors: Potential in Cancer Therapy</span> <span class="citation_source-journal">J. Cell. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">600</span><span class="NLM_x">–</span> <span class="NLM_lpage">608</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2009&pages=600-608&author=P.+A.+Marksauthor=W.-S.+Xu&title=Histone+Deacetylase+Inhibitors%3A+Potential+in+Cancer+Therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarks%26aufirst%3DP.%2BA.%26aulast%3DXu%26aufirst%3DW.-S.%26atitle%3DHistone%2520Deacetylase%2520Inhibitors%253A%2520Potential%2520in%2520Cancer%2520Therapy%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2009%26volume%3D107%26spage%3D600%26epage%3D608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Pandolfi, P. P.</span><span> </span><span class="NLM_article-title">Histone Deacetylases and Transcriptional Therapy with Their Inhibitors</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">S17</span><span class="NLM_x">–</span> <span class="NLM_lpage">19</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2001&pages=S17-19&issue=Suppl+1&author=P.+P.+Pandolfi&title=Histone+Deacetylases+and+Transcriptional+Therapy+with+Their+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPandolfi%26aufirst%3DP.%2BP.%26atitle%3DHistone%2520Deacetylases%2520and%2520Transcriptional%2520Therapy%2520with%2520Their%2520Inhibitors%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2001%26volume%3D48%26issue%3DSuppl%25201%26spage%3DS17%26epage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Mann, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Justice, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazdur, R. FDA</span><span> </span><span class="NLM_article-title">Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-cell Lymphoma</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1247</span><span class="NLM_x">–</span> <span class="NLM_lpage">1252</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=1247-1252&author=B.+S.+Mannauthor=J.+R.+Johnsonauthor=M.+H.+Cohenauthor=R.+Justiceauthor=R.+FDA+Pazdur&title=Approval+Summary%3A+Vorinostat+for+Treatment+of+Advanced+Primary+Cutaneous+T-cell+Lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMann%26aufirst%3DB.%2BS.%26aulast%3DJohnson%26aufirst%3DJ.%2BR.%26aulast%3DCohen%26aufirst%3DM.%2BH.%26aulast%3DJustice%26aufirst%3DR.%26aulast%3DPazdur%26aufirst%3DR.%2BFDA%26atitle%3DApproval%2520Summary%253A%2520Vorinostat%2520for%2520Treatment%2520of%2520Advanced%2520Primary%2520Cutaneous%2520T-cell%2520Lymphoma%26jtitle%3DOncologist%26date%3D2007%26volume%3D12%26spage%3D1247%26epage%3D1252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Qian, D. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kachhap, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atadja, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pili, R.</span><span> </span><span class="NLM_article-title">The Histone Deacetylase Inhibitor NVP-LAQ824 Inhibits Angiogenesis and Has a Greater Antitumor Effect in Combination with the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor PTK787/ZK222584</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">6626</span><span class="NLM_x">–</span> <span class="NLM_lpage">6634</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=6626-6634&author=D.+Z.+Qianauthor=X.+Wangauthor=S.+K.+Kachhapauthor=Y.+Katoauthor=Y.+Weiauthor=L.+Zhangauthor=P.+Atadjaauthor=R.+Pili&title=The+Histone+Deacetylase+Inhibitor+NVP-LAQ824+Inhibits+Angiogenesis+and+Has+a+Greater+Antitumor+Effect+in+Combination+with+the+Vascular+Endothelial+Growth+Factor+Receptor+Tyrosine+Kinase+Inhibitor+PTK787%2FZK222584"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DD.%2BZ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DKachhap%26aufirst%3DS.%2BK.%26aulast%3DKato%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DAtadja%26aufirst%3DP.%26aulast%3DPili%26aufirst%3DR.%26atitle%3DThe%2520Histone%2520Deacetylase%2520Inhibitor%2520NVP-LAQ824%2520Inhibits%2520Angiogenesis%2520and%2520Has%2520a%2520Greater%2520Antitumor%2520Effect%2520in%2520Combination%2520with%2520the%2520Vascular%2520Endothelial%2520Growth%2520Factor%2520Receptor%2520Tyrosine%2520Kinase%2520Inhibitor%2520PTK787%252FZK222584%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D6626%26epage%3D6634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Bali, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pranpat, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swaby, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiskus, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balasis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocha, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Victoria, Richon</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapil, Bhalla</span><span> </span><span class="NLM_article-title">. Activity of Suberoylanilide Hydroxamic Acid Against Human Breast Cancer Cells with Amplification of Her-2</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">6382</span><span class="NLM_x">–</span> <span class="NLM_lpage">6389</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm901453q&amp;key=10.1158%2F1078-0432.CCR-05-0344" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm901453q&amp;key=16144943" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm901453q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpslansbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=6382-6389&author=P.+Baliauthor=M.+Pranpatauthor=R.+Swabyauthor=W.+Fiskusauthor=H.+Yamaguchiauthor=M.+Balasisauthor=K.+Rochaauthor=H.-G.+Wangauthor=Richon+Victoriaauthor=Bhalla+Kapil&title=.+Activity+of+Suberoylanilide+Hydroxamic+Acid+Against+Human+Breast+Cancer+Cells+with+Amplification+of+Her-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of Suberoylanilide Hydroxamic Acid Against Human Breast Cancer Cells with Amplification of Her-2</span></div><div class="casAuthors">Bali, Purva; Pranpat, Michael; Swaby, Ramona; Fiskus, Warren; Yamaguchi, Hirohito; Balasis, Maria; Rocha, Kathy; Wang, Hong-Gang; Richon, Victoria; Bhalla, Kapil</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6382-6389</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: We detd. the effects of suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, on hsp90 and its client proteins Her-2, AKT, and c-Raf, as well as evaluated the cytotoxic effects of cotreatment of SAHA with trastuzumab or docetaxel in human breast cancer BT-474 and SKBR-3 cells contg. amplification of Her-2.  Exptl. Design: The cells were treated with SAHA (1.0-5.0 μmol/L) and/or trastuzumab (5-40 μg/mL) or docetaxel (5-20 nmol/L).  Following this, apoptosis and the levels of p21WAF1, p27KIP1, AKT, c-Raf, and Her-2, as well as of the key regulators of apoptosis were detd.  Synergistic interaction between drugs was evaluated by median dose-effect anal.  Results: Treatment with SAHA up-regulated p21WAF1 and p27KIP1 levels, increased the percentage of cells in G2-M phase of the cell cycle, as well as induced apoptosis in a dose-dependent manner.  This was assocd. with up-regulation of the pro-death Bak and Bim, as well as with attenuation of the levels of Her-2 and XIAP, survivin, Bcl-2, and Bcl-xL proteins.  SAHA treatment induced acetylation of hsp90.  This reduced the chaperone assocn. of Her-2 with hsp90, promoting polyubiquitylation and degrdn. of Her-2.  SAHA also attenuated the levels of c-Raf and AKT.  Cotreatment with SAHA significantly increased trastuzumab or docetaxel-induced apoptosis of BT-474 and SKBR-3 cells.  Addnl., median dose-effect anal. revealed that cotreatment with SAHA and trastuzumab or docetaxel induced synergistic cytotoxic effects against the breast cancer cells.  Conclusions: These preclin. findings support the development of SAHA in combination with docetaxel and/or trastuzumab against Her-2-amplified breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOxGcKxvQnOrVg90H21EOLACvtfcHk0lgICWw_xHysXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpslansbk%253D&md5=23d52dbf57795a4b78af8df220f84f5d</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-0344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-0344%26sid%3Dliteratum%253Aachs%26aulast%3DBali%26aufirst%3DP.%26aulast%3DPranpat%26aufirst%3DM.%26aulast%3DSwaby%26aufirst%3DR.%26aulast%3DFiskus%26aufirst%3DW.%26aulast%3DYamaguchi%26aufirst%3DH.%26aulast%3DBalasis%26aufirst%3DM.%26aulast%3DRocha%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DH.-G.%26aulast%3DVictoria%26aufirst%3DRichon%26aulast%3DKapil%26aufirst%3DBhalla%26atitle%3D.%2520Activity%2520of%2520Suberoylanilide%2520Hydroxamic%2520Acid%2520Against%2520Human%2520Breast%2520Cancer%2520Cells%2520with%2520Amplification%2520of%2520Her-2%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D6382%26epage%3D6389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Bali, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sigua, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vishvanath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scuto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Annavarapu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiskus, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moscinski, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atadja, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhalla, K.</span><span> </span><span class="NLM_article-title">Superior Activity of the Combination of Histone Deacetylase Inhibitor LAQ824 and the FLT-3 Kinase Inhibitor PKC412 Against Human Acute Myelogenous Leukemia Cells with Mutant FLT-3</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">4991</span><span class="NLM_x">–</span> <span class="NLM_lpage">4997</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm901453q&amp;key=10.1158%2F1078-0432.CCR-04-0210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm901453q&amp;key=15297399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm901453q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtlSitrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=4991-4997&author=P.+Baliauthor=P.+Georgeauthor=P.+Cohenauthor=J.+Taoauthor=F.+Guoauthor=C.+Siguaauthor=A.+Vishvanathauthor=A.+Scutoauthor=S.+Annavarapuauthor=W.+Fiskusauthor=L.+Moscinskiauthor=P.+Atadjaauthor=K.+Bhalla&title=Superior+Activity+of+the+Combination+of+Histone+Deacetylase+Inhibitor+LAQ824+and+the+FLT-3+Kinase+Inhibitor+PKC412+Against+Human+Acute+Myelogenous+Leukemia+Cells+with+Mutant+FLT-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 Kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3</span></div><div class="casAuthors">Bali, Purva; George, Prince; Cohen, Pamela; Tao, Jianguo; Guo, Fei; Sigua, Celia; Vishvanath, Anasuya; Scuto, Anna; Annavarapu, Srinivas; Fiskus, Warren; Moscinski, Lynn; Atadja, Peter; Bhalla, Kapil</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4991-4997</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mutant FLT-3 receptor tyrosine kinase is a client protein of the mol. chaperone heat shock protein 90 and is commonly present and contributes to the leukemia phenotype in acute myelogenous leukemia (AML).  LAQ824, a cinnamyl hydroxamate histone deacetylase inhibitor, is known to induce acetylation and inhibition of heat shock protein 90.  Here, we detd. the effects of LAQ824 and/or PKC412 (a FLT-3 kinase inhibitor) on the levels of mutant FLT-3 and its downstream signaling, as well as growth arrest and cell-death of cultured and primary human AML cells.  The effect of LAQ824 and/or PKC412 treatment was detd. on the levels of FLT-3 and phosphorylated (p)-FLT-3, on downstream pro-growth and pro-survival effectors, e.g., p-STAT5, p-AKT, and p-extracellular signal-regulated kinase (ERK) 1/2, and on the cell cycle status and apoptosis in the cultured MV4-11 and primary AML cells with mutant FLT-3.  Treatment with LAQ824 promoted proteasomal degrdn. and attenuation of the levels of FLT-3 and p-FLT-3, assocd. with cell cycle G1-phase accumulation and apoptosis of MV4-11 cells.  This was accompanied by attenuation of p-STAT5, p-AKT, and p-ERK1/2 levels.  STAT-5 DNA-binding activity and the levels of c-Myc and oncostatin M were also down-regulated.  Cotreatment with LAQ824 and PKC412 synergistically induced apoptosis of MV4-11 cells and induced more apoptosis of the primary AML cells expressing mutant FLT-3.  This was also assocd. with more attenuation of p-FLT-3, p-AKT, p-ERK1/2, and p-STAT5.  The combination of LAQ824 and PKC412 is highly active against human AML cells with mutant FLT-3, which merits in vivo studies of the combination against human AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPJeLfYNFiTbVg90H21EOLACvtfcHk0lgICWw_xHysXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtlSitrs%253D&md5=375c881c176bfec9a1ddf8b5616d576d</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-0210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-0210%26sid%3Dliteratum%253Aachs%26aulast%3DBali%26aufirst%3DP.%26aulast%3DGeorge%26aufirst%3DP.%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DTao%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DF.%26aulast%3DSigua%26aufirst%3DC.%26aulast%3DVishvanath%26aufirst%3DA.%26aulast%3DScuto%26aufirst%3DA.%26aulast%3DAnnavarapu%26aufirst%3DS.%26aulast%3DFiskus%26aufirst%3DW.%26aulast%3DMoscinski%26aufirst%3DL.%26aulast%3DAtadja%26aufirst%3DP.%26aulast%3DBhalla%26aufirst%3DK.%26atitle%3DSuperior%2520Activity%2520of%2520the%2520Combination%2520of%2520Histone%2520Deacetylase%2520Inhibitor%2520LAQ824%2520and%2520the%2520FLT-3%2520Kinase%2520Inhibitor%2520PKC412%2520Against%2520Human%2520Acute%2520Myelogenous%2520Leukemia%2520Cells%2520with%2520Mutant%2520FLT-3%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26spage%3D4991%26epage%3D4997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Edwards, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atadja, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhalla, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haura, E. B.</span><span> </span><span class="NLM_article-title">Effect of the Histone Deacetylase Inhibitor LBH589 Against Epidermal Growth Factor Receptor-dependent Human Lung Cancer Cells</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2515</span><span class="NLM_x">–</span> <span class="NLM_lpage">2524</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm901453q&amp;key=10.1158%2F1535-7163.MCT-06-0761" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm901453q&amp;key=17876048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm901453q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVCgur7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=2515-2524&author=A.+Edwardsauthor=J.+Liauthor=P.+Atadjaauthor=K.+Bhallaauthor=E.+B.+Haura&title=Effect+of+the+Histone+Deacetylase+Inhibitor+LBH589+Against+Epidermal+Growth+Factor+Receptor-dependent+Human+Lung+Cancer+Cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells</span></div><div class="casAuthors">Edwards, Arthur; Li, Jiannong; Atadja, Peter; Bhalla, Kapil; Haura, Eric B.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2515-2524</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Activating mutations in the epidermal growth factor receptor (EGFR) selectively activate signal transducers and activators of transcription (STAT) and Akt survival signaling pathways important in lung cancer cell growth and survival.  Many kinases, such as EGFR, rely on heat shock protein 90 (Hsp90) chaperone function for conformational maturation and proper function.  Histone deacetylase inhibitors (HDACi) have been suggested to regulate signaling protein interactions via modulation of protein chaperone function through Hsp90.  For these reasons, we evaluated the effect of a HDACi in lung cancer cells with defined EGFR status.  Cell lines with defined EGFR status and sensitivity to EGFR tyrosine kinase inhibitors were exposed to the HDACi LBH589, and the effects on cell survival, proliferation, and downstream signaling were evaluated.  LBH589 resulted in increased acetylation of Hsp90 and reduced assocn. of Hsp90 with EGFR, Akt, and STAT3.  LBH589 selectively depleted proteins important in signaling cascades in cell lines harboring EGFR kinase mutations, such as EGFR, STAT3, and Akt, and these cells underwent apoptosis following exposure to LBH589.  In addn., we found depletion of STAT3-dependent survival proteins, including Bcl-xL, Mcl-1, and Bcl-2.  Conversely, LBH589 had little effect on apoptosis in cells not dependent on EGFR for survival, no changes were identified in the expression of EGFR or other survival proteins, and the predominant effect was cell cycle arrest rather than apoptosis.  A 10-fold increase in LBH589 was necessary to observe durable depletion of EGFR and Akt in cells not harboring EGFR mutation.  Treatment of cells with erlotinib and LBH589 resulted in synergistic effects on lung cancer cells dependent on EGFR for growth and/or survival.  Based on these results, LBH589 can acetylate Hsp90, deplete EGFR and other key survival signaling proteins, and trigger apoptosis only in lung cancer cells harboring EGFR mutations.  Therefore, EGFR mutation status may be predictive of outcome with LBH589 and possibly other HDACi.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN5rKS34gOErVg90H21EOLACvtfcHk0lgICWw_xHysXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVCgur7F&md5=79502c403a42e08255178e55b6f238b4</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0761%26sid%3Dliteratum%253Aachs%26aulast%3DEdwards%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DAtadja%26aufirst%3DP.%26aulast%3DBhalla%26aufirst%3DK.%26aulast%3DHaura%26aufirst%3DE.%2BB.%26atitle%3DEffect%2520of%2520the%2520Histone%2520Deacetylase%2520Inhibitor%2520LBH589%2520Against%2520Epidermal%2520Growth%2520Factor%2520Receptor-dependent%2520Human%2520Lung%2520Cancer%2520Cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D2515%26epage%3D2524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Fuino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bali, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donapaty, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atadja, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhalla, K.</span><span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitor LAQ824 Down-regulates Her-2 and Sensitizes Human Breast Cancer Cells to Trastuzumab, Taxotere, Gemcitabine, and Epothilone B</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">971</span><span class="NLM_x">–</span> <span class="NLM_lpage">984</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm901453q&amp;key=14578462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm901453q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosVCqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=971-984&author=L.+Fuinoauthor=P.+Baliauthor=S.+Wittmannauthor=S.+Donapatyauthor=F.+Guoauthor=H.+Yamaguchiauthor=H.-G.+Wangauthor=P.+Atadjaauthor=K.+Bhalla&title=Histone+Deacetylase+Inhibitor+LAQ824+Down-regulates+Her-2+and+Sensitizes+Human+Breast+Cancer+Cells+to+Trastuzumab%2C+Taxotere%2C+Gemcitabine%2C+and+Epothilone+B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B</span></div><div class="casAuthors">Fuino, Lianne; Bali, Purva; Wittmann, Sylvie; Donapaty, Sreenivas; Guo, Fei; Yamaguchi, Hirohito; Wang, Hong-Gang; Atadja, Peter; Bhalla, Kapil</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">971-984</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Histone deacetylase inhibitors induce hyperacetylation of the amino-terminal lysine residues of the core nucleosomal histones, which results in chromatin remodeling and altered gene expression.  Present studies demonstrate that exposure to a novel hydroxamic acid analog histone deacetylase inhibitor, LAQ824, induced p21WAF1 and p27KIP1 and caused growth arrest and apoptosis of human breast cancer SKBR-3 and BT-474 cells that possess amplification and overexpression of Her-2/neu.  Treatment with LAQ824 depleted the mRNA and protein levels of Her-2/neu-encoded Her-2, which was assocd. with attenuation of pAKT, c-Raf-1, and phosphorylated mitogen-activated protein kinase levels.  LAQ824 also induced the acetylation of heat shock protein (hsp) 90, resulting in inhibition of its binding to ATP, which has been shown to impair the chaperone assocn. of hsp 90 with its client proteins, Her-2, AKT, and c-Raf-1.  Consistent with this, treatment with LAQ824 shifted the binding of Her-2 from hsp 90 to hsp 70, promoting proteasomal degrdn. of Her-2.  Thus, LAQ824 depletes Her-2 through two mechanisms: attenuation of its mRNA levels and promotion of its degrdn. by the proteasome.  Following LAQ824 treatment, the cell membrane assocn., autotyrosine phosphorylation, and colocalization of Her-2 with HER-3 also declined.  Cotreatment with LAQ824 significantly increased trastuzumab-induced apoptosis of BT-474 and SKBR-3 cells.  This was assocd. with greater attenuation of Her-2, c-Raf-1, and pAKT levels.  LAQ824 also enhanced taxotere-induced, epothilone B-induced, and gemcitabine-induced apoptosis of BT-474 and SKBR-3 cells.  These findings suggest that LAQ824 is active against human breast cancer cells and has the potential to improve the efficacy of trastuzumab, taxotere, gemcitabine, and epothilone B against breast cancer with Her-2/neu amplification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7FPwt-FCSyLVg90H21EOLACvtfcHk0ljZSqwg0JT3Qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosVCqt7g%253D&md5=d7ba8ec62f9e1013ccbed795c8f1abf6</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFuino%26aufirst%3DL.%26aulast%3DBali%26aufirst%3DP.%26aulast%3DWittmann%26aufirst%3DS.%26aulast%3DDonapaty%26aufirst%3DS.%26aulast%3DGuo%26aufirst%3DF.%26aulast%3DYamaguchi%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DH.-G.%26aulast%3DAtadja%26aufirst%3DP.%26aulast%3DBhalla%26aufirst%3DK.%26atitle%3DHistone%2520Deacetylase%2520Inhibitor%2520LAQ824%2520Down-regulates%2520Her-2%2520and%2520Sensitizes%2520Human%2520Breast%2520Cancer%2520Cells%2520to%2520Trastuzumab%252C%2520Taxotere%252C%2520Gemcitabine%252C%2520and%2520Epothilone%2520B%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2003%26volume%3D2%26spage%3D971%26epage%3D984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Lai, C.-J.; Bao, R.; Tao, X; Wang, J.; Atoyan, R.; Qu, H; Wang, D.-G.; Yin, L; Samson, M; Forrester, J; Zifcak, B.; Xu, G.-X.; DellaRocca, S.; Zhai, H.-X.; Cai, X; Qian, C.</span><span> </span><span class="NLM_article-title">CUDC-101, a Multi-targeted Inhibitor of HDAC, EGFR and HER2, with Potent in vitro and in vivo Anti-cancer Activity</span>. Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Lai%2C+C.-J.%3B+Bao%2C+R.%3B+Tao%2C+X%3B+Wang%2C+J.%3B+Atoyan%2C+R.%3B+Qu%2C+H%3B+Wang%2C+D.-G.%3B+Yin%2C+L%3B+Samson%2C+M%3B+Forrester%2C+J%3B+Zifcak%2C+B.%3B+Xu%2C+G.-X.%3B+DellaRocca%2C+S.%3B+Zhai%2C+H.-X.%3B+Cai%2C+X%3B+Qian%2C+C.+CUDC-101%2C+a+Multi-targeted+Inhibitor+of+HDAC%2C+EGFR+and+HER2%2C+with+Potent+in+vitro+and+in+vivo+Anti-cancer+Activity.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DC.-J.%26atitle%3DCUDC-101%252C%2520a%2520Multi-targeted%2520Inhibitor%2520of%2520HDAC%252C%2520EGFR%2520and%2520HER2%252C%2520with%2520Potent%2520in%2520vitro%2520and%2520in%2520vivo%2520Anti-cancer%2520Activity" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Yu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friday, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCollum, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atadja, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, A. A.</span><span> </span><span class="NLM_article-title">Abrogation of MAPK and Akt Signaling by AEE788 Synergistically Potentiates Histone Deacetylase Inhibitor-Induced Apoptosis through Reactive Oxygen Species Generation</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1140</span><span class="NLM_x">–</span> <span class="NLM_lpage">1148</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm901453q&amp;key=10.1158%2F1078-0432.CCR-06-1751" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm901453q&amp;key=17317822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm901453q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvF2hsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=1140-1148&author=C.+Yuauthor=B.+B.+Fridayauthor=J.-P.+Laiauthor=A.+McCollumauthor=P.+Atadjaauthor=L.+R.+Robertsauthor=A.+A.+Adjei&title=Abrogation+of+MAPK+and+Akt+Signaling+by+AEE788+Synergistically+Potentiates+Histone+Deacetylase+Inhibitor-Induced+Apoptosis+through+Reactive+Oxygen+Species+Generation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Abrogation of MAPK and Akt Signaling by AEE788 Synergistically Potentiates Histone Deacetylase Inhibitor-Induced Apoptosis through Reactive Oxygen Species Generation</span></div><div class="casAuthors">Yu, Chunrong; Friday, Bret B.; Lai, Jin-Ping; McCollum, Andrea; Atadja, Peter; Roberts, Lewis R.; Adjei, Alex A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1140-1148</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: To evaluate the effects of combining the multiple receptor tyrosine kinase inhibitor AEE788 and histone deacetylase (HDAC) inhibitors on cytotoxicity in a broad spectrum of cancer cell lines, including cisplatin-resistant ovarian adenocarcinoma cells.  Exptl. Design: Multiple cancer cell lines were treated in vitro using AEE788 and HDAC inhibitors (LBH589, LAQ824, and trichostatin A), either alone or in combination.  Effects on cytotoxicity were detd. by growth and morphol. assays.  Effects of the combination on cell signaling pathways were detd. by Western blotting, and the results were confirmed using pathway-specific inhibitors and transfection of constitutively active proteins.  Results: Cell treatment with AEE788 and HDAC inhibitors (LBH589, LAQ824, and trichostatin A) in combination resulted in synergistic induction of apoptosis in non-small-cell lung cancer (MV522, A549), ovarian cancer (SKOV-3), and leukemia (K562, Jurkat, and ML-1) cells and in OV202hp cisplatin-resistant human ovarian cancer cells.  AEE788 alone or in combination with LBH589 inactivated mitogen-activated protein kinase (MAPK) and Akt cascades.  Inhibition of either MAPK and/or Akt enhanced LBH589-induced apoptosis.  In contrast, constitutively active MAPK or Akt attenuated LBH589 or LBH589 + AEE788-induced apoptosis.  Increased apoptosis was correlated with enhanced reactive oxygen species (ROS) generation.  The free radical scavenger N-acetyl-L-cysteine not only substantially suppressed the ROS accumulation but also blocked the induction of apoptosis mediated by cotreatment with AEE788 and LBH589.  Conclusions: Collectively, these results show that MAPK and Akt inactivation along with ROS generation contribute to the synergistic cytotoxicity of the combination of AEE788 and HDAC inhibitors in a variety of human cancer cell types.  This combination regimen warrants further preclin. and possible clin. study for a broad spectrum of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWUHPx_ds6mrVg90H21EOLACvtfcHk0ljZSqwg0JT3Qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvF2hsLg%253D&md5=3348f1067262e46bb6ba8c8c3d2cb212</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-1751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-1751%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DC.%26aulast%3DFriday%26aufirst%3DB.%2BB.%26aulast%3DLai%26aufirst%3DJ.-P.%26aulast%3DMcCollum%26aufirst%3DA.%26aulast%3DAtadja%26aufirst%3DP.%26aulast%3DRoberts%26aufirst%3DL.%2BR.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DAbrogation%2520of%2520MAPK%2520and%2520Akt%2520Signaling%2520by%2520AEE788%2520Synergistically%2520Potentiates%2520Histone%2520Deacetylase%2520Inhibitor-Induced%2520Apoptosis%2520through%2520Reactive%2520Oxygen%2520Species%2520Generation%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D1140%26epage%3D1148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Chou, T. C</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talalay, P.</span><span> </span><span class="NLM_article-title">Quantitative Analysis of Dose-effect Relationships: the Combined Effects of Multiple Drugs or Enzyme Inhibitors</span> <span class="citation_source-journal">Adv. Enzyme Regul.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">55</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm901453q&amp;key=10.1016%2F0065-2571%2884%2990007-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm901453q&amp;key=6382953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm901453q&amp;key=1%3ACAS%3A528%3ADyaL2cXktlaksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1984&pages=27-55&author=T.+C+Chouauthor=P.+Talalay&title=Quantitative+Analysis+of+Dose-effect+Relationships%3A+the+Combined+Effects+of+Multiple+Drugs+or+Enzyme+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative analysis of dose-effect relationships:  the combined effects of multiple drugs or enzyme inhibitors</span></div><div class="casAuthors">Chou, Ting Chao; Talalay, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Enzyme Regulation</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">27-55</span>CODEN:
                <span class="NLM_cas:coden">AEZRA2</span>;
        ISSN:<span class="NLM_cas:issn">0065-2571</span>.
    </div><div class="casAbstract">A simplified exptl. design method for the anal. of multiple drug effects and for detg. summation, synergism, and antagonism is described.  The method is not limited by: whether the dose-effect relations are hyperbolic or sigmoidal, whether the effects are mutually exclusive or nonexclusive, whether the ligand interactions are competitive, noncompetitive, or uncompetitive, or whether the drugs are agonists or antagonists.  The method is independent of the no. of drugs involved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX4wNupCqgpbVg90H21EOLACvtfcHk0ljz8kotDW-7kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXktlaksLk%253D&md5=055a2711b52dde49389c3f526352333d</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2F0065-2571%2884%2990007-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0065-2571%252884%252990007-4%26sid%3Dliteratum%253Aachs%26aulast%3DChou%26aufirst%3DT.%2BC%26aulast%3DTalalay%26aufirst%3DP.%26atitle%3DQuantitative%2520Analysis%2520of%2520Dose-effect%2520Relationships%253A%2520the%2520Combined%2520Effects%2520of%2520Multiple%2520Drugs%2520or%2520Enzyme%2520Inhibitors%26jtitle%3DAdv.%2520Enzyme%2520Regul.%26date%3D1984%26volume%3D22%26spage%3D27%26epage%3D55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Bolden, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peart, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnstone, R. E.</span><span> </span><span class="NLM_article-title">Anticancer Activities of Histone Deacetylase Inhibitors</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">769</span><span class="NLM_x">–</span> <span class="NLM_lpage">784</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm901453q&amp;key=10.1038%2Fnrd2133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm901453q&amp;key=16955068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm901453q&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVCltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=769-784&author=J.+E.+Boldenauthor=M.+J.+Peartauthor=R.+E.+Johnstone&title=Anticancer+Activities+of+Histone+Deacetylase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Anticancer activities of histone deacetylase inhibitors</span></div><div class="casAuthors">Bolden, Jessica E.; Peart, Melissa J.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">769-784</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) are enzymes involved in the remodelling of chromatin, and have a key role in the epigenetic regulation of gene expression.  In addn., the activity of non-histone proteins can be regulated through HDAC-mediated hypo-acetylation.  In recent years, inhibition of HDACs has emerged as a potential strategy to reverse aberrant epigenetic changes assocd. with cancer, and several classes of HDAC inhibitors have been found to have potent and specific anticancer activities in preclin. studies.  However, such studies have also indicated that the effects of HDAC inhibitors could be considerably broader and more complicated than originally understood.  Here we summarize recent advances in the understanding of the mol. events that underlie the anticancer effects of HDAC inhibitors, and discuss how such information could be used in optimizing the development and application of these agents in the clinic, either as monotherapies or in combination with other anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhfqS1awkOHbVg90H21EOLACvtfcHk0ljz8kotDW-7kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVCltrY%253D&md5=91e55ee942fda3e4e2055ddf299fc866</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnrd2133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2133%26sid%3Dliteratum%253Aachs%26aulast%3DBolden%26aufirst%3DJ.%2BE.%26aulast%3DPeart%26aufirst%3DM.%2BJ.%26aulast%3DJohnstone%26aufirst%3DR.%2BE.%26atitle%3DAnticancer%2520Activities%2520of%2520Histone%2520Deacetylase%2520Inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D769%26epage%3D784" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Keri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orfi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eros, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hegymegi-Barakonyi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szantai-Kis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horvath, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waczek, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marosfalvi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabadkai, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pato, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greff, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hafenbradl, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daub, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klebl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span> </span><span class="NLM_article-title">Signal Transduction Therapy with Rationally Designed Kinase Inhibitors</span> <span class="citation_source-journal">Curr. Signal Transduction Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">67</span><span class="NLM_x">–</span> <span class="NLM_lpage">95</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm901453q&amp;key=10.2174%2F157436206775269190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm901453q&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhs1Gis7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=67-95&author=G.+Keriauthor=L.+Orfiauthor=D.+Erosauthor=B.+Hegymegi-Barakonyiauthor=C.+Szantai-Kisauthor=Z.+Horvathauthor=F.+Waczekauthor=J.+Marosfalviauthor=I.+Szabadkaiauthor=J.+Patoauthor=Z.+Greffauthor=D.+Hafenbradlauthor=H.+Daubauthor=G.+Mullerauthor=B.+Kleblauthor=A.+Ullrich&title=Signal+Transduction+Therapy+with+Rationally+Designed+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Signal transduction therapy with rationally designed kinase inhibitors</span></div><div class="casAuthors">Keri, Gyorgy; Orfi, Laszlo; Eros, Daniel; Hegymegi-Barakonyi, Balint; Szantai-Kis, Csaba; Horvath, Zoltan; Waczek, Frigyes; Marosfalvi, Jeno; Szabadkai, Istvan; Pato, Janos; Greff, Zoltan; Hafenbradl, Doris; Daub, Henrik; Muller, Gerhard; Klebl, Bert; Ullrich, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Current Signal Transduction Therapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-95</span>CODEN:
                <span class="NLM_cas:coden">CSTTBV</span>;
        ISSN:<span class="NLM_cas:issn">1574-3624</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Signal transduction therapy has become one of the most important areas of drug research.  Signaling disorders represent a major cause for the pathol. states and many of the recently identified validated target mols. of drug research are signal transduction related macromols., mostly kinases.  Rational drug design is aimed to achieve the selective inhibition of distinct pathol. relevant signaling enzymes or receptors.  In the previous years, the concept of rational drug design has been expanded for a complex process including pathomechanism-based target selection, target validation, structural biol., mol. modeling, structure-activity relationships, pharmacophore-based compd. selection and pharmacol. optimization.  The two main branches of the chem. rational drug design are structure-based design and ligand-based design.  Some important examples for the application of 3D structure-based rational drug design in the development of clin. relevant kinase inhibitors are presented.  The Nested Chem. Library (NCL) technol. is a ligand-based design approach and relies on a knowledge-based approach, where focused libraries around published leads and selected cores are used to generate extended pharmacophore models (Prediction Oriented QSAR).  NCL was designed on the platform of a diverse kinase inhibitor library, consisting of small mol. heterocycles, which are organized around 108 core structures.  Some examples for testing the library on various targets and Prediction Oriented QSAR models will also be presented.  The core elements of the kinase family-biased masterkey concept are the so-called privileged structures that emerge from a sophisticated mol. design and optimization process that encodes for a target family-wide structural commonality in ligand binding.  The combination of a kinase family-wide imprinted commonality with addnl. structural fragments in the mol. periphery of a once established privileged structure allows to synthesize highly active and selective kinase inhibitors.  In addn., several kinase inhibitors in preclin. or clin. development and application of 3D structure based rational drug design in the development of clin. relevant kinase inhibitors are reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrciqRCaicLB7Vg90H21EOLACvtfcHk0ljec6xhnRioqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhs1Gis7Y%253D&md5=2193e359dee7044ed8ecd873e76f0583</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.2174%2F157436206775269190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157436206775269190%26sid%3Dliteratum%253Aachs%26aulast%3DKeri%26aufirst%3DG.%26aulast%3DOrfi%26aufirst%3DL.%26aulast%3DEros%26aufirst%3DD.%26aulast%3DHegymegi-Barakonyi%26aufirst%3DB.%26aulast%3DSzantai-Kis%26aufirst%3DC.%26aulast%3DHorvath%26aufirst%3DZ.%26aulast%3DWaczek%26aufirst%3DF.%26aulast%3DMarosfalvi%26aufirst%3DJ.%26aulast%3DSzabadkai%26aufirst%3DI.%26aulast%3DPato%26aufirst%3DJ.%26aulast%3DGreff%26aufirst%3DZ.%26aulast%3DHafenbradl%26aufirst%3DD.%26aulast%3DDaub%26aufirst%3DH.%26aulast%3DMuller%26aufirst%3DG.%26aulast%3DKlebl%26aufirst%3DB.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DSignal%2520Transduction%2520Therapy%2520with%2520Rationally%2520Designed%2520Kinase%2520Inhibitors%26jtitle%3DCurr.%2520Signal%2520Transduction%2520Ther.%26date%3D2006%26volume%3D1%26spage%3D67%26epage%3D95" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Acharya, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sparreboom, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venitz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Figg, W. D.</span><span> </span><span class="NLM_article-title">Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">917</span><span class="NLM_x">–</span> <span class="NLM_lpage">932</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2005&pages=917-932&author=M.+R.+Acharyaauthor=A.+Sparreboomauthor=J.+Venitzauthor=W.+D.+Figg&title=Rational+Development+of+Histone+Deacetylase+Inhibitors+as+Anticancer+Agents%3A+A+Review"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAcharya%26aufirst%3DM.%2BR.%26aulast%3DSparreboom%26aufirst%3DA.%26aulast%3DVenitz%26aufirst%3DJ.%26aulast%3DFigg%26aufirst%3DW.%2BD.%26atitle%3DRational%2520Development%2520of%2520Histone%2520Deacetylase%2520Inhibitors%2520as%2520Anticancer%2520Agents%253A%2520A%2520Review%26jtitle%3DMol.%2520Pharmacol.%26date%3D2005%26volume%3D68%26spage%3D917%26epage%3D932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Collins, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span> </span><span class="NLM_article-title">Design and Development of Signal Transduction Inhibitors for Cancer Treatment: Experience and Challenges with Kinase Targets</span> <span class="citation_source-journal">Curr. Signal Transduction Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">13</span><span class="NLM_x">–</span> <span class="NLM_lpage">23</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm901453q&amp;key=10.2174%2F157436206775269181" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm901453q&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhs1Gis7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=13-23&author=I.+Collinsauthor=P.+Workman&title=Design+and+Development+of+Signal+Transduction+Inhibitors+for+Cancer+Treatment%3A+Experience+and+Challenges+with+Kinase+Targets"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Design and development of signal transduction inhibitors for cancer treatment: experience and challenges with kinase targets</span></div><div class="casAuthors">Collins, Ian; Workman, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Current Signal Transduction Therapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-23</span>CODEN:
                <span class="NLM_cas:coden">CSTTBV</span>;
        ISSN:<span class="NLM_cas:issn">1574-3624</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The last several years have seen major progress towards the goal of translating our growing understanding of the mol. basis of cancer into drugs with improved therapeutic activity and selectivity.  Tremendous advances have been made but significant obstacles remain.  In this review we assess our experience in the design and development of signal transduction drugs for cancer treatment, with a specific focus on small mol. kinase inhibitors.  The druggability of cancer kinome targets is exemplified by imatinib, gefitinib, erlotinib and many other emerging agents.  We assess the current status of the design of potent and selective kinase inhibitors, which has benefited greatly from high throughput screening and structure-based approaches.  A diverse range of kinase inhibitory scaffolds is now available based on these methods.  Multi-parameter optimization now focuses as much on pharmacokinetic and metabolic properties as it does on target potency and selectivity.  Development of a 'mol. audit trail' requiring assays to demonstrate mechanism of action in vitro and in vivo is essential.  Current issues include our relatively poor ability to predict the level of kinase selectivity in the intact cell, uncertainties around the most desirable selectivity profile, and the emergence of drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4PMWClBEM9rVg90H21EOLACvtfcHk0ljec6xhnRioqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhs1Gis7s%253D&md5=02782d829d340091081de5f8d72c31fb</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.2174%2F157436206775269181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157436206775269181%26sid%3Dliteratum%253Aachs%26aulast%3DCollins%26aufirst%3DI.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DDesign%2520and%2520Development%2520of%2520Signal%2520Transduction%2520Inhibitors%2520for%2520Cancer%2520Treatment%253A%2520Experience%2520and%2520Challenges%2520with%2520Kinase%2520Targets%26jtitle%3DCurr.%2520Signal%2520Transduction%2520Ther.%26date%3D2006%26volume%3D1%26spage%3D13%26epage%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Stamos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span> </span><span class="NLM_article-title">Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">46265</span><span class="NLM_x">–</span> <span class="NLM_lpage">46272</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2002&pages=46265-46272&author=J.+Stamosauthor=M.+X.+Sliwkowskiauthor=C.+Eigenbrot&title=Structure+of+the+Epidermal+Growth+Factor+Receptor+Kinase+Domain+Alone+and+in+Complex+with+a+4-Anilinoquinazoline+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStamos%26aufirst%3DJ.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DEigenbrot%26aufirst%3DC.%26atitle%3DStructure%2520of%2520the%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Kinase%2520Domain%2520Alone%2520and%2520in%2520Complex%2520with%2520a%25204-Anilinoquinazoline%2520Inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D48%26spage%3D46265%26epage%3D46272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Wang, D.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helquist, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiech, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiest†, O.</span><span> </span><span class="NLM_article-title">Toward Selective Histone Deacetylase Inhibitor Design: Homology Modeling, Docking Studies, and Molecular Dynamics Simulations of Human Class I Histone Deacetylases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">6936</span><span class="NLM_x">–</span> <span class="NLM_lpage">6947</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0505011" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm901453q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtV2jsLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6936-6947&author=D.-F.+Wangauthor=P.+Helquistauthor=N.+L.+Wiechauthor=O.+Wiest%E2%80%A0&title=Toward+Selective+Histone+Deacetylase+Inhibitor+Design%3A+Homology+Modeling%2C+Docking+Studies%2C+and+Molecular+Dynamics+Simulations+of+Human+Class+I+Histone+Deacetylases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Toward Selective Histone Deacetylase Inhibitor Design: Homology Modeling, Docking Studies, and Molecular Dynamics Simulations of Human Class I Histone Deacetylases</span></div><div class="casAuthors">Wang, Di-Fei; Helquist, Paul; Wiech, Norbert L.; Wiest, Olaf</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6936-6947</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) play an important role in gene transcription.  Inhibitors of HDACs induce cell differentiation and suppress cell proliferation in tumor cells.  Although many HDAC inhibitors have been designed and synthesized, selective inhibition for class I HDAC isoforms is a goal that has yet to be achieved.  To understand the difference between class I HDAC isoforms that could be exploited for the design of isoform-specific HDAC inhibitors, the authors have built three-dimensional models of four class I histone deacetylases, HDAC1, HDAC2, HDAC3, and HDAC8.  Comparison of the homol. model of HDAC8 with the recently published x-ray structure shows excellent agreement and validates the approach.  A series of HDAC inhibitors were docked to the homol. models to understand the similarities and differences between the binding modes.  Mol. dynamic simulations of these HDAC-inhibitor complexes indicate that the interaction between the protein surface and inhibitor is playing an important role; also some active site residues show some flexibility, which is usually not included in routine docking protocols.  The implications of these results for the design of isoform-selective HDAC inhibitors are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqb6SYJC1ObVLVg90H21EOLACvtfcHk0ljec6xhnRioqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtV2jsLnL&md5=0b59815173df7f16feb9ba66c8b4da83</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm0505011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0505011%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DD.-F.%26aulast%3DHelquist%26aufirst%3DP.%26aulast%3DWiech%26aufirst%3DN.%2BL.%26aulast%3DWiest%25E2%2580%25A0%26aufirst%3DO.%26atitle%3DToward%2520Selective%2520Histone%2520Deacetylase%2520Inhibitor%2520Design%253A%2520Homology%2520Modeling%252C%2520Docking%2520Studies%252C%2520and%2520Molecular%2520Dynamics%2520Simulations%2520of%2520Human%2520Class%2520I%2520Histone%2520Deacetylases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6936%26epage%3D6947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Finnin, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donigian, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richon, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rifkind, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marks, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslow, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavletich, N. P.</span><span> </span><span class="NLM_article-title">Structures of a Histone Deacetylase Homologue Bound to the TSA and SAHA Inhibitors</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">401</span><span class="NLM_x">, </span> <span class="NLM_fpage">188</span><span class="NLM_x">–</span> <span class="NLM_lpage">193</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm901453q&amp;key=10.1038%2F43710" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm901453q&amp;key=10490031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm901453q&amp;key=1%3ACAS%3A528%3ADyaK1MXlvFKgtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=401&publication_year=1999&pages=188-193&author=M.+S.+Finninauthor=J.+R.+Donigianauthor=A.+Cohenauthor=V.+M.+Richonauthor=R.+A.+Rifkindauthor=P.+A.+Marksauthor=R.+Breslowauthor=N.+P.+Pavletich&title=Structures+of+a+Histone+Deacetylase+Homologue+Bound+to+the+TSA+and+SAHA+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors</span></div><div class="casAuthors">Finnin, Michael S.; Donigian, Jill R.; Cohen, Alona; Richon, Victoria M.; Rifkind, Richard A.; Marks, Paul A.; Breslow, Ronald; Pavletich, Nikola P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">401</span>
        (<span class="NLM_cas:issue">6749</span>),
    <span class="NLM_cas:pages">188-193</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) mediate changes in nucleosome conformation and are important in the regulation of gene expression.  HDACs are involved in cell-cycle progression and differentiation, and their deregulation is assocd. with several cancers.  HDAC inhibitors, such as trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA), have anti-tumor effects, as they can inhibit cell growth, induce terminal differentiation and prevent the formation of tumors in mice models, and they are effective in the treatment of promyelocytic leukemia.  Here we describe the structure of the histone deacetylase catalytic core, as revealed by the crystal structure of a homolog from the hyperthermophilic bacterium Aquifex aeolicus, that shares 35.2% identity with human HDAC1 over 375 residues, deacetylates histones in vitro and is inhibited by TSA and SAHA.  The deacetylase, deacetylase-TSA and deacetylase-SAHA structures reveal an active site consisting of a tubular pocket, a zinc-binding site and two Asp-His charge-relay systems, and establish the mechanism of HDAC inhibition.  The residues that make up the active site and contact the inhibitors are conserved across the HDAC family.  These structures also suggest a mechanism for the deacetylation reaction and provide a framework for the further development of HDAC inhibitors as antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrG0lsZMMo37Vg90H21EOLACvtfcHk0lhpLL_ve9EKNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvFKgtrc%253D&md5=29bbc6d3ba9a9d2a8c330349ae8199a8</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2F43710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F43710%26sid%3Dliteratum%253Aachs%26aulast%3DFinnin%26aufirst%3DM.%2BS.%26aulast%3DDonigian%26aufirst%3DJ.%2BR.%26aulast%3DCohen%26aufirst%3DA.%26aulast%3DRichon%26aufirst%3DV.%2BM.%26aulast%3DRifkind%26aufirst%3DR.%2BA.%26aulast%3DMarks%26aufirst%3DP.%2BA.%26aulast%3DBreslow%26aufirst%3DR.%26aulast%3DPavletich%26aufirst%3DN.%2BP.%26atitle%3DStructures%2520of%2520a%2520Histone%2520Deacetylase%2520Homologue%2520Bound%2520to%2520the%2520TSA%2520and%2520SAHA%2520Inhibitors%26jtitle%3DNature%26date%3D1999%26volume%3D401%26spage%3D188%26epage%3D193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Gibson, K. H.</span><span> </span><span class="NLM_article-title">Quinazoline Derivatives</span>. U.S. Patent 5,770,599,<span class="NLM_x"> </span><span class="NLM_year">1998</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1998&author=K.+H.+Gibson&title=Quinazoline+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGibson%26aufirst%3DK.%2BH.%26atitle%3DQuinazoline%2520Derivatives%26date%3D1998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Barker, A. J.</span><span> </span><span class="NLM_article-title">Quinazoline Derivatives Useful for Treatment of Neoplastic Disease</span>. U.S. Patent5,457,105,<span class="NLM_x"> </span><span class="NLM_year">1995</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1995&author=A.+J.+Barker&title=Quinazoline+Derivatives+Useful+for+Treatment+of+Neoplastic+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBarker%26aufirst%3DA.%2BJ.%26atitle%3DQuinazoline%2520Derivatives%2520Useful%2520for%2520Treatment%2520of%2520Neoplastic%2520Disease%26date%3D1995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Alley, M. C.; Hollingshead, M. D.; Dykes, D.</span><span> </span><span class="NLM_article-title">Human Tumor Xenograft Models in NCI Drug Development</span>. In  <span class="citation_source-book">Anticancer drug development guide</span>; <span class="NLM_contrib-group">Teicher, B. A.; Andrews, P. A.</span>, Eds.; <span class="NLM_publisher-name">Humana Press Inc.</span>: <span class="NLM_publisher-loc">Totowa, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2004</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">125</span>− <span class="NLM_lpage">152</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&pages=125-152&author=M.+C.+Alley&author=M.+D.+Hollingshead&author=D.+Dykesauthor=B.+A.+Teicher&author=P.+A.+Andrews&title=Anticancer+drug+development+guide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DAlley%26aufirst%3DM.%2BC.%26atitle%3DHuman%2520Tumor%2520Xenograft%2520Models%2520in%2520NCI%2520Drug%2520Development%26btitle%3DAnticancer%2520drug%2520development%2520guide%26aulast%3DTeicher%26aufirst%3DB.%2BA.%26pub%3DHumana%2520Press%2520Inc%26date%3D2004%26spage%3D125%26epage%3D152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i39"><a href="/doi/suppl/10.1021/jm901453q">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_26865"></div></div></div></div></div><hr /></hr><p class="last">Details of synthesis and analytical data, the LCMS method used for the determination of purity and the HPLC method used for compound separation, HDAC and RTK inhibition synergy data, HDAC class I and class II inhibitory activity of <b>8</b>. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm901453q/suppl_file/jm901453q_si_001.pdf">jm901453q_si_001.pdf (164.39 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm901453q&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Fjm901453q%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2010.53.issue-5%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm901453q" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a62bd0ee82308","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
